<DOCNO> WSJ900801-0140
It PRP
would MD
also RB
clear VB
the DT
way NN
for IN
Schering-Plough JJ
Corp. NNP
to TO
market NN
the DT
biotechnology NN
product NN
for IN
a DT
form NN
of IN
the DT
disease NN
which WDT
is VBZ
formally RB
known VBN
as IN
chronic JJ
non-A NNP
, ,
non-B NNP
hepatitis VBZ
. .
About IN
half DT
a DT
million NN
Americans NNPS
now RB
suffer VBP
this DT
form NN
of IN
liver NN
inflammation NN
, ,
which WDT
is VBZ
spread VBN
by IN
tainted VBN
blood NN
transfusions NNS
, ,
unclean JJ
hypodermic JJ
needles NNS
and CC
sexual JJ
contact NN
. .
About IN
150 CD
, ,
000 CD
new JJ
cases NNS
are VBP
diagnosed VBN
each DT
year NN
, ,
of IN
which WDT
half DT
progress NN
to TO
a DT
state NN
of IN
chronic JJ
infection NN
. .
A DT
virus NN
responsible JJ
for IN
about IN
85 CD
% NN
of IN
such JJ
cases NNS
was VBD
recently RB
identified VBD
and CC
dubbed VBN
hepatitis NNS
C NNP
, ,
making VBG
antibody NN
testing NN
possible JJ
. .
World-wide JJ
, ,
the DT
number NN
of IN
cases NNS
of IN
the DT
disease NN
is VBZ
increasing VBG
and CC
has VBZ
assumed VBN
`` ``
epidemic JJ
'' ''
proportions NNS
in IN
Japan NNP
, ,
according VBG
to TO
Robert NNP
J. NNP
Spiegel NNP
, ,
a DT
Schering NNP
vice NN
president NN
of IN
clinical JJ
research NN
. .
Chronic NNP
hepatitis VBZ
sufferers NNS
, ,
who WP
are VBP
at IN
increased VBN
risk NN
of IN
death NN
from IN
cirrhosis NN
of IN
the DT
liver NN
or CC
liver RB
cancer NN
, ,
would MD
be VB
candidates NNS
for IN
alpha NN
interferon NN
treatment NN
under IN
the DT
panel's NNP
recommendation NN
. .
Schering VBG
, ,
based VBN
in IN
Kenilworth NNP
, ,
N.J. NNP
, ,
said VBD
it PRP
was VBD
'' ''
immensely RB
pleased VBN
'' ''
by IN
yesterday NN
's POS
action NN
, ,
which WDT
virtually RB
ensures VBZ
a DT
much JJ
broader NN
market NN
for IN
interferon NN
. .
The DT
drug NN
previously RB
has VBZ
been VBN
approved VBN
for IN
only RB
a DT
few JJ
small JJ
niches NNS
, ,
mostly RB
in IN
cancer NN
treatment NN
. .
The DT
action NN
also RB
marks VBZ
a DT
major JJ
milestone NN
in IN
the DT
evolution NN
of IN
biotechnology NN
industry NN
, ,
where WRB
interferon NN
held VBN
the DT
rank NN
of IN
a DT
pioneer NN
, ,
previously RB
consigned VBD
to TO
play VB
a DT
bit NN
part NN
, ,
but CC
now RB
stepping VBG
up RP
to TO
fill VB
what WP
may MD
become VB
a DT
major JJ
role NN
. .
In IN
New NNP
York NNP
Stock NNP
Exchange NNP
composite JJ
trading NN
, ,
Schering NNP
closed VBD
at IN
$ $
48.875 CD
, ,
up RB
37.5 CD
cents NNS
. .
To TO
win VB
the DT
panel NN
's POS
approval NN
, ,
Schering NNP
scientists NNS
presented VBD
data NNS
on IN
more JJR
than IN
300 CD
patients NNS
, ,
showing VBG
that IN
liver JJR
inflammation NN
subsided VBD
in IN
53 CD
% NN
of IN
the DT
patients NNS
treated VBD
with IN
alpha NN
interferon NN
, ,
as IN
opposed VBN
to TO
7 CD
% NN
of IN
untreated VBN
patients NNS
. .
Conversely RB
, ,
16 CD
% NN
of IN
the DT
untreated VBN
control NN
group NN
worsened VBD
during IN
the DT
study NN
, ,
compared VBN
with IN
2 CD
% NN
of IN
the DT
treated VBN
group NN
. .
`` ``
These DT
are VBP
impressive JJ
data NNS
, ,
'' ''
said VBD
Jordan NNP
Gutterman NNP
, ,
a DT
panel NN
member NN
and CC
a DT
pioneer NN
interferon NN
researcher NN
at IN
the DT
University NNP
of IN
Texas NNP
's POS
M.D JJ
. .
Anderson NNP
Cancer NNP
Center NNP
. .
Side NNP
effects NNS
consisted VBD
mostly RB
of IN
flu-like JJ
symptoms NNS
including VBG
fatigue NN
and CC
nausea NN
. .
To TO
date NN
, ,
interferon NN
has VBZ
received VBN
approval NN
for IN
use NN
in IN
a DT
rare NN
cancer NN
known VBN
as IN
hairy-cell NNP
leukemia NN
, ,
which WDT
affects NNS
about IN
2 CD
, ,
500 CD
people NNS
in IN
the DT
U.S. NNP
, ,
and CC
in IN
Kaposi NNP
's POS
Sarcoma NNP
, ,
an DT
AIDS-related JJ
malignancy NN
with IN
a DT
roughly RB
equal JJ
number NN
of IN
patients NNS
, ,
Schering NNP
said VBD
. .
The DT
FDA NNP
has VBZ
also RB
approved VBD
its PRP$
use NN
in IN
treating NN
genital NN
warts NNS
. .
But CC
analysts NNS
said VBD
FDA NNP
approval NN
for IN
chronic JJ
non-A NN
, ,
non-B NNP
hepatitis VBZ
would MD
expand VB
its PRP$
potential JJ
market NN
at IN
least JJS
five-fold JJ
. .
`` ``
We PRP
see VBP
this DT
as IN
adding NN
another DT
$ $
100 CD
million CD
to TO
Schering NNP
's POS
annual JJ
interferon NN
sales NNS
, ,
'' ''
doubling VBG
last JJ
year's NNS
level NN
, ,
said VBD
Michael NNP
Sorell NNP
, ,
an DT
analyst NN
with IN
Morgan NNP
Stanley NNP
in IN
New NNP
York NNP
. .
Looking VBG
ahead RB
to TO
continuing VBG
studies NNS
in IN
other JJ
cancers NNS
, ,
not RB
to TO
mention VB
in IN
AIDS NNP
and CC
hepatitis VBZ
B NNP
, ,
Dr. NNP
Sorell NNP
predicted VBD
$ $
300 CD
million CD
to TO
$ $
400 CD
million CD
in IN
sales NNS
`` ``
looks NNS
readily RB
achievable JJ
'' ''
by IN
1993 CD
to TO
1994 CD
. .
In IN
the DT
evolution NN
of IN
biotechnology NN
, ,
Schering NNP
's POS
Dr. NNP
Spielgel NNP
said VBD
, ,
`` ``
Interferon NNP
is VBZ
an DT
interesting JJ
story NN
as IN
the DT
pioneering NN
biotech NN
product NN
. .
`` ``
It PRP
may MD
also RB
prove VB
to TO
be VB
a DT
classic JJ
case NN
history NN
of IN
the DT
new JJ
biological JJ
agents NNS
which WDT
start NN
small JJ
, ,
and CC
expand NN
to TO
fill VB
larger JJR
therapeutic JJ
roles NNS
as IN
scientific JJ
knowledge NN
about IN
their PRP$
activity NN
in IN
the DT
body NN
and CC
their PRP$
potential JJ
use NN
expands NNS
. .
Interferon NNP
was VBD
touted VBN
in IN
the DT
1970s CD
as IN
a DT
panacea NN
, ,
only RB
to TO
prove VB
disappointing JJ
and CC
only RB
narrowly RB
useful JJ
at IN
first JJ
. .
`` ``
A DT
few JJ
years NNS
ago RB
, ,
when WRB
interleukin-2 -NONE-
made VBN
the DT
headlines NNS
, ,
people NNS
said VBD
: :
`Interferon JJ
-- :
so IN
what WP
? .
' POS
'' ''
Dr. NNP
Spiegel NNP
said VBD
. .
`` ``
But CC
it's VBZ
stood NN
the DT
test NN
of IN
time NN
, ,
and CC
today NN
's POS
action NN
puts NNS
us PRP
in IN
a DT
whole JJ
new JJ
league NN
. .
`` ``
On IN
Monday NNP
, ,
an DT
FDA NNP
panel NN
withheld VBD
approval NN
from IN
interleukin-2 -NONE-
as IN
a DT
treatment NN
for IN
kidney NN
cancer NN
, ,
demanding VBG
additional JJ
information NN
from IN
its PRP$
maker NN
, ,
Cetus NNP
Corp. NNP
of IN
Emeryville NNP
, ,
Calif NNP
. .
In IN
a DT
separate JJ
action NN
, ,
the DT
FDA NNP
advisory NN
panel NN
recommended VBD
that IN
the DT
agency NN
grant NN
Treatment NNP
IND NNP
( NNP
investigational JJ
new JJ
drug NN
) :
status NN
to TO
Immunex NNP
Corp. NNP
's POS
GM-CSF JJ
product NN
. .
GHM-CSF JJ
is VBZ
a DT
blood-cell JJ
growth NN
factor NN
that IN
shows VBZ
promise NN
as IN
a DT
treatment NN
for IN
bone NN
marrow NN
transplant NN
failure NN
in IN
cancer NN
patients NNS
and CC
those DT
suffering NN
certain JJ
kinds NNS
of IN
anemia NN
. .
However RB
, ,
the DT
panel NN
asked VBD
Seattle-based JJ
Immunex NNP
for IN
more JJR
study NN
data NNS
before IN
making VBG
a DT
formal JJ
recommendation NN
to TO
the DT
FDA NNP
on IN
market NN
approval NN
. .
Treatment NNP
IND NNP
status NN
would MD
make VB
the DT
drug NN
more JJR
widely RB
available JJ
free JJ
of IN
charge NN
to TO
patients NNS
during IN
studies NNS
. .
About IN
5 CD
, ,
000 CD
patients NNS
receive JJ
bone NN
marrow NN
transplants NNS
each DT
year NN
. .

<DOCNO> AP900419-0001
A DT
single JJ
round NN
of IN
treatment NN
with IN
an DT
experimental JJ
new JJ
medicine NN
appears VBZ
to TO
be VB
highly RB
effective JJ
against IN
a DT
rare NN
form NN
of IN
leukemia NN
and CC
may MD
help VB
fight NN
other JJ
kinds NNS
of IN
blood NN
cancer NN
as IN
well RB
, ,
says VBZ
a DT
study NN
published VBN
today NN
. .
The DT
new JJ
drug NN
was VBD
developed VBN
at IN
Scripps NNP
Clinic NNP
and CC
Research NNP
Foundation NNP
in IN
La NNP
Jolla NNP
, ,
Calif. NNP
, ,
where WRB
doctors NNS
tested VBN
it PRP
on IN
patients NNS
with IN
hairy NN
cell NN
leukemia NN
. .
In IN
almost RB
every DT
case NN
, ,
the DT
medicine NN
erased VBD
all DT
signs NNS
of IN
the DT
disease NN
. .
Hairy NNP
cell VBD
leukemia NN
affects NNS
the DT
white JJ
blood NN
cells NNS
that WDT
make VBP
disease-fighting JJ
antibodies NNS
. .
Doctors NNS
are VBP
also RB
testing VBG
the DT
drug NN
against IN
chronic JJ
lymphocytic JJ
leukemia NN
, ,
non-Hodgkins VBZ
lymphoma NN
and CC
cutaneous JJ
T NNP
cell NN
lymphoma NN
. .
The DT
Scripps NNP
doctors NNS
concluded VBD
that IN
the DT
medicine NN
, ,
called VBN
2-chlorodeoxyadenosine CD
, ,
or CC
2-CdA CD
, ,
`` ``
may MD
well RB
be VB
the DT
drug NN
of IN
choice NN
in IN
the DT
treatment NN
of IN
hairy NN
cell NN
leukemia NN
. .
'' ''
The DT
study NN
was VBD
directed VBN
by IN
Dr. NNP
Lawrence NNP
D. NNP
Piro NNP
and CC
published VBD
in IN
the DT
New NNP
England NNP
Journal NNP
of IN
Medicine NNP
. .
In IN
their PRP$
study NN
, ,
doctors NNS
gave VBD
the DT
drug NN
to TO
12 CD
patients NNS
. .
Of IN
these DT
, ,
11 CD
have VBP
remained VBN
completely RB
free JJ
of IN
all DT
signs NNS
of IN
the DT
disease NN
for IN
periods NNS
up IN
to TO
four CD
years NNS
. .
The DT
doctors NNS
cautioned VBD
that IN
longer JJR
follow-up JJ
will MD
be VB
necessary JJ
before IN
they PRP
can MD
be VB
sure JJ
they PRP
have VBP
actually RB
cured VBN
the DT
disease NN
. .
Two CD
other JJ
treatments NNS
for IN
hairy NN
cell NN
leukemia NN
have VBP
been VBN
developed VBN
in IN
recent JJ
years NNS
. .
They PRP
are VBP
interferon RB
and CC
deoxycoformycin VB
, ,
a DT
drug NN
that WDT
is VBZ
similar JJ
to TO
2-CdA CD
. .
However RB
, ,
interferon NN
is VBZ
less JJR
effective JJ
, ,
and CC
both DT
of IN
those DT
treatments NNS
produce VBP
serious JJ
side NN
effects NNS
. .
By IN
contrast NN
, ,
the DT
only JJ
unwanted JJ
effect NN
of IN
2-CdA CD
was VBD
a DT
few JJ
days NNS
of IN
fever NN
. .
Patients NNS
experienced VBD
no DT
nausea NN
, ,
hair NN
loss NN
, ,
rashes VBZ
or CC
other JJ
symptoms NNS
typical JJ
of IN
cancer NN
therapy NN
. .
Also RB
unlike VBP
other JJ
treatments NNS
, ,
this DT
one CD
appears VBZ
to TO
work VB
after IN
a DT
single JJ
seven-day NN
course NN
of IN
therapy NN
. .
The DT
Scripps NNP
Clinic NNP
reached VBD
an DT
agreement NN
recently RB
with IN
Johnson NNP
& CC
amp VB
; :
Johnson NNP
's POS
Ortho NNP
Pharmaceuticals NNPS
to TO
produce VB
the DT
drug NN
, ,
which WDT
is VBZ
not RB
yet RB
approved VBD
for IN
routine NN
use NN
. .

<DOCNO> AP900104-0061
Chemotherapy NNP
drugs NNS
that WDT
were VBD
used VBN
to TO
treat VB
ovarian JJ
cancer NN
may MD
have VB
sharply RB
increased VBN
the DT
risk NN
of IN
leukemia NN
, ,
a DT
study NN
has VBZ
found VBN
. .
Researchers NNS
found VBD
that IN
among IN
women NNS
treated VBN
between IN
1960 CD
and CC
1985 CD
, ,
the DT
risk NN
of IN
leukemia NN
was VBD
12 CD
times NNS
higher JJR
in IN
those DT
who WP
received VBN
chemotherapy VBP
rather RB
than IN
surgery NN
alone RB
, ,
according VBG
to TO
the DT
study NN
published VBD
in IN
today NN
's POS
New NNP
England NNP
Journal NNP
of IN
Medicine NNP
. .
Although IN
the DT
study NN
did VBD
not RB
measure VB
the DT
benefits NNS
of IN
treatment NN
, ,
chemotherapy NN
drugs NNS
given VBN
during IN
that DT
time NN
frequently RB
failed VBD
to TO
stop VB
ovarian JJ
cancer NN
. .
But CC
doctors NNS
say VBP
that IN
newer JJR
drugs NNS
now RB
in IN
use NN
against IN
this DT
form NN
of IN
cancer NN
are VBP
more RBR
effective JJ
, ,
and CC
their PRP$
benefits NNS
probably RB
outweigh JJ
their PRP$
risks NNS
. .
The DT
research NN
, ,
directed VBD
by IN
Dr. NNP
John NNP
M. NNP
Kaldor NNP
of IN
the DT
International NNP
Agency NNP
for IN
Research NNP
on IN
Cancer NNP
in IN
Lyon NNP
, ,
France NNP
, ,
was VBD
based VBN
on IN
114 CD
women NNS
with IN
leukemia NNS
who WP
were VBD
among IN
99 CD
, ,
113 CD
survivors NNS
of IN
ovarian JJ
cancer NN
in IN
seven CD
European JJ
countries NNS
and CC
Canada NNP
. .
Doctors NNS
have VBP
long RB
known VBN
that IN
the DT
powerful JJ
medicines NNS
used VBN
to TO
attack VB
cancer NN
may MD
also RB
cause VB
the DT
disease NN
. .
The DT
latest JJS
research NN
demonstrates NNS
the DT
magnitude NN
of IN
this DT
risk NN
. .
In IN
a DT
second JJ
study NN
, ,
the DT
same JJ
researchers NNS
found VBD
that IN
the DT
risk NN
of IN
leukemia NN
is VBZ
also RB
substantially RB
increased VBN
in IN
people NNS
given VBN
chemotherapy NN
for IN
Hodgkin NNP
's POS
disease NN
, ,
another DT
form NN
of IN
cancer NN
. .
But CC
since IN
Hodgkin NNP
's POS
disease NN
is VBZ
often RB
curable JJ
with IN
drugs NNS
, ,
the DT
benefits NNS
of IN
treatment NN
clearly RB
outweigh JJ
the DT
risks NNS
. .
In IN
this DT
work NN
, ,
the DT
doctors NNS
reviewed VBD
163 CD
cases NNS
of IN
leukemia NN
among IN
29 CD
, ,
552 CD
Hodgkin NNP
's POS
disease NN
patients NNS
. .
They PRP
found VBD
that IN
the DT
risk NN
of IN
leukemia NN
was VBD
nine CD
times NNS
higher JJR
among IN
those DT
who WP
got VBD
chemotherapy VBP
instead RB
of IN
radiation NN
treatment NN
. .
`` ``
The DT
risk NN
in IN
Hodgkin NNP
's POS
disease NN
is VBZ
well RB
worth JJ
it PRP
, ,
because IN
the DT
treatment NN
does VBZ
extend NN
life NN
. .
In IN
ovarian JJ
cancer NN
, ,
it PRP
's VBZ
not RB
necessarily RB
worth JJ
it PRP
, ,
'' ''
commented VBD
Dr. NNP
Charles NNP
A. NNP
Coltman NNP
Jr. NNP
of IN
the DT
University NNP
of IN
Texas NNP
Health NNP
Science NNP
Center NNP
at IN
San NNP
Antonio NNP
. .
Several JJ
of IN
the DT
cancer NN
drugs NNS
taken VBN
by IN
the DT
European NNP
women NNS
for IN
ovarian JJ
cancer NN
are VBP
no RB
longer RBR
used VBN
. .
`` ``
Management NN
of IN
ovarian JJ
cancer NN
is VBZ
moving VBG
ahead RB
very RB
rapidly RB
, ,
'' ''
said VBD
Coltman NNP
. .
`` ``
Some DT
of IN
the DT
more RBR
recent JJ
studies NNS
suggest VBP
an DT
impact NN
on IN
survival NN
'' ''
that WDT
outweighs VBZ
the DT
increased VBN
risk NN
of IN
leukemia NN
. .

<DOCNO> AP880630-0223
Scientists NNS
say VBP
they PRP
took VBD
a DT
step NN
toward IN
improving VBG
bone NN
marrow NN
transplants NNS
for IN
people NNS
with IN
cancer NN
and CC
radiation NN
sickness NN
by IN
purifying NN
, ,
or CC
isolating VBG
, ,
a DT
type NN
of IN
cell NN
crucial JJ
to TO
development NN
of IN
blood NN
and CC
immunity NN
in IN
mice NN
. .
Isolation NN
of IN
the DT
special JJ
cell NN
type NN
, ,
called VBN
a DT
stem NN
cell NN
, ,
eluded VBD
researchers NNS
for IN
30 CD
years NNS
until IN
achieved JJ
by IN
doctors NNS
at IN
Stanford NNP
University NNP
Medical NNP
Center NNP
in IN
Northern NNP
California NNP
and CC
Royal NNP
Melbourne NNP
Hospital NNP
in IN
Australia NNP
. .
The DT
research NN
is VBZ
outlined VBN
in IN
Friday NNP
's POS
issue NN
of IN
the DT
journal NN
Science NNP
. .
The DT
researchers NNS
are VBP
well RB
on IN
their PRP$
way NN
to TO
purifying NN
human NN
stem NN
cells NNS
and CC
growing VBG
them PRP
in IN
the DT
laboratory NN
, ,
an DT
accomplishment NN
that IN
could MD
make VB
bone NN
marrow NN
transplantation NN
safer NN
and CC
more JJR
available JJ
, ,
said VBD
Dr. NNP
Irving NNP
Weissman NNP
, ,
a DT
Stanford NNP
professor NN
of IN
pathology NN
and CC
cancer NN
biology NN
who WP
headed VBN
the DT
study NN
team NN
. .
Bone NN
marrow NN
transplants NNS
are VBP
used VBN
to TO
replace VB
damaged JJ
or CC
diseased VBN
marrow NN
, ,
the DT
substance NN
inside NN
bones NNS
that WDT
produces VBZ
blood NN
and CC
provides VBZ
immunity NN
from IN
disease NN
. .
Transplant NNP
recipients NNS
include VBP
some DT
leukemia NN
patients NNS
, ,
other JJ
cancer NN
patients NNS
made VBN
ill NN
by IN
chemotherapy NN
and CC
radiation NN
therapy NN
, ,
people NNS
sickened VBD
by IN
accidental JJ
radiation NN
exposure NN
, ,
and CC
those DT
with IN
certain JJ
disorders NNS
of IN
the DT
blood NN
and CC
the DT
immune NN
system NN
. .
Only RB
about IN
one CD
in IN
20 CD
, ,
000 CD
cells NNS
in IN
bone NN
marrow NN
is VBZ
a DT
stem NN
cell NN
, ,
said VBD
Weissman NNP
. .
But CC
the DT
rare NN
cells NNS
are VBP
ultimately RB
responsible JJ
for IN
making VBG
and CC
replacing VBG
other JJ
short-lived JJ
blood NN
cells NNS
, ,
including VBG
red VBN
cells NNS
, ,
platelets NNS
and CC
the DT
B NNP
and CC
T NNP
types NNS
of IN
white JJ
blood NN
cells NNS
responsible JJ
for IN
immunity NN
. .
As IN
a DT
result NN
, ,
stem NN
cells NNS
are VBP
the DT
most RBS
important JJ
part NN
of IN
transplanted VBN
bone NN
marrow NN
. .
But CC
such JJ
transplants NNS
often RB
fail VBP
unless IN
the DT
donor NN
and CC
recipient JJ
are VBP
matched VBN
closely RB
. .
That DT
's VBZ
because IN
some DT
white JJ
blood NN
cells NNS
in IN
donor NN
marrow NN
attack NN
the DT
recipient JJ
's POS
tissues NNS
in IN
a DT
sort NN
of IN
reverse NN
rejection NN
called VBN
graft-versus-host -NONE-
disease NN
. .
If IN
human JJ
stem NN
cells NNS
can MD
be VB
purified VBN
, ,
they PRP
might MD
be VB
transplanted VBN
without IN
other JJ
cells NNS
in IN
bone NN
marrow NN
, ,
thus RB
avoiding VBG
the DT
failure NN
of IN
the DT
transplants NNS
, ,
Weissman NNP
said VBD
. .
Purified NNP
human NN
stem NN
cells NNS
also RB
could MD
eliminate VB
the DT
need NN
to TO
find VB
closely RB
matched VBN
marrow NN
donors NNS
, ,
making VBG
marrow NN
transplants NNS
more RBR
widely RB
available JJ
, ,
he PRP
added VBD
. .
Pure NN
stem NN
cells NNS
also RB
could MD
make VB
it PRP
safer JJR
for IN
leukemia NN
patients NNS
to TO
have VB
some DT
of IN
their PRP$
own JJ
marrow NN
removed VBD
and CC
then RB
have VBP
it PRP
replaced VBD
later JJ
after IN
they PRP
have VBP
been VBN
subjected VBN
to TO
radiation NN
therapy NN
. .
Radiation NN
kills NNS
the DT
remaining VBG
marrow NN
at IN
the DT
same JJ
time NN
it PRP
kills VBZ
cancer NN
cells NNS
in IN
marrow NN
, ,
he PRP
said VBD
. .
When WRB
leukemia NN
patients NNS
have VBP
some DT
marrow NN
removed VBD
and CC
later JJ
replaced VBD
, ,
it PRP
can MD
contain VB
some DT
cancer NN
cells NNS
, ,
which WDT
spur NN
recurrence NN
of IN
the DT
leukemia NN
, ,
or CC
blood NN
cancer NN
. .
By IN
separating NN
stem NN
cells NNS
from IN
the DT
extracted VBN
marrow NN
, ,
the DT
stem NN
cells NNS
can MD
be VB
reimplanted VBN
free JJ
of IN
any DT
cancer NN
cells NNS
, ,
preventing VBG
the DT
cancer NN
from IN
recurring VBG
, ,
Weissman NNP
said VBD
. .
The DT
researcher NN
also RB
said VBD
that IN
in IN
several JJ
years NNS
, ,
purifying VBG
human NN
stem NN
cells NNS
could MD
speed VB
development NN
of IN
gene NN
therapy NN
for IN
inherited VBN
blood NN
diseases NNS
. .
Gene NNP
therapy NN
involves VBZ
the DT
replacement NN
of IN
disease-causing JJ
genes NNS
_ NNP
the DT
basic JJ
units NNS
of IN
heredity NN
_ NNP
with IN
healthy JJ
genes NNS
. .

<DOCNO> AP900405-0064
Medical JJ
experts NNS
expressed VBN
skepticism NN
about IN
reports NNS
that IN
a DT
licensed JJ
drug NN
alleviated VBD
AIDS NNP
patients NNS
' POS
symptoms NNS
after IN
it PRP
was VBD
prepared VBN
in IN
a DT
novel NN
way NN
. .
Researchers NNS
said VBD
data NNS
is VBZ
too RB
inconclusive JJ
to TO
embrace VB
the DT
results NNS
reported VBD
on IN
Wednesday NNP
by IN
Dr. NNP
Joseph NNP
M. NNP
Cummins NNP
, ,
head NN
of IN
the DT
Amarillo NNP
Cell NNP
Culture NNP
Co. NNP
Inc. NNP
Cummins NNP
said VBD
that IN
alpha NN
interferon NN
given VBN
to TO
patients NNS
in IN
a DT
wafer NN
form NN
in IN
small JJ
amounts NNS
`` ``
has VBZ
reduced VBN
the DT
symptoms NNS
of IN
a DT
person NN
suffering NN
from IN
AIDS NNP
. .
'' ''
A DT
veterinarian JJ
, ,
Cummins NNP
said VBD
he PRP
began VBD
experiments NNS
with IN
interferon NN
to TO
treat VB
illnesses NNS
in IN
cattle NN
. .
He PRP
offered VBD
a DT
pure NN
form NN
of IN
the DT
drug NN
to TO
Dr. NNP
Davy NNP
K. NNP
Koech NNP
, ,
the DT
director NN
of IN
the DT
Kenyan NNP
Medical NNP
Research NNP
Institute NNP
in IN
Nairobi NNP
, ,
for IN
use NN
on IN
AIDS NNP
patients NNS
. .
`` ``
Dr. NNP
Koech NNP
was VBD
desperate JJ
enough RB
to TO
try VB
something NN
new JJ
, ,
'' ''
Cummins NNP
said VBD
Wednesday NNP
. .
`` ``
And CC
he PRP
is VBZ
reporting VBG
positive JJ
results NNS
with IN
every DT
patient NN
he PRP
has VBZ
treated VBN
. .
'' ''
In IN
the DT
current JJ
issue NN
of IN
Biotechnology NNP
Newswatch NNP
, ,
Koech NNP
reported VBD
that IN
within IN
days NNS
of IN
taking VBG
oral JJ
alpha NN
interferon NN
all DT
of IN
his PRP$
99 CD
AIDS NNP
patients NNS
in IN
the DT
test NN
group NN
developed VBD
an DT
appetite NN
. .
Fever RB
, ,
diarrhea NN
and CC
fungal JJ
infections NNS
and CC
other JJ
symptoms NNS
subsided VBD
, ,
the DT
report NN
said VBD
. .
Dr. NNP
Anthony NNP
S. NNP
Fauci NNP
, ,
head NN
of IN
the DT
National NNP
Institutes NNPS
of IN
Allergy NNP
and CC
Infectious NNP
Disease NNP
in IN
Bethesda NNP
, ,
Md. NNP
, ,
said VBD
Wednesday NNP
the DT
results NNS
from IN
Africa NNP
were VBD
`` ``
astounding VBG
and CC
very RB
difficult JJ
to TO
believe VB
, ,
'' ''
but CC
`` ``
you PRP
have VBP
to TO
keep VB
an DT
open JJ
mind NN
. .
'' ''
Dr. NNP
Sidney NNP
Wolfe NNP
, ,
director NN
of IN
the DT
Health NNP
Research NNP
Group NNP
in IN
Washington NNP
, ,
D.C. NNP
, ,
said VBD
there EX
is VBZ
not RB
enough RB
data NNS
on IN
the DT
tests NNS
to TO
make VB
an DT
opinion NN
. .
Cummins NNS
agreed VBD
that IN
more JJR
tests NNS
need VBP
to TO
be VB
done VBN
. .
`` ``
People NNS
do VBP
n't RB
have VB
to TO
believe VB
it PRP
, ,
but CC
let VB
's VBZ
test NN
it PRP
, ,
'' ''
he PRP
said VBD
. .
`` ``
We PRP
need VBP
to TO
see VB
if IN
it PRP
's VBZ
a DT
true JJ
and CC
natural JJ
way NN
to TO
treat VB
AIDS NNP
. .
'' ''
Koech NNP
's POS
research NN
showed VBD
interferon NN
led VBN
to TO
a DT
significant JJ
increase NN
in IN
the DT
number NN
of IN
CD4 NNP
lymphocytes VBZ
, ,
the DT
white JJ
blood NN
cell NN
destroyed VBD
by IN
the DT
HIV NNP
virus VBZ
, ,
which WDT
causes NNS
acquired VBD
immune JJ
deficiency NN
syndrome NN
. .
Alpha NNP
interferon VBD
has VBZ
been VBN
scrutinized VBN
for IN
its PRP$
antiviral JJ
activity NN
since IN
its PRP$
discovery NN
more JJR
than IN
30 CD
years NNS
ago RB
. .
The DT
U.S. NNP
Food NNP
and CC
Drug NNP
Administration NNP
has VBZ
approved VBN
alpha NN
interferon NN
to TO
treat VB
Kaposi NNP
's POS
sarcoma NN
, ,
a DT
cancer NN
that WDT
occurs VBZ
commonly RB
among IN
people NNS
with IN
AIDS NNP
. .
But CC
the DT
drug NN
has VBZ
not RB
generally RB
been VBN
tested VBN
in IN
pill NN
form NN
because IN
of IN
the DT
belief NN
it PRP
would MD
be VB
destroyed VBN
by IN
stomach NN
acid NN
. .
Koech NNP
prepared VBD
the DT
drug NN
in IN
wafer NN
form NN
so RB
that IN
small JJ
doses NNS
could MD
be VB
absorbed VBN
through IN
the DT
mouth NN
. .
Cummins NNS
said VBD
a DT
veterinarian JJ
called VBN
him PRP
last JJ
year NN
seeking VBG
interferon NN
`` ``
to TO
treat VB
a DT
big JJ
dog NN
for IN
leukemia NN
. .
'' ''
Cummins NNP
later JJ
learned VBD
the DT
man NN
had VBD
AIDS NNP
and CC
was VBD
using VBG
the DT
interferon NN
to TO
treat VB
himself PRP
. .
The DT
man NN
agreed VBD
to TO
talk VB
to TO
The DT
Associated NNP
Press NNP
upon IN
condition NN
of IN
anonymiity NN
. .
The DT
47-year-old JJ
man NN
said VBD
interferon NN
was VBD
keeping VBG
him PRP
alive JJ
. .
`` ``
I PRP
contracted VBD
AIDS NNP
along IN
with IN
three CD
other JJ
people NNS
who WP
split NN
infected VBD
blood NN
during IN
a DT
transfusion NN
, ,
'' ''
he PRP
said VBD
Wednesday NNP
. .
`` ``
They PRP
are VBP
both DT
dead JJ
and CC
I PRP
am VBP
still RB
here RB
. .
'' ''
The DT
man NN
, ,
who WP
said VBD
he PRP
was VBD
diagnosed VBN
with IN
AIDS NNP
three CD
years NNS
ago RB
, ,
said VBD
the DT
drug NN
stimulated VBD
his PRP$
appetite NN
, ,
boosted VBD
his PRP$
low JJ
CD4 NNP
count NN
and CC
eradicated VBD
fever RB
blisters NNS
. .
Dr. NNP
Jordan NNP
U. NNP
Gutterman NNP
, ,
an DT
interferon NN
expert NN
at IN
the DT
M.D JJ
. .
Anderson NNP
Center NNP
in IN
Houston NNP
, ,
said VBD
Wednesday NNP
that IN
Cummins NNPS
' POS
use NN
of IN
interferon NN
to TO
treat VB
animals NNS
with IN
leukemia NN
produced VBN
`` ``
some DT
intriguing JJ
results NNS
. .
'' ''
`` ``
We PRP
are VBP
going VBG
to TO
start VB
studies NNS
ourselves NNS
with IN
interferon NN
for IN
cancer NN
treatment NN
, ,
'' ''
Gutterman NNP
said VBD
. .
`` ``
More JJR
studies NNS
need VBP
to TO
be VB
done VBN
to TO
provide VB
confirmation NN
for IN
the DT
results NNS
being VBG
reported VBN
. .
'' ''

<DOCNO> AP901008-0062
Dr. NNP
E. NNP
Donnall NNP
Thomas NNP
, ,
who WP
blazed VBN
a DT
new JJ
path NN
for IN
the DT
treatment NN
of IN
leukemia NN
when WRB
he PRP
performed VBD
the DT
first JJ
human NN
bone NN
marrow NN
transplant NN
in IN
1956 CD
, ,
said VBD
today NN
he PRP
always RB
considered VBN
the DT
Nobel NNP
Prize NNP
`` ``
a DT
long JJ
shot NN
at IN
best JJS
. .
'' ''
Thomas NNP
, ,
70 CD
, ,
of IN
Bellevue NNP
, ,
Wash. NNP
, ,
and CC
Joseph NNP
E. NNP
Murray NNP
, ,
71 CD
, ,
were VBD
awarded VBN
the DT
Nobel NNP
Prize NNP
in IN
medicine NN
today NN
, ,
officials NNS
in IN
Stockhom NNP
, ,
Sweden NNP
announced VBD
. .
Murray NNP
, ,
affiliated VBD
with IN
Brigham NNP
and CC
Women NNP
's POS
Hospital NNP
in IN
Boston NNP
, ,
was VBD
recognized VBN
for IN
his PRP$
discovery NN
of IN
a DT
method NN
to TO
prevent VB
tissue NN
rejection NN
when WRB
organs NNS
are VBP
transplanted VBN
in IN
people NNS
. .
Thomas NNP
, ,
with IN
the DT
Fred NNP
Hutchinson NNP
Cancer NNP
Research NNP
Center NNP
in IN
Seattle NNP
, ,
said VBD
he PRP
learned VBD
of IN
the DT
good JJ
news NN
when WRB
awakened VBN
by IN
a DT
reporter NN
's POS
telephone NN
call NN
early RB
this DT
morning NN
. .
`` ``
I PRP
really RB
thought VBD
this DT
work NN
was VBD
too RB
clinical JJ
to TO
ever RB
win VB
the DT
prize NN
, ,
'' ''
Thomas NNP
said VBD
. .
`` ``
There EX
are VBP
many JJ
scientist-researchers NNS
out IN
there RB
who WP
are VBP
eligible JJ
for IN
this DT
prize NN
. .
`` ``
It PRP
's VBZ
a DT
long JJ
shot NN
at IN
best JJS
, ,
and CC
it PRP
would MD
be VB
a DT
mistake NN
to TO
waste VB
time NN
thinking VBG
about IN
winning VBG
it PRP
. .
'' ''
The DT
prize NN
shared VBD
by IN
Murray NNP
and CC
Thomas NNP
, ,
worth NN
$ $
695 CD
, ,
000 CD
, ,
is VBZ
endowed VBN
by IN
the DT
will MD
of IN
dynamite JJ
inventor NN
Alfred NNP
Nobel NNP
, ,
who WP
died VBD
in IN
1896 CD
. .
Thomas NNP
said VBD
he PRP
has VBZ
n't RB
had VBD
time NN
yet RB
to TO
think VB
of IN
what WP
he PRP
will MD
do VB
with IN
the DT
money NN
. .
Thomas NNP
, ,
who WP
took VBD
after IN
his PRP$
father NN
and CC
fulfilled VBD
his PRP$
childhood NN
desire NN
to TO
become VB
a DT
doctor NN
, ,
performed VBN
the DT
first JJ
human NN
bone NN
marrow NN
transplant NN
in IN
Cooperstown NNP
, ,
N.Y. NNP
, ,
in IN
1956 CD
. .
The DT
surgical JJ
procedure NN
has VBZ
become VBN
standard JJ
treatment NN
for IN
many JJ
sufferers NNS
of IN
leukemia NN
and CC
lymphoma NN
, ,
which WDT
are VBP
types NNS
of IN
cancer NN
. .
Thomas NNP
joined VBD
the DT
University NNP
of IN
Washington NNP
faculty NN
in IN
1963 CD
and CC
went VBD
to TO
the DT
Hutchinson NNP
center NN
when WRB
it PRP
opened VBD
in IN
1975 CD
. .
The DT
center NN
is VBZ
now RB
one CD
of IN
the DT
world'sleading JJ
cancer NN
treatment NN
and CC
research NN
institutions NNS
. .
`` ``
I PRP
think VBP
it PRP
's VBZ
a DT
recognition NN
of IN
a DT
lot NN
of IN
work NN
by IN
a DT
lot NN
of IN
people NNS
who WP
have VBP
worked VBN
on IN
the DT
problems NNS
over IN
the DT
years NNS
. .
I PRP
have VBP
a DT
medical JJ
team NN
here RB
of IN
some DT
50 CD
physicians NNS
and CC
Ph.D.s NNS
who WP
now RB
work VBP
with IN
me PRP
on IN
this DT
. .
It PRP
's VBZ
been VBN
very RB
gratifying VBG
to TO
see VB
the DT
procedure NN
become NN
accepted VBD
as IN
the DT
primary JJ
form NN
of IN
treatment NN
for IN
leukemia NN
, ,
'' ''
Thomas NNP
said VBD
. .
In IN
a DT
bone NN
marrow NN
transplant NN
, ,
the DT
patient NN
's POS
diseased VBN
marrow NN
is VBZ
destroyed VBN
by IN
chemotherapy NN
and CC
radiation NN
. .
Disease-free JJ
marrow NN
is VBZ
removed VBN
by IN
needle NN
from IN
the DT
hip NN
bone NN
of IN
a DT
donor NN
, ,
often RB
a DT
relative JJ
, ,
and CC
dripped VBD
intravenously RB
into IN
the DT
patient NN
. .
In IN
time NN
, ,
the DT
transplanted VBN
cells NNS
begin VBP
to TO
grow VB
in IN
the DT
patient NN
's POS
marrow NN
and CC
produce VB
new JJ
white JJ
and CC
red VBD
blood NN
cells NNS
and CC
platelets NNS
. .

<DOCNO> AP900727-0024
Researchers NNS
have VBP
been VBN
unable JJ
to TO
definitively RB
link VB
fallout IN
from IN
atomic JJ
explosions NNS
in IN
Nevada NNP
during IN
the DT
1950s CD
to TO
the DT
higher JJR
than IN
normal JJ
leukemia NN
rate NN
in IN
neighboring VBG
Utah NNP
, ,
although IN
a DT
new JJ
study NN
does VBZ
suggest VBP
a DT
link NN
. .
Weapons NNS
tests NNS
in IN
Nevada NNP
by IN
the DT
old JJ
U.S. NNP
Atomic NNP
Energy NNP
Commission NNP
may MD
have VB
caused VBN
the DT
higher JJR
cancer NN
rate NN
in IN
the DT
neighboring NN
state NN
, ,
but CC
the DT
evidence NN
is VBZ
weak JJ
, ,
according VBG
to TO
a DT
study NN
conducted VBN
by IN
University NNP
of IN
Utah NNP
researchers NNS
to TO
be VB
published VBN
in IN
next JJ
week's NNS
Journal NNP
of IN
the DT
American NNP
Medical NNP
Association NNP
. .
`` ``
The DT
excess NN
of IN
acute NN
leukemias NNS
in IN
southwestern NN
Utah NNP
is VBZ
probably RB
not RB
due JJ
to TO
chance NN
and CC
may MD
be VB
attributable JJ
to TO
fallout VB
radiation NN
. .
However RB
, ,
the DT
estimated VBN
number NN
of IN
cases NNS
attributable JJ
to TO
fallout VB
in IN
this DT
region NN
is VBZ
small JJ
, ,
and CC
these DT
cases NNS
are VBP
indistinguishable JJ
from IN
other JJ
factors NNS
, ,
'' ''
the DT
study NN
said VBD
. .
If IN
a DT
direct JJ
relationship NN
could MD
have VB
been VBN
established VBN
between IN
fallout IN
and CC
leukemias NNS
`` ``
there EX
would MD
also RB
have VB
been VBN
a DT
substantial JJ
number NN
of IN
cases NNS
attributable JJ
to TO
fallout VB
in IN
the DT
rest NN
of IN
the DT
state NN
, ,
because IN
of IN
its PRP$
much JJ
larger NN
population NN
, ,
'' ''
the DT
study NN
said VBD
. .
But CC
no DT
such JJ
increased VBN
risk NN
was VBD
found VBN
outside IN
southwest JJS
Utah NNP
, ,
it PRP
said VBD
. .
`` ``
There EX
was VBD
an DT
excess JJ
of IN
acute JJ
leukemia NN
cases NNS
, ,
but CC
it PRP
was VBD
not RB
statistically RB
significant JJ
, ,
'' ''
concluded VBD
Dr. NNP
Joseph NNP
L. NNP
Lyon NNP
, ,
one CD
of IN
the DT
researchers NNS
with IN
the DT
University NNP
of IN
Utah NNP
's POS
Department NNP
of IN
Family NNP
and CC
Preventative NNP
Medicine NNP
. .
The DT
U.S. NNP
House NNP
last JJ
month NN
approved VBD
a DT
bill NN
creating VBG
a DT
$ $
100 CD
million CD
trust NN
fund NN
to TO
compensate VB
those DT
living VBG
downwind NN
from IN
the DT
Nevada NNP
test NN
site NN
for IN
alleged JJ
radiation NN
injuries NNS
. .
Up IN
to TO
1 CD
, ,
300 CD
alleged VBN
fallout IN
victims NNS
could MD
collect VB
up RP
to TO
$ $
50 CD
, ,
000 CD
each DT
under IN
the DT
legislation NN
, ,
now RB
being VBG
considered VBN
by IN
the DT
Senate NNP
. .
More JJR
than IN
100 CD
atomic JJ
bombs NNS
were VBD
set VBN
off RP
above IN
ground NN
in IN
Nevada NNP
between IN
1951 CD
and CC
1958 CD
, ,
researchers NNS
said VBD
. .
Fallout IN
from IN
those DT
blasts NNS
spread VBP
across IN
southwestern JJ
Utah NNP
. .
In IN
one CD
county NN
, ,
the DT
average JJ
resident NN
was VBD
exposed VBN
to TO
nearly RB
30 CD
times NNS
as RB
much JJ
radiation NN
as IN
occurred VBN
naturally RB
, ,
researchers NNS
found VBD
. .
But CC
because IN
leukemia NNS
leaves NNS
no DT
traces NNS
as IN
to TO
its PRP$
source NN
, ,
it PRP
was VBD
impossible JJ
to TO
determine VB
whether IN
individual JJ
deaths NNS
were VBD
caused VBN
by IN
exposure NN
to TO
fallout VB
, ,
Lyon NNP
said VBD
Thursday NNP
. .
`` ``
You PRP
ca MD
n't RB
say VB
this DT
leukemia NN
was VBD
caused VBN
by IN
smoking NN
, ,
this DT
one CD
was VBD
caused VBN
by IN
radiation NN
_ NNP
there EX
's VBZ
nothing NN
in IN
the DT
disease NN
that IN
says VBZ
what WP
it PRP
was VBD
caused VBN
by IN
. .
You PRP
ca MD
n't RB
sort VB
out RP
the DT
random NN
cases NNS
from IN
those DT
involving VBG
fallout IN
, ,
'' ''
Lyon NNP
said VBD
. .
Researchers NNS
analyzed VBD
more JJR
than IN
6 CD
, ,
500 CD
deaths NNS
in IN
Utah NNP
between IN
1952 CD
and CC
1981 CD
for IN
the DT
$ $
6.8 CD
million CD
, ,
federally RB
funded VBN
study NN
. .
They PRP
confined VBD
their PRP$
analysis NN
to TO
members NNS
of IN
the DT
Mormon NNP
Church NNP
, ,
because IN
church NN
records NNS
could MD
be VB
used VBN
to TO
determine VB
who WP
had VBD
died VBN
and CC
moved VBD
into IN
or CC
out IN
of IN
the DT
area NN
during IN
the DT
testing NN
period NN
. .
Earlier JJR
studies NNS
indicated VBD
the DT
state NN
's POS
leukemia NN
rate NN
was VBD
1.45 CD
times NNS
higher JJR
than IN
that DT
across NN
the DT
country NN
, ,
and CC
2.45 CD
times NNS
higher JJR
for IN
children NNS
. .
But CC
those DT
studies NNS
did VBD
n't RB
directly RB
link VB
that IN
higher JJR
rate NN
to TO
radiation NN
fallout IN
, ,
Lyon NNP
said VBD
. .
The DT
study NN
did VBD
show NN
an DT
apparently RB
significant JJ
link NN
between IN
fallout IN
and CC
leukemia NN
among IN
those DT
who WP
were VBD
younger JJR
than IN
20 CD
when WRB
they PRP
were VBD
exposed VBN
to TO
the DT
radiation NN
. .
In IN
Washington NNP
County NNP
, ,
where WRB
the DT
highest JJS
radiation NN
levels NNS
were VBD
recorded VBN
, ,
there EX
were VBD
17 CD
leukemia NNS
deaths NNS
. .
Five CD
were VBD
among IN
people NNS
younger JJR
than IN
20 CD
when WRB
exposed VBN
, ,
making VBG
them PRP
nearly RB
eight CD
times NNS
more JJR
likely JJ
to TO
die VB
from IN
acute JJ
leukemia NN
than IN
others NNS
their PRP$
age NN
. .
But CC
researchers NNS
said VBD
that IN
study NN
sample NNS
was VBD
too RB
small JJ
to TO
be VB
significant JJ
. .

<DOCNO> WSJ880803-0161
In IN
your PRP$
second-front-page NN
article NN
`` ``
Approved JJ
Drugs NNS
Find NNP
Unapproved NNP
Uses NNP
'' ''
( :
July NNP
12 CD
) CD
, ,
your PRP$
approach NN
to TO
the DT
problem NN
of IN
Food NNP
and CC
Drug NNP
Administration NNP
approval NN
of IN
medicines NNS
fails NNS
to TO
take VB
into IN
account NN
the DT
complexities NNS
of IN
modern JJ
medicine NN
. .
For IN
example NN
, ,
picture NN
yourself PRP
sitting VBG
in IN
front NN
of IN
me PRP
in IN
my PRP$
office NN
. .
`` ``
Mr. NNP
X NNP
, ,
'' ''
I PRP
might MD
begin VB
, ,
`` ``
you PRP
unfortunately RB
have VBP
a DT
rare NN
cancer NN
of IN
the DT
adrenal JJ
gland NN
. .
Treatment NNP
of IN
this DT
is VBZ
very RB
difficult JJ
, ,
and CC
up RP
to TO
this DT
point NN
, ,
all DT
patients NNS
with IN
this DT
have VBP
died VBN
. .
However RB
, ,
at IN
one CD
of IN
our PRP$
recent JJ
cancer NN
meetings NNS
, ,
there EX
were VBD
two CD
reports NNS
that WDT
a DT
combination NN
of IN
the DT
chemotherapy NN
drugs NNS
etoposide VBP
and CC
cisplatin NN
were VBD
able JJ
to TO
shrink VB
this DT
cancer NN
in IN
10 CD
of IN
11 CD
patients NNS
. .
These DT
are VBP
not RB
experimental JJ
drugs NNS
, ,
but CC
drugs NNS
well RB
known VBN
to TO
us PRP
for IN
the DT
treatment NN
of IN
other JJ
cancers NNS
. .
Unfortunately RB
, ,
these DT
drugs NNS
are VBP
not RB
approved VBN
for IN
this DT
cancer NN
, ,
since IN
adrenocortical JJ
cancer NN
strikes VBZ
only RB
a DT
few JJ
hundred VBN
patients NNS
a DT
year NN
. .
`` ``
`` ``
Well NNP
, ,
Doc NNP
, ,
'' ''
you PRP
answer JJR
, ,
`` ``
I PRP
'll MD
go VB
ahead RB
and CC
take VB
the DT
drugs NNS
anyway VBP
; :
those DT
odds NNS
sound VBP
pretty RB
good JJ
. .
`` ``
`` ``
Yes VBZ
, ,
they PRP
do VBP
, ,
Mr. NNP
X NNP
. .
Unfortunately RB
, ,
your PRP$
insurer NN
does VBZ
not RB
pay VB
for IN
any DT
medicines NNS
given VBN
for IN
'unapproved JJ
' ''
indications NNS
. .
Since IN
you PRP
have VBP
a DT
rare NN
disease NN
, ,
you PRP
certainly RB
can MD
not RB
expect VB
these DT
drug NN
companies NNS
to TO
spend VB
millions NNS
of IN
dollars NNS
to TO
get VB
approval NN
for IN
such JJ
a DT
rare NN
problem NN
, ,
can MD
you PRP
? .
If IN
you PRP
owned VBN
stock NN
in IN
them PRP
, ,
you PRP
'd MD
throw VB
the DT
management NN
out IN
. .
I PRP
'd MD
like VB
to TO
give VB
you PRP
the DT
drugs NNS
, ,
but CC
since IN
you PRP
live VBP
in IN
Massachusetts NNP
, ,
your PRP$
insurer NN
makes VBZ
me PRP
take VBP
assignment NN
for IN
your PRP$
treatment NN
, ,
and CC
not RB
only RB
will MD
they PRP
not RB
pay VBP
me PRP
, ,
by IN
law NN
you PRP
ca MD
n't RB
pay VB
me PRP
out RP
of IN
your PRP$
pocket NN
either NN
. .
These DT
are VBP
expensive JJ
drugs NNS
, ,
and CC
we PRP
ca MD
n't RB
give VB
them PRP
away RB
. .
`` ``
`` ``
But CC
Doc NNP
, ,
you PRP
're VBP
an DT
expert NN
in IN
cancer NN
medicine NN
; :
certainly RB
if IN
you PRP
tell VBP
the DT
insurer NN
that IN
this DT
is VBZ
the DT
best JJS
thing NN
for IN
me PRP
, ,
it PRP
will MD
be VB
OK. NNP
'' ''
`` ``
I PRP
wish VBP
it PRP
were VBD
that IN
simple JJ
, ,
Mr. NNP
X NNP
, ,
'' ''
I PRP
go VBP
on IN
, ,
`` ``
but CC
your PRP$
policy NN
clearly RB
states VBZ
that IN
only RB
drugs NNS
approved VBN
by IN
the DT
FDA NNP
for IN
that DT
disease NN
can MD
be VB
reimbursed VBN
; :
how WRB
else RB
can MD
they PRP
hold VBP
down RP
runaway NN
costs NNS
? .
But CC
do VBP
n't RB
feel VB
bad JJ
; :
you PRP
're VBP
not RB
alone RB
. .
Why WRB
, ,
when WRB
etoposide JJ
first JJ
came NN
out IN
every DT
oncologist NN
already RB
knew VBD
that IN
it PRP
was VBD
the DT
best JJS
single JJ
drug NN
for IN
small JJ
cell NN
lung NN
cancer NN
. .
There EX
are VBP
a DT
lot NN
of IN
those DT
patients NNS
( VBP
why WRB
could MD
n't RB
you PRP
get VB
a DT
common JJ
disease NN
? .
) NN
and CC
it PRP
only RB
took VBD
the DT
FDA NNP
a DT
few JJ
years NNS
to TO
approve VB
the DT
application NN
for IN
that DT
use NN
. .
Of IN
course NN
, ,
the DT
average JJ
patient NN
with IN
that DT
disease NN
lived VBD
only RB
11 CD
months NNS
then RB
, ,
but CC
what WP
are VBP
10 CD
, ,
000 CD
or CC
20 CD
, ,
000 CD
lives NNS
compared VBN
with IN
the DT
safety NN
of IN
a DT
whole JJ
country NN
, ,
not RB
to TO
mention VB
the DT
asset NN
base NN
of IN
the DT
insurance NN
companies NNS
? .
`` ``
`` ``
Well NNP
, ,
I PRP
certainly RB
understand VBP
the DT
problem NN
, ,
Doc NNP
. .
Let NNP
's POS
just RB
write JJ
to TO
the DT
FDA NNP
, ,
tell VBD
them PRP
the DT
facts NNS
you PRP
told VBD
me PRP
, ,
and CC
they PRP
'll MD
approve VB
it PRP
. .
`` ``
`` ``
You PRP
may MD
understand VB
your PRP$
problem NN
, ,
Mr. NNP
X NNP
, ,
but CC
you PRP
do VBP
n't RB
understand VB
the DT
FDA NNP
. .
First NNP
of IN
all DT
, ,
they PRP
require VBP
a DT
fairly RB
large JJ
amount NN
of IN
data NNS
to TO
approve VB
a DT
drug NN
, ,
but CC
there EX
are VBP
n't RB
enough JJ
cases NNS
of IN
your PRP$
disease NN
in IN
a DT
year NN
to TO
give VB
a DT
large JJ
enough RB
data NNS
base NN
. .
Second JJ
, ,
only RB
the DT
company NN
that WDT
manufactures VBZ
the DT
drug NN
can MD
apply VB
for IN
approval NN
. .
As IN
we PRP
discussed VBD
, ,
that IN
usually RB
requires VBZ
several JJ
years NNS
and CC
costs NNS
tens NNS
of IN
millions NNS
of IN
dollars NNS
. .
Once RB
a DT
drug NN
is VBZ
on IN
the DT
market NN
for IN
a DT
common JJ
disease NN
, ,
why WRB
on IN
earth JJ
should MD
they PRP
spend VBP
the DT
money NN
for IN
a DT
rare NN
disease NN
? .
They PRP
'd MD
never RB
make VB
back RB
their PRP$
investment NN
. .
`` ``
`` ``
But CC
, ,
Doc NNP
, ,
I PRP
'm VBP
going VBG
to TO
die VB
of IN
this DT
, ,
'' ''
you PRP
plead VBP
. .
`` ``
This DT
just RB
is VBZ
n't RB
fair JJ
. .
Anyway NNP
, ,
my PRP$
insurance NN
broker NN
always RB
told VBD
me PRP
it PRP
would MD
pay VB
for IN
everything NN
. .
`` ``
`` ``
I PRP
sympathize VBP
, ,
but CC
think VBP
of IN
the DT
whole JJ
country NN
. .
Why WRB
, ,
this DT
policy NN
has VBZ
saved VBN
thousands NNS
from IN
damaging VBG
their PRP$
scalps NNS
trying VBG
to TO
grow VB
hair NN
with IN
minoxidil NN
. .
Anyway NNP
, ,
this DT
morning NN
already RB
, ,
I PRP
've VBP
had VBN
to TO
tell VB
one CD
women NNS
with IN
chronic JJ
myelocytic JJ
leukemia NN
that WDT
I PRP
would MD
like VB
to TO
treat VB
her PRP$
with IN
alpha-interferon JJ
, ,
but CC
unfortunately RB
she PRP
did VBD
n't RB
have VB
hairy JJ
cell NN
leukemia NN
. .
Another DT
woman NN
with IN
breast JJ
cancer NN
needed VBN
mitoxantrone NN
, ,
and CC
I PRP
tried VBD
to TO
figure VB
out RP
how WRB
I PRP
could MD
convince VB
her PRP
insurer JJR
that IN
she PRP
had VBD
acute JJ
leukemia NN
. .
`` ``
`` ``
Doc NNP
, ,
at IN
least JJS
my PRP$
insurance NN
premiums NNS
have VBP
been VBN
held VBN
down RP
. .
But CC
how WRB
could MD
we VB
have VBP
come VBN
to TO
something NN
like IN
this DT
, ,
in IN
this DT
day NN
and CC
age NN
? .
I PRP
figured VBD
that IN
by IN
1990 CD
we PRP
'd MD
have VB
thought VBN
about IN
it PRP
. .
`` ``
`` ``
Well NNP
, ,
at IN
least JJS
you PRP
wo MD
n't RB
have VB
to TO
worry VB
about IN
the DT
side NN
effects NNS
. .
`` ``
Joseph NNP
J. NNP
Muscato NNP
M.D NNP
. .
Columbia NNP
, ,
Mo NNP
. .

<DOCNO> WSJ880128-0006
More JJR
evidence NN
emerged VBD
that IN
a DT
cancer NN
virus NN
is VBZ
contaminating VBG
the DT
nation NN
's POS
supply NN
of IN
banked VBN
blood NN
. .
Researchers NNS
in IN
New NNP
York NNP
City NNP
reported VBD
evidence NN
that IN
some DT
hospital JJ
patients NNS
who WP
had VBD
received VBN
multiple NN
blood NN
transfusions NNS
had VBD
been VBN
infected VBN
with IN
the DT
virus NNS
. .
This DT
follows VBZ
other JJ
, ,
tentative JJ
reports NNS
in IN
recent JJ
months NNS
hinting VBG
that IN
1 CD
% NN
to TO
4 CD
% NN
of IN
blood NN
donors NNS
in IN
some DT
localities NNS
and CC
as IN
many JJ
as IN
9 CD
% NN
of IN
drug NN
addicts NNS
tested VBD
in IN
New NNP
York NNP
City NNP
may MD
be VB
infected VBN
with IN
the DT
virus NNS
. .
Such JJ
reports NNS
prompted VBD
the DT
American NNP
Red NNP
Cross NNP
last JJ
November NNP
to TO
urge VB
rapid JJ
development NN
and CC
federal JJ
approval NN
of IN
a DT
definitive JJ
test NN
that WDT
could MD
be VB
used VBN
to TO
screen VB
blood NN
donors NNS
for IN
evidence NN
of IN
infection NN
by IN
the DT
cancer NN
virus VBZ
. .
The DT
cancer NN
virus VBZ
is VBZ
related VBN
to TO
the DT
AIDS NNP
virus VBZ
and CC
is VBZ
believed VBN
to TO
be VB
spread VBN
by IN
the DT
same JJ
routes NNS
, ,
that IN
is VBZ
, ,
by IN
blood NN
transfusions NNS
, ,
sexual JJ
contact NN
and CC
the DT
sharing NN
of IN
contaminated VBN
needles NNS
among IN
drug NN
addicts NNS
. .
The DT
virus NN
is VBZ
known VBN
to TO
cause VB
a DT
rare NN
but CC
rapidly RB
fatal JJ
type NN
of IN
leukemia NN
that IN
, ,
until IN
now RB
, ,
has VBZ
been VBN
confined VBN
largely RB
to TO
southern VB
Japan NNP
, ,
and CC
certain JJ
areas NNS
in IN
Africa NNP
and CC
the DT
Caribbean NNP
. .
It PRP
also RB
has VBZ
been VBN
linked VBN
to TO
a DT
multiple NN
sclerosis NN
-- :
like IN
nerve NN
ailment NN
, ,
called VBN
tropical JJ
spastic JJ
paraparesis NN
, ,
occurring VBG
in IN
children NNS
in IN
the DT
Caribbean NNP
. .
The DT
virus NN
is VBZ
known VBN
as IN
HTLV-1 -NONE-
, ,
for IN
human JJ
T-cell JJ
leukemia NN
virus VBZ
. .
The DT
presence NN
of IN
the DT
virus NN
in IN
the DT
blood NN
supply NN
poses NNS
an DT
unusual JJ
public JJ
health NN
dilemma NN
. .
Although IN
only RB
1 CD
% NN
of IN
people NNS
infected VBN
with IN
the DT
virus NNS
develop VBP
leukemia NN
, ,
the DT
blood NN
cancer NN
does VBZ
n't RB
occur VB
until IN
many JJ
years NNS
, ,
perhaps RB
decades VBZ
, ,
after IN
the DT
initial JJ
infection NN
. .
An DT
increase NN
in IN
the DT
incidence NN
of IN
leukemia NN
that IN
would MD
confirm VB
that IN
the DT
virus NN
is VBZ
spreading VBG
among IN
Americans NNPS
might MD
n't RB
occur VB
for IN
another DT
decade NN
. .
By IN
that DT
time NN
, ,
millions NNS
might MD
have VB
become VBN
infected VBN
, ,
leading VBG
to TO
an DT
epidemic JJ
of IN
tens NNS
of IN
thousands NNS
of IN
cases NNS
lasting VBG
well RB
into IN
the DT
next JJ
century NN
. .
The DT
newest JJS
evidence NN
of IN
the DT
virus NN
's POS
presence NN
in IN
the DT
blood NN
supply NN
was VBD
reported VBN
in IN
the DT
New NNP
England NNP
Journal NNP
of IN
Medicine NNP
by IN
a DT
research NN
team NN
at IN
Memorial NNP
Sloan-Kettering NNP
Cancer NNP
Center NNP
in IN
New NNP
York NNP
. .
They PRP
tested VBD
blood NN
samples NNS
from IN
211 CD
patients NNS
who WP
had VBD
been VBN
treated VBN
at IN
the DT
center NN
for IN
various JJ
types NNS
of IN
leukemia NN
. .
None NN
of IN
the DT
patients NNS
suffered VBD
the DT
T-cell NNP
type NN
of IN
leukemia NN
caused VBN
by IN
the DT
virus NN
, ,
but CC
all DT
had VBD
received VBN
multiple NN
transfusions NNS
of IN
blood NN
during IN
their PRP$
therapy NN
. .
Six CD
of IN
the DT
patients NNS
had VBD
antibodies NNS
to TO
HTLV-1 -NONE-
, ,
indicating VBG
they PRP
had VBD
been VBN
exposed VBN
to TO
the DT
virus NN
. .
All DT
of IN
these DT
patients NNS
died VBD
of IN
their PRP$
blood NN
cancers NNS
long RB
before IN
there EX
was VBD
any DT
chance NN
of IN
developing VBG
disease NN
from IN
the DT
HTLV-1 NN
. .
The DT
researchers NNS
said VBD
they PRP
could MD
n't RB
determine VB
when WRB
the DT
six CD
patients NNS
had VBD
been VBN
infected VBN
. .
The DT
tests NNS
were VBD
run VBN
on IN
blood NN
samples NNS
that WDT
had VBD
been VBN
taken VBN
and CC
stored VBD
for IN
other JJ
reasons NNS
. .
But CC
in IN
three CD
of IN
the DT
patients NNS
, ,
samples NNS
were VBD
available JJ
that IN
were VBD
taken VBN
before IN
the DT
transfusions NNS
. .
These DT
were VBD
negative JJ
for IN
the DT
virus NN
antibodies NNS
, ,
while IN
samples NNS
from IN
the DT
same JJ
patients NNS
taken VBN
after IN
transfusions NNS
were VBD
positive JJ
. .
There EX
was VBD
n't RB
any DT
way NN
of IN
determining VBG
who WP
donated VBN
the DT
contaminated VBN
blood NN
. .
Last JJ
fall NN
, ,
the DT
Red NNP
Cross NNP
said VBD
it PRP
had VBD
completed VBN
preliminary JJ
screening NN
of IN
blood NN
from IN
40 CD
, ,
000 CD
healthy JJ
donors NNS
and CC
found VBN
10 CD
who WP
might MD
be VB
positive JJ
for IN
HTLV-1 -NONE-
exposure NN
. .
More JJR
elaborate JJ
and CC
time-consuming JJ
tests NNS
now RB
are VBP
being VBG
done NN
to TO
check VB
the DT
accuracy NN
of IN
this DT
preliminary JJ
screening NN
. .
This DT
prevalence NN
, ,
though IN
tiny JJ
, ,
is VBZ
about IN
the DT
same JJ
as IN
the DT
prevalence NN
of IN
the DT
acquired VBN
immune NN
deficiency NN
syndrome NN
virus VBZ
in IN
donated VBN
blood NN
before IN
screening VBG
programs NNS
began VBD
. .
Studies NNS
in IN
Japan NNP
have VBP
confirmed VBN
that IN
HTLV-1 -NONE-
can MD
be VB
transmitted VBN
by IN
blood NN
transfusions NNS
, ,
but CC
so RB
far RB
there EX
are VBP
n't RB
any DT
known VBN
cases NNS
of IN
T-cell NNP
leukemia NN
developing VBG
in IN
people NNS
so IN
infected JJ
. .
The DT
New NNP
York NNP
scientists NNS
noted VBD
, ,
however RB
, ,
that IN
patients NNS
such JJ
as IN
theirs NNS
, ,
who WP
receive JJ
multiple NN
transfusions NNS
, ,
can MD
serve VB
as IN
a DT
`` ``
sensitive JJ
indicator NN
'' ''
of IN
the DT
virus NN
's POS
presence NN
in IN
the DT
blood NN
supply NN
. .

<DOCNO> AP880607-0013
A DT
new JJ
treatment NN
is VBZ
available JJ
for IN
the DT
estimated VBN
8 CD
million CD
Americans NNS
who WP
suffer VBP
each DT
year NN
from IN
genital JJ
warts NNS
. .
The DT
Food NNP
and CC
Drug NNP
Administration NNP
announced VBD
Monday NNP
that IN
it PRP
has VBZ
OK NNP
'd NNP
direct JJ
injection NN
of IN
genetically RB
engineered VBN
alpha NN
interferon NN
into IN
the DT
warts NNS
. .
The DT
FDA NNP
said VBD
a DT
study NN
of IN
192 CD
patients NNS
showed VBD
they PRP
exhibited VBD
marked VBN
improvement NN
after IN
receiving VBG
interferon NN
injections NNS
three CD
times NNS
a DT
week NN
for IN
up IN
to TO
three CD
weeks NNS
. .
Of IN
the DT
192 CD
, ,
42 CD
percent NN
experienced VBD
complete JJ
clearing NN
of IN
all DT
their PRP$
treated VBN
warts NNS
, ,
24 CD
percent NN
had VBD
a DT
75 CD
percent NN
to TO
99 CD
percent NN
reduction NN
in IN
the DT
size NN
of IN
their PRP$
treated VBN
warts NNS
and CC
18 CD
percent NN
had VBD
a DT
50 CD
percent NN
to TO
74 CD
percent NN
reduction NN
in IN
the DT
size NN
of IN
their PRP$
treated VBN
warts NNS
, ,
the DT
FDA NNP
said VBD
. .
Previously RB
, ,
the DT
most RBS
effective JJ
treatments NNS
were VBD
painful JJ
and CC
potentially RB
scarring VBG
removal NN
by IN
freezing NN
or CC
burning VBG
. .
Some DT
types NNS
of IN
genital JJ
warts NNS
can MD
be VB
treated VBN
with IN
direct JJ
application NN
of IN
conventional JJ
anti-infective JJ
drugs NNS
, ,
but CC
this DT
treatment NN
often RB
is VBZ
not RB
effective JJ
. .
Alpha NNP
interferon VBD
was VBD
first JJ
approved VBN
in IN
June NNP
1986 CD
as IN
a DT
treatment NN
for IN
hairy NN
cell NN
leukemia NN
_ NNP
a DT
rare NN
form NN
of IN
leukemia NN
. .
Although IN
the DT
presence NN
of IN
genital JJ
warts NNS
is VBZ
more RBR
distressing VBG
than IN
health-threatening JJ
, ,
some DT
studies NNS
have VBP
suggested VBN
there EX
could MD
be VB
a DT
relationship NN
in IN
women NNS
between IN
the DT
warts NNS
and CC
later JJ
development NN
of IN
cervical JJ
cancer NN
. .
Adverse NNP
reactions NNS
experienced VBD
during IN
clinical JJ
trials NNS
were VBD
mild VBN
flu-like JJ
symptoms NNS
. .
The DT
drug NN
is VBZ
not RB
recommended VBN
for IN
use NN
in IN
pregnant JJ
women NNS
since IN
animal JJ
studies NNS
have VBP
shown VBN
the DT
treatment NN
may MD
cause VB
abortions NNS
. .
Schering VBG
Corp. NNP
of IN
Kenilworth NNP
, ,
N.J. NNP
, ,
will MD
market VB
the DT
alpha NN
interferon NN
treatment NN
under IN
the DT
Intron-A NNP
brand NN
name NN
. .

<DOCNO> WSJ900419-0016
The DT
results NNS
need VBP
to TO
be VB
replicated VBN
by IN
other JJ
researchers NNS
before IN
definitive JJ
conclusions NNS
can MD
be VB
made VBN
, ,
and CC
the DT
long-term JJ
effect NN
of IN
the DT
treatment NN
remains VBZ
unknown NN
. .
But CC
the DT
initial JJ
experience NN
with IN
the DT
compound NN
is VBZ
especially RB
promising VBG
, ,
and CC
an DT
apparent JJ
improvement NN
over IN
other JJ
therapy NN
for IN
the DT
disease NN
, ,
scientists NNS
said VBD
. .
`` ``
There EX
are VBP
n't RB
many JJ
{ :
drugs NNS
} VBP
where WRB
you PRP
can MD
administer VB
one CD
course NN
of IN
treatment NN
and CC
have VB
the DT
disease NN
go NN
away RB
and CC
stay NN
away RB
for IN
as RB
long JJ
as IN
four CD
years NNS
, ,
'' ''
says VBZ
Lawrence NNP
Piro NNP
, ,
chief NN
of IN
cancer NN
research NN
at IN
Scripps NNP
Clinic NNP
& CC
amp VB
; :
Research NNP
Foundation NNP
, ,
La NNP
Jolla NNP
, ,
Calif. NNP
, ,
where WRB
the DT
drug NN
was VBD
developed VBN
. .
`` ``
The DT
leukemia NN
has VBZ
n't RB
come VBN
back RB
in IN
any DT
of IN
the DT
patients NNS
we PRP
treated VBD
. .
`` ``
The DT
study NN
is VBZ
published VBN
in IN
today NN
's POS
New NNP
England NNP
Journal NNP
of IN
Medicine NNP
. .
`` ``
It PRP
is VBZ
without IN
doubt NN
the DT
most JJS
effective JJ
treatment NN
for IN
hairy-cell JJ
leukemia NN
, ,
in IN
terms NNS
of IN
rapidity NN
of IN
response NN
, ,
'' ''
adds VBZ
Elihu NNP
H. NNP
Estey NNP
, ,
a DT
cancer NN
researcher NN
at IN
the DT
University NNP
of IN
Texas-M.D JJ
. .
Anderson NNP
Cancer NNP
Center NNP
, ,
Houston NNP
. .
Dr. NNP
Estey NNP
recently RB
began VBD
treating VBG
patients NNS
with IN
2-CdA CD
and CC
has VBZ
had VBN
similar JJ
results NNS
with IN
five CD
patients NNS
. .
`` ``
It PRP
's VBZ
a DT
striking JJ
finding NN
, ,
'' ''
he PRP
says VBZ
. .
`` ``
It PRP
's VBZ
very RB
unlikely RB
to TO
be VB
a DT
fluke NN
. .
`` ``
Hairy-cell JJ
leukemia NN
, ,
so-called JJ
because IN
of IN
the DT
appearance NN
of IN
the DT
cancerous JJ
cells NNS
under IN
the DT
microscope NN
, ,
affects NNS
about IN
6 CD
, ,
000 CD
people NNS
in IN
the DT
U.S. NNP
, ,
with IN
600 CD
new JJ
cases NNS
a DT
year NN
. .
As IN
the DT
disease NN
progresses VBZ
, ,
patients NNS
become VBP
anemic JJ
, ,
are VBP
vulnerable JJ
to TO
infection NN
and CC
often RB
need VBP
blood NN
transfusions NNS
. .
Until IN
the DT
mid-1980s NNS
, ,
treatments NNS
were VBD
ineffective JJ
, ,
and CC
patients NNS
often RB
died VBD
of IN
blood NN
problems NNS
and CC
infections NNS
. .
Since IN
then RB
, ,
alpha NN
interferon NN
, ,
a DT
drug NN
sold VBN
by IN
Hoffmann-La NNP
Roche NNP
Inc. NNP
and CC
Schering-Plough JJ
Corp. NNP
and CC
an DT
experimental JJ
drug NN
called VBN
deoxycoformycin NN
have VBP
significantly RB
reduced VBN
death NN
rates NNS
from IN
hairy-cell NNP
leukemia NN
. .
Hoffmann-La NN
Roche NNP
is VBZ
the DT
U.S. NNP
subsidiary NN
of IN
F. NNP
Hoffmann-La NNP
Roche NNP
& CC
amp VB
; :
Co. NNP
of IN
Switzerland NNP
. .
But CC
neither DT
drug NN
is VBZ
as RB
effective JJ
as IN
2-CdA CD
appears NNS
to TO
be VB
in IN
low JJ
doses NNS
and CC
both DT
can MD
cause VB
such PDT
side NN
effects NNS
as IN
nausea NN
, ,
vomiting VBG
, ,
skin NN
rashes NNS
and CC
nervous-system JJ
disorders NNS
, ,
researchers NNS
say VBP
. .
`` ``
With IN
the DT
lack NN
of IN
toxicity NN
and CC
the DT
ease NN
with IN
which WDT
people NNS
go VBP
into IN
remission NN
{ :
with IN
2-CdA CD
} CD
, ,
I PRP
think VBP
there's JJ
something NN
really RB
going VBG
on IN
here RB
, ,
'' ''
says VBZ
Ellin NNP
Berman NNP
, ,
a DT
staff NN
leukemia NN
doctor NN
at IN
Memorial NNP
Sloan NNP
Kettering NNP
Cancer NNP
Center NNP
, ,
New NNP
York NNP
. .
Scripps NNS
said VBD
it PRP
negotiated VBD
an DT
agreement NN
with IN
a DT
subsidiary NN
of IN
Johnson NNP
& CC
amp VB
; :
Johnson NNP
, ,
New NNP
Brunswick NNP
, ,
N.J. NNP
, ,
to TO
produce VB
and CC
distribute VB
2-CdA CD
to TO
other JJ
centers NNS
for IN
broader JJR
clinical JJ
trials NNS
. .
The DT
researchers NNS
said VBD
the DT
drug NN
is VBZ
easy JJ
to TO
produce VB
and CC
thus RB
is VBZ
likely JJ
to TO
be VB
less JJR
expensive JJ
than IN
other JJ
cancer NN
treatments NNS
. .
In IN
the DT
12-patient JJ
study NN
, ,
2-CdA CD
, ,
short JJ
for IN
2-chlorodeoxyadenosine CD
, ,
was VBD
administered VBN
continuously RB
for IN
seven CD
days NNS
to TO
patients NNS
aged VBN
36 CD
to TO
61 CD
. .
Within NNP
eight VBD
to TO
10 CD
weeks NNS
, ,
11 CD
of IN
the DT
patients NNS
had VBD
no DT
trace NN
of IN
cancer NN
in IN
their PRP$
blood NN
or CC
bone NN
marrow NN
; :
the DT
12th JJ
had VBD
a DT
small JJ
amount NN
remaining VBG
in IN
the DT
marrow NN
, ,
but CC
he PRP
declined VBD
further RB
bone NN
marrow NN
monitoring VBG
, ,
Dr. NNP
Piro NNP
said VBD
. .
His PRP$
blood NN
tests NNS
are VBP
normal JJ
, ,
Dr. NNP
Piro NNP
added VBD
. .
None NN
of IN
the DT
patients NNS
have VBP
had VBN
a DT
relapse NN
; :
complete JJ
remission NN
has VBZ
lasted VBN
from IN
seven CD
to TO
46 CD
months NNS
after IN
treatment NN
, ,
according VBG
to TO
the DT
study NN
. .
`` ``
When WRB
you PRP
can MD
make VB
all PDT
the DT
disease NN
go NN
away RB
with IN
a DT
single JJ
infusion NN
of IN
therapy NN
, ,
you PRP
have VBP
a DT
disease NN
which WDT
may MD
be VB
able JJ
to TO
be VB
cured VBN
, ,
'' ''
Dr. NNP
Piro NNP
said VBD
. .
But CC
because IN
hairy-cell JJ
leukemia NN
proliferates NNS
slowly RB
, ,
a DT
relapse NN
could MD
occur VB
long JJ
after IN
treatment NN
. .
Longer NNP
follow-up NNP
is VBZ
necessary JJ
to TO
determine VB
whether IN
2-CdA CD
actually RB
cures VBZ
the DT
disease NN
. .
The DT
drug NN
was VBD
first JJ
made VBN
about IN
10 CD
years NNS
ago RB
at IN
Scripps NNP
by IN
Dennis NNP
A. NNP
Carson NNP
, ,
who WP
studied VBN
severe JJ
combined VBN
immunodeficiency NN
disease NN
, ,
made VBN
famous JJ
a DT
few JJ
years NNS
ago RB
by IN
the DT
Texas NNP
boy NN
that WDT
lived VBD
in IN
a DT
bubble JJ
. .
People NNS
with IN
that DT
disease NN
lack VBP
an DT
enzyme NN
that IN
processes NNS
deoxyadenosine VBP
, ,
a DT
chemical JJ
that IN
, ,
without IN
the DT
enzyme NN
, ,
builds VBZ
up RP
in IN
infection-fighting JJ
white JJ
blood NN
cells NNS
and CC
kills NNS
them PRP
. .
Since IN
cancer NN
patients NNS
have VBP
the DT
enzyme NN
, ,
Scripps NNP
scientists NNS
developed VBD
a DT
compound NN
that WDT
mimics NNS
deoxyadenosine VBP
, ,
but CC
tricks NNS
the DT
enzyme NN
so RB
it PRP
ca MD
n't RB
be VB
processed VBN
. .
The DT
compound NN
then RB
kills VBZ
the DT
white JJ
blood NN
cells NNS
, ,
including VBG
those DT
that WDT
are VBP
cancerous JJ
. .
New NNP
, ,
normal JJ
white JJ
cells NNS
are VBP
then RB
generated VBN
in IN
the DT
bone NN
marrow NN
. .
Because IN
hairy-cell JJ
leukemia NN
is VBZ
rare JJ
, ,
a DT
12-patient JJ
study NN
'' ''
is VBZ
considered VBN
a DT
pretty RB
good JJ
series NN
, ,
'' ''
says VBZ
Sloan-Kettering's -NONE-
Dr. NNP
Berman NNP
. .
`` ``
It PRP
's VBZ
ironic JJ
that IN
we PRP
have VBP
three CD
active JJ
drugs NNS
for IN
a DT
disease NN
that WDT
's VBZ
fairly RB
rare JJ
, ,
but CC
for IN
some DT
of IN
the DT
more RBR
common JJ
forms NNS
of IN
leukemia NN
, ,
we PRP
do VBP
n't RB
yet RB
have VB
good JJ
treatments NNS
. .
`` ``
Dr. NNP
Piro NNP
said VBD
2-CdA CD
has VBZ
also RB
been VBN
used VBN
effectively RB
in IN
initial JJ
trials NNS
to TO
treat VB
more JJR
common JJ
cancers NNS
, ,
including VBG
chronic JJ
lymphocytic JJ
leukemia NN
, ,
non-Hodgkins VBZ
lymphoma NN
and CC
cutaneous JJ
T-cell NN
lymphoma NN
. .
About IN
50 CD
% NN
to TO
60 CD
% NN
of IN
patients NNS
-- :
most JJS
of IN
whom WP
had VBD
failed VBN
other JJ
treatments NNS
-- :
responded VBD
to TO
the DT
drug NN
, ,
some DT
with IN
complete JJ
remission NN
, ,
he PRP
said VBD
. .
`` ``
Now RB
, ,
we PRP
will MD
use VB
{ :
2-CdA CD
} CD
as IN
a DT
first JJ
treatment NN
to TO
see VB
if IN
response NN
and CC
remission NN
are VBP
higher JJR
, ,
'' ''
he PRP
said VBD
. .
Meanwhile RB
, ,
researchers NNS
at IN
University NNP
of IN
California NNP
at IN
San NNP
Francisco NNP
are VBP
testing VBG
2-CdA CD
on IN
AIDS-related JJ
lymphoma NN
. .

<DOCNO> AP881122-0017
Alpha NNP
interferon VBD
, ,
a DT
natural JJ
disease NN
fighter NN
already RB
used VBN
to TO
treat VB
leukemia NN
, ,
can MD
now RB
be VB
used VBN
to TO
battle VB
Kaposi's JJ
sarcoma NN
, ,
a DT
cancer NN
that WDT
primarily RB
attacks VBZ
AIDS NNP
patients NNS
. .
The DT
Food NNP
and CC
Drug NNP
Administration NNP
announced VBD
Monday NNP
that IN
alpha NN
interferon NN
was VBD
shown VBN
in IN
tests NNS
to TO
be VB
effective JJ
against IN
Kaposi NNP
's POS
and CC
now RB
is VBZ
approved VBN
for IN
treatment NN
of IN
the DT
cancer NN
that IN
has VBZ
become VBN
common JJ
among IN
AIDS NNP
victims NNS
. .
Alpha NNP
interferon VBD
is VBZ
a DT
disease-fighter JJ
that IN
is VBZ
present JJ
in IN
the DT
body NN
naturally RB
in IN
small JJ
amounts NNS
, ,
but CC
has VBZ
been VBN
artifically RB
produced VBN
in IN
large JJ
quantities NNS
in IN
recent JJ
years NNS
through IN
the DT
use NN
of IN
gene-splicing JJ
techniques NNS
. .
It PRP
previously RB
had VBD
been VBN
approved VBN
for IN
treatment NN
of IN
hairy-cell NNP
leukemia NN
and CC
for IN
genital JJ
warts NNS
. .
Frank NNP
E. NNP
Young NNP
, ,
FDA NNP
commissioner NN
, ,
said VBD
approval NN
of IN
the DT
man-made JJ
alpha NN
interferon NN
`` ``
shows VBZ
biotechnology NN
's POS
emerging NN
role NN
in IN
helping NN
modern NN
medicine NN
fight NN
some DT
of IN
the DT
most RBS
serious JJ
diseases NNS
which WDT
plague JJ
mankind NN
. .
'' ''
Kaposi NNP
's POS
sarcoma NN
, ,
named VBD
for IN
a DT
European JJ
doctor NN
who WP
first RB
described VBD
it PRP
more JJR
than IN
100 CD
years NNS
ago RB
, ,
was VBD
a DT
rare NN
cancer NN
until IN
the DT
appearance NN
early RB
in IN
this DT
decade NN
of IN
AIDS NNP
, ,
or CC
acquired VBN
immune JJ
deficiency NN
syndrome NN
. .
The DT
cancer NN
causes NNS
purple VBP
or CC
brown IN
lesions NNS
on IN
the DT
skin NN
and CC
can MD
attack VB
the DT
lungs NNS
, ,
brain NN
and CC
gastrointestinal JJ
tract NN
. .
Kaposi NNP
's POS
can MD
cause VB
death NN
when WRB
it PRP
attacks VBZ
the DT
lungs NNS
or CC
other JJ
vital JJ
organs NNS
, ,
although IN
most JJS
AIDS NNS
patients NNS
die VB
of IN
other JJ
causes NNS
. .
Alpha NNP
interferon VBD
was VBD
used VBN
experimentally RB
to TO
treat VB
Kaposi NNP
's POS
in IN
a DT
number NN
of IN
studies NNS
, ,
including VBG
some DT
conducted JJ
at IN
the DT
National NNP
Institute NNP
of IN
Allergy NNP
and CC
Infectious NNP
Diseases NNP
, ,
part NN
of IN
the DT
National NNP
Institutes NNPS
of IN
Health NNP
. .
Anthony NNP
S. NNP
Fauci NNP
, ,
the DT
NIAID NNP
director NN
, ,
said VBD
that IN
studies NNS
by IN
H. NNP
Clifford NNP
Lane NNP
of IN
the DT
NIAID NNP
`` ``
demonstrated VBN
that DT
alpha NN
interferon NN
was VBD
an DT
effective JJ
anti-Kaposi NN
's POS
sarcoma NN
agent NN
'' ''
in IN
patients NNS
who WP
were VBD
in IN
the DT
early JJ
stages NNS
of IN
the DT
AIDS NNP
infection NN
. .
According VBG
to TO
the DT
FDA NNP
, ,
several JJ
human JJ
studies NNS
showed VBD
that IN
high JJ
doses NNS
of IN
alpha NN
inteferon NN
would MD
reduce VB
Kaposi NNP
's POS
tumors NNS
in IN
40 CD
to TO
45 CD
percent NN
of IN
patients NNS
who WP
were VBD
in IN
early JJ
stages NNS
of IN
the DT
AIDS NNP
infection NN
. .
AIDS NNS
patients NNS
who WP
were VBD
helped VBN
most JJS
were VBD
those DT
whose WP$
blood NN
showed VBD
a DT
T4-helper JJ
cell NN
count NN
of IN
above IN
200 CD
per IN
square JJ
centimeter NN
, ,
and CC
who WP
have VBP
not RB
experienced VBN
other JJ
opportunistic JJ
infections NNS
. .
T4-helper JJ
cells NNS
are VBP
part NN
of IN
the DT
body NN
's POS
immune NN
system NN
and CC
are VBP
attacked VBN
by IN
the DT
AIDS NNP
virus VBZ
. .
Healthy NNP
people NNS
have VBP
a DT
T4-helper JJ
cell NN
count NN
of IN
800 CD
to TO
1 CD
, ,
000 CD
. .
Those DT
with IN
more JJR
advanced JJ
AIDS NNS
tend VBP
to TO
have VB
T4-helper JJ
cell NN
counts NNS
below IN
200 CD
and CC
do VBP
not RB
benefit VB
from IN
the DT
alpha NN
interferon NN
treatment NN
. .
Alpha NNP
interferon VBD
was VBD
first JJ
identified VBN
in IN
1957 CD
as IN
a DT
hormone-like JJ
protein NN
that WDT
is VBZ
a DT
natural JJ
disease-fighting NN
component NN
of IN
the DT
blood NN
. .
In IN
the DT
early JJ
1980s CD
, ,
researchers NNS
were VBD
able JJ
to TO
insert VB
the DT
gene NN
coded VBD
for IN
alpha NN
interferon NN
into IN
a DT
bacteria NN
which WDT
then RB
produces VBZ
the DT
protein NN
in IN
large JJ
quantities NNS
. .
This DT
is VBZ
the DT
technique NN
called VBD
gene-splicing JJ
. .
The DT
FDA NNP
said VBD
that IN
alpha NN
interferon NN
is VBZ
marketed VBN
by IN
Schering NNP
Corp. NNP
of IN
Kenilworth NNP
, ,
N.J. NNP
, ,
under IN
the DT
brand NN
name NN
Intron-A NNP
, ,
and CC
by IN
Hoffmann-La NNP
Roche NNP
of IN
Nutley NNP
, ,
N.J. NNP
under IN
the DT
brand NN
name NN
Roferon NNP
. .
Both DT
products NNS
were VBD
first RB
approved VBN
in IN
1986 CD
for IN
the DT
treatment NN
of IN
hairy-cell NNP
leukemia NN
, ,
and CC
last JJ
June NNP
for IN
the DT
treatment NN
of IN
genital JJ
warts NNS
. .
AIDS NNS
is VBZ
a DT
contagious JJ
disease NN
that WDT
attacks VBZ
the DT
body NN
's POS
immune NN
system NN
, ,
rendering VBG
it PRP
incapable JJ
of IN
resisting NN
other JJ
diseases NNS
and CC
infections NNS
. .
The DT
virus NN
most JJS
often RB
is VBZ
spread VBN
through IN
contact NN
with IN
blood NN
, ,
blood NN
products NNS
or CC
semen NNS
from IN
infected VBN
persons NNS
. .
AIDS NNS
is VBZ
incurable JJ
and CC
fatal JJ
. .
As IN
of IN
Nov. NNP
7 CD
, ,
AIDS NNP
had VBD
been VBN
diagnosed VBN
in IN
77 CD
, ,
994 CD
Americans NNS
, ,
of IN
whom WP
more JJR
than IN
half PDT
, ,
or CC
43 CD
, ,
888 CD
, ,
have VBP
died VBN
since IN
June NNP
1 CD
, ,
1981 CD
, ,
according VBG
to TO
the DT
government NN
. .

<DOCNO> AP900809-0104
A DT
leukemia NN
patient NN
received VBD
her PRP
mother RB
's VBZ
bone NN
marrow NN
Thursday NNP
, ,
after IN
doctors NNS
failed VBD
to TO
find VB
a DT
perfect NN
match NN
among IN
50 CD
, ,
000 CD
people NNS
who WP
volunteered VBN
as IN
donors NNS
. .
Allison NNP
Atlas NNP
, ,
20 CD
, ,
had VBD
the DT
transplant NN
at IN
Fred NNP
Hutchison NNP
Cancer NNP
Research NNP
Center NNP
in IN
Seattle NNP
. .
Her PRP$
mother NN
, ,
Arline NNP
, ,
54 CD
, ,
was VBD
the DT
donor NN
. .
The DT
plight NN
of IN
Miss NNP
Atlas NNP
, ,
a DT
New NNP
York NNP
University NNP
student NN
from IN
Bethesda NNP
, ,
Md. NNP
, ,
prompted VBD
50 CD
, ,
000 CD
people NNS
to TO
volunteer NN
for IN
bone NN
marrow NN
tests NNS
. .
There EX
was VBD
no DT
perfect NN
match NN
for IN
Miss NNP
Atlas NNP
, ,
but CC
10 CD
other JJ
leukemia NN
patients NNS
got VBD
donors NNS
. .
Mrs. NNP
Atlas NNP
' POS
marrow NN
matched VBD
four CD
of IN
six CD
antigens NNS
, ,
or CC
cell NN
identifiers NNS
, ,
from IN
her PRP$
daughter NN
's POS
marrow NN
. .
Doctors NNS
said VBD
Miss NNP
Atlas NNP
would MD
have VB
had VBD
a DT
60 CD
percent NN
chance NN
of IN
recovery NN
if IN
the DT
donated VBN
marrow NN
was VBD
a DT
perfect NN
match NN
. .
Her PRP$
chances NNS
are VBP
reduced VBN
`` ``
somewhat RB
'' ''
but CC
other JJ
patients NNS
with IN
the DT
same JJ
degree NN
of IN
mismatch NN
have VBP
recovered VBN
, ,
said VBD
hospital JJ
spokeswoman NN
Alice NNP
Burgess NNP
said VBD
. .
Without IN
the DT
transplant NN
, ,
she PRP
would MD
live VB
less RBR
than IN
a DT
year NN
, ,
Burgess NNP
said VBD
. .
Leukemia NNP
causes NNS
white VBP
blood NN
cells NNS
to TO
multiply RB
uncontrollably RB
. .
Bone NN
marrow NN
produces NNS
blood NN
, ,
and CC
doctors NNS
combat VBP
the DT
cancer NN
by IN
replacing NN
the DT
diseased VBN
marrow NN
. .
The DT
Atlas NNP
family NN
's POS
public JJ
campaign NN
last JJ
fall NN
raised VBD
$ $
3 CD
million CD
to TO
process NN
blood NN
samples NNS
from IN
the DT
50 CD
, ,
000 CD
people NNS
in IN
the DT
United NNP
States NNPS
and CC
Israel NNP
who WP
registered VBN
with IN
the DT
National NNP
Marrow NNP
Donor NNP
Program NNP
. .

<DOCNO> AP900809-0001
A DT
leukemia NN
patient NN
whose WP$
plight NN
prompted VBD
50 CD
, ,
000 CD
people NNS
to TO
step VB
forward RB
as IN
possible JJ
bone-marrow NN
donors NNS
will MD
undergo VB
a DT
transplant NN
of IN
bone NN
marrow NN
from IN
her PRP$
mother NN
Thursday NNP
, ,
a DT
hospital NN
spokeswoman NN
said VBD
Wednesday NNP
. .
The DT
operation NN
on IN
Allison NNP
Atlas NNP
, ,
20 CD
, ,
is VBZ
expected VBN
to TO
take VB
at IN
least JJS
four CD
hours NNS
and CC
could MD
last VB
six CD
hours NNS
or CC
more JJR
, ,
said VBD
Fred NNP
Hutchinson NNP
Cancer NNP
Research NNP
Center NNP
spokeswoman NN
Alice NNP
Burgess NNP
. .
Doctors NNS
are VBP
scheduled VBN
to TO
extract VB
the DT
marrow NN
from IN
Miss NNP
Atlas' NNP
mother NN
at IN
9 CD
a.m. NNP
, ,
the DT
spokeswoman NN
said VBD
. .
The DT
marrow NN
from IN
her PRP$
mother NN
matches NNS
only RB
four CD
of IN
six CD
antigens NNS
, ,
or CC
cell NN
identifiers NNS
. .
But CC
the DT
New NNP
York NNP
University NNP
student NN
from IN
Bethesda NNP
, ,
Md. NNP
, ,
decided VBD
to TO
undergo VB
the DT
operation NN
while IN
she PRP
is VBZ
still RB
strong JJ
enough RB
. .
She PRP
began VBD
chemotherapy NN
July NNP
31 CD
, ,
and CC
has VBZ
responded VBN
well RB
, ,
Burgess NNP
said VBD
. .
Doctors NNS
said VBD
a DT
patient NN
with IN
Miss NNP
Atlas NNP
' POS
type NN
of IN
leukemia NN
can MD
expect VB
a DT
60 CD
percent NN
chance NN
of IN
recovery NN
if IN
the DT
transplant NN
marrow NN
is VBZ
perfectly RB
matched VBN
. .
Without IN
a DT
transplant NN
, ,
they PRP
say VBP
the DT
disease NN
is VBZ
100 CD
percent NN
fatal NN
. .
In IN
leukemia NN
, ,
a DT
form NN
of IN
cancer NN
, ,
white JJ
blood NN
cells NNS
multiply RB
uncontrollably RB
. .
Bone NN
marrow NN
produces NNS
blood NN
, ,
and CC
doctors NNS
can MD
combat VB
the DT
cancer NN
by IN
replacing NN
the DT
diseased VBN
marrow NN
with IN
healthy JJ
tissue NN
. .
Miss NNP
Atlas NNP
' POS
condition NN
prompted VBD
a DT
campaign NN
by IN
her PRP$
family NN
last JJ
fall NN
to TO
find VB
a DT
perfectly RB
matched VBN
donor NN
. .
They PRP
were VBD
unsuccessful JJ
, ,
but CC
the DT
effort NN
raised VBD
$ $
3 CD
million CD
to TO
process NN
blood NN
samples NNS
from IN
the DT
50 CD
, ,
000 CD
people NNS
in IN
the DT
United NNP
States NNPS
and CC
Israel NNP
who WP
volunteered VBN
. .
Ten CD
patients NNS
found VBD
perfect NN
donors NNS
. .

<DOCNO> AP900523-0025
In IN
a DT
unique JJ
assault NN
on IN
leukemia NN
, ,
doctors NNS
have VBP
found VBN
that IN
a DT
form NN
of IN
vitamin NN
A DT
will MD
turn VB
cancer NN
cells NNS
into IN
normal JJ
ones NNS
. .
Medicine NNP
's POS
usual JJ
way NN
of IN
combating VBG
cancer NN
is VBZ
to TO
kill VB
it PRP
. .
Doctors NNS
administer VBP
powerful JJ
toxic JJ
drugs NNS
in IN
the DT
hopes NNS
that IN
they PRP
will MD
destroy VB
more RBR
cancerous JJ
cells NNS
than IN
healthy JJ
ones NNS
. .
The DT
new JJ
approach NN
instead RB
tries VBZ
to TO
reform NN
cancer NN
cells NNS
. .
It PRP
changes VBZ
the DT
cells NNS
' POS
genetic JJ
program NN
, ,
bypassing VBG
the DT
genetic JJ
mix NN
up IN
that DT
makes VBZ
them PRP
kill MD
. .
In IN
this DT
way NN
, ,
the DT
treatment NN
induces NNS
the DT
cancer NN
cells NNS
to TO
live VB
, ,
to TO
grow VB
and CC
eventually RB
to TO
die VB
by IN
the DT
same JJ
rules NNS
that WDT
govern NN
the DT
rest NN
of IN
the DT
body NN
. .
The DT
drug NN
, ,
a DT
synthetic JJ
form NN
of IN
vitamin NN
A DT
called VBN
all-trans NNS
retinoic JJ
acid NN
, ,
was VBD
developed VBN
in IN
China NNP
and CC
tested VBD
in IN
France NNP
. .
Though IN
it PRP
has VBZ
drawbacks NNS
and CC
works NNS
in IN
just RB
one CD
rare JJ
form NN
of IN
leukemia NN
, ,
doctors NNS
hope VBP
it PRP
will MD
provide VB
clues NNS
for IN
short-circuiting JJ
the DT
basic JJ
errors NNS
that WDT
underlie NN
all DT
cancers NNS
. .
`` ``
The DT
dogma NN
has VBZ
been VBN
to TO
try VB
to TO
kill VB
cancer NN
cells NNS
, ,
'' ''
said VBD
Dr. NNP
Laurent NNP
Degos NNP
. .
`` ``
Is VBZ
it PRP
possible JJ
to TO
change VB
a DT
cell NN
, ,
and CC
not RB
kill VBP
it PRP
, ,
so RB
it PRP
becomes VBZ
normal JJ
? .
'' ''
Degos NNP
, ,
a DT
researcher NN
at IN
Hopital NNP
Saint-Louis NNP
in IN
Paris NNP
, ,
presented VBD
evidence NN
that IN
this DT
indeed NN
is VBZ
possible JJ
in IN
a DT
report NN
Tuesday NNP
at IN
the DT
annual JJ
meeting NN
of IN
the DT
American NNP
Society NNP
of IN
Clinical NNP
Oncology NNP
. .
He PRP
tested VBD
the DT
drug NN
on IN
victims NNS
of IN
acute JJ
promyelocytic JJ
leukemia NN
, ,
a DT
rare NN
blood NN
cancer NN
that WDT
strikes VBZ
a DT
few JJ
hundred VBN
people NNS
in IN
the DT
United NNP
States NNPS
each DT
year NN
. .
All DT
of IN
them PRP
had VBD
failed VBN
earlier JJR
standard JJ
therapy NN
. .
He PRP
achieved VBD
complete JJ
, ,
though IN
often RB
temporary JJ
, ,
elimination NN
of IN
all DT
signs NNS
of IN
the DT
disease NN
in IN
16 CD
of IN
17 CD
patients NNS
who WP
had VBD
relapsed VBN
for IN
the DT
first JJ
time NN
. .
There EX
was VBD
complete JJ
remission NN
in IN
one CD
of IN
four CD
patients NNS
who WP
had VBD
relapsed VBN
a DT
second JJ
time NN
. .
`` ``
There EX
was VBD
no DT
killing NN
of IN
cells NNS
, ,
but CC
they PRP
change VBP
, ,
'' ''
said VBD
Degos NNP
. .
`` ``
We PRP
see VBP
more JJR
mature NN
cells NNS
. .
'' ''
This DT
form NN
of IN
leukemia NN
is VBZ
caused VBN
by IN
a DT
specific JJ
genetic JJ
defect NN
, ,
the DT
mislocation NN
of IN
a DT
piece NN
of IN
one CD
string VBG
of IN
genes NNS
, ,
or CC
chromosome VB
, ,
onto IN
another DT
chromosome NN
. .
As IN
a DT
result NN
, ,
the DT
cells NNS
get VBP
stuck NN
in IN
their PRP$
juvenile JJ
stage NN
. .
They PRP
fail VBP
to TO
mature VB
normally RB
and CC
eventually RB
die VB
. .
Treatment NNP
with IN
all-trans NNS
retinoic JJ
acid NN
appears VBZ
to TO
bump VB
the DT
cells NNS
past VBP
this DT
roadblock NN
in IN
their PRP$
development NN
so IN
they PRP
grow VBP
old JJ
. .
`` ``
This DT
is VBZ
a DT
smashing NN
development NN
, ,
'' ''
commented VBD
Dr. NNP
Charles NNP
Schiffer NNP
of IN
the DT
University NNP
of IN
Maryland NNP
. .
`` ``
It PRP
has VBZ
impressed VBN
even RB
the DT
most RBS
cynical JJ
. .
This DT
is VBZ
a DT
different JJ
approach NN
to TO
anything NN
we PRP
have VBP
done VBN
in IN
this DT
disease NN
in IN
the DT
past JJ
. .
'' ''
Dr. NNP
Bruce NNP
Chesen NNP
of IN
the DT
National NNP
Cancer NNP
Institute NNP
said VBD
the DT
institute NN
plans VBZ
soon RB
to TO
sponsor VB
four CD
small JJ
safety NN
studies NNS
of IN
the DT
drug NN
. .
Once RB
those DT
are VBP
done VBN
, ,
it PRP
will MD
begin VB
a DT
larger JJR
review NN
of IN
its PRP$
effectiveness NN
. .
Though IN
the DT
synthetic JJ
vitamin NN
wiped VBD
out RP
obvious JJ
signs NNS
of IN
the DT
leukemia NN
, ,
the DT
disease NN
frequently RB
came VBD
back RB
, ,
apparently RB
because IN
some DT
cancer NN
cells NNS
were VBD
resistant JJ
to TO
the DT
drug NN
. .
Degas NNP
said VBD
it PRP
may MD
be VB
necessary JJ
to TO
combine NN
the DT
treatment NN
with IN
standard JJ
chemotherapy NN
to TO
try VB
to TO
obliterate VB
the DT
few JJ
remaining VBG
cancer NN
cells NNS
. .
The DT
drug NN
was VBD
developed VBN
in IN
China NNP
by IN
Wang NNP
Zeng NNP
Yi NNP
, ,
dean JJ
of IN
Shanghai NNP
University NNP
II NNP
, ,
a DT
French-speaking JJ
medical JJ
school NN
. .
It PRP
is VBZ
now RB
being VBG
produced VBN
by IN
Hoffman NNP
LaRoche NNP
, ,
the DT
pharmaceutical JJ
firm NN
. .
In IN
an DT
earlier JJR
report NN
, ,
doctors NNS
said VBD
they PRP
found VBD
that IN
the DT
acne NN
medicine NN
Accutane NNP
, ,
another DT
synthetic JJ
form NN
of IN
vitamin NN
A DT
, ,
prevents VBZ
new JJ
tumors NNS
from IN
developing VBG
in IN
people NNS
treated VBN
for IN
smoking-related JJ
throat NN
cancer NN
. .
Among IN
other JJ
research NN
presented VBD
at IN
the DT
meeting NN
: :
_Dr NNP
. .
Steven NNP
A. NNP
Rosenberg NNP
of IN
the DT
National NNP
Cancer NNP
Institute NNP
outlined VBD
the DT
first JJ
results NNS
of IN
his PRP$
pioneering NN
attempt NN
to TO
insert VB
foreign JJ
genes NNS
into IN
cancer NN
patients NNS
. .
The DT
initial JJ
effort NN
, ,
carried VBD
out RP
on IN
seven CD
melanoma NN
patients NNS
, ,
was VBD
intended VBN
to TO
show VB
that IN
gene NN
therapy NN
is VBZ
possible JJ
. .
Doctors NNS
removed VBD
cancer-fighting JJ
blood NN
cells NNS
from IN
the DT
patients' NN
tumors NNS
, ,
inserted VBD
a DT
bacteria NN
gene NN
into IN
them PRP
and CC
then RB
put VBD
them PRP
back RB
into IN
the DT
patients NNS
' POS
bodies NNS
. .
The DT
manipulated VBN
cells NNS
zeroed VBN
in IN
on IN
their PRP$
tumors NNS
. .
The DT
doctors NNS
hope VBP
soon RB
to TO
repeat VB
the DT
experiment NN
, ,
this DT
time NN
inserting VBG
a DT
gene NN
that WDT
produces VBZ
a DT
cancer-killing JJ
chemical NN
called VBN
tumer NN
necrosis NN
factor NN
. .
_A NNP
survey NN
of IN
American JJ
and CC
Caribbean NNP
blacks NNS
in IN
central JJ
Brooklyn NNP
showed VBD
that IN
a DT
surprising JJ
4 CD
percent NN
were VBD
infected VBN
with IN
cancer-causing JJ
human NN
T-cell NN
leukemia NN
virus VBZ
Type NNP
1 CD
, ,
or CC
HTLV-I NNP
. .
Dr. NNP
Harvey NNP
Dosik NNP
of IN
Interfaith NNP
Medical NNP
Center NNP
in IN
Brooklyn NNP
said VBD
the DT
infection NN
rate NN
is VBZ
200 CD
times NNS
higher JJR
than IN
that DT
seen VBN
nationwide NN
in IN
blood NN
donors NNS
. .
_Dr NNP
. .
Lode NNP
J. NNP
Swinnen NNP
of IN
Loyola NNP
University NNP
in IN
Chicago NNP
said VBD
he PRP
had VBD
found VBN
evidence NN
that IN
OKT3 NNP
, ,
an DT
antibody NN
treatment NN
widely RB
given VBN
to TO
recipients NNS
of IN
organ JJ
transplants NNS
, ,
significantly RB
increases VBZ
their PRP$
risk NN
of IN
non-Hodgkins NNS
lymphoma VBP
, ,
a DT
blood NN
cancer NN
. .
He PRP
reviewed VBD
154 CD
heart NN
transplant NN
patients NNS
and CC
found VBN
that IN
11 CD
percent NN
of IN
those DT
getting VBG
OKT3 NNP
since IN
1986 CD
had VBD
developed VBN
the DT
disease NN
. .

<DOCNO> AP900111-0061
A DT
form NN
of IN
blood NN
cancer NN
that WDT
strikes VBZ
children NNS
appears VBZ
to TO
be VB
sometimes RB
linked VBN
with IN
genetic JJ
damage NN
that WDT
hinders NNS
the DT
body NN
's POS
ability NN
to TO
make VB
interferon NN
, ,
according VBG
to TO
a DT
study NN
published VBN
today NN
. .
The DT
researchers NNS
speculate VBP
that IN
genes NNS
that WDT
oversee NN
the DT
body's NNP
production NN
of IN
interferon NN
, ,
a DT
disease-fighting JJ
substance NN
, ,
may MD
play VB
a DT
role NN
in IN
warding NN
off IN
the DT
development NN
of IN
cancer NN
. .
The DT
researchers NNS
speculate VBP
that IN
the DT
interferon NN
genes NNS
may MD
act VB
as IN
regulators NNS
that IN
stop NN
the DT
body NN
's POS
cells NNS
from IN
becoming VBG
cancerous JJ
. .
The DT
researchers NNS
, ,
based VBN
at IN
the DT
University NNP
of IN
Chicago NNP
, ,
found VBD
an DT
association NN
between IN
loss NN
of IN
the DT
genes NNS
and CC
development NN
of IN
acute NN
lymphoblastic JJ
leukemia NN
, ,
the DT
most RBS
common JJ
form NN
of IN
childhood NN
leukemia NN
. .
They PRP
tested VBD
62 CD
patients NNS
with IN
this DT
kind NN
of IN
leukemia NN
and CC
found VBD
that IN
29 CD
percent NN
of IN
them PRP
were VBD
missing VBG
the DT
interferon NN
genes NNS
. .
Their PRP$
work NN
, ,
directed VBD
by IN
Dr. NNP
Manuel NNP
O. NNP
Diaz NNP
, ,
was VBD
published VBN
in IN
the DT
New NNP
England NNP
Journal NNP
of IN
Medicine NNP
. .
It PRP
adds VBZ
to TO
the DT
growing VBG
list NN
of IN
cancers NNS
that WDT
have VBP
been VBN
associated VBN
with IN
the DT
presence NN
or CC
absence NN
of IN
particular JJ
genes NNS
. .
Some DT
genes NNS
, ,
known VBN
oncogenes NNS
, ,
are VBP
though IN
to TO
trigger JJR
cancer NN
. .
Cancer NN
can MD
also RB
occur VB
when WRB
other JJ
genes NNS
, ,
known VBN
as IN
anti-oncogenes NNS
, ,
are VBP
missing VBG
. .
Interferon NNP
plays VBZ
a DT
variety NN
of IN
roles NNS
in IN
regulating VBG
the DT
body's JJ
immune NN
defenses NNS
and CC
controlling VBG
cell NN
growth NN
. .
The DT
production NN
of IN
two CD
forms NNS
of IN
interferon NN
, ,
known VBN
as IN
alpha NN
and CC
beta-1 -NONE-
, ,
are VBP
controlled VBN
by IN
two CD
genes NNS
that WDT
are VBP
close RB
together RB
on IN
chromosome NN
9 CD
in IN
the DT
body NN
's POS
library NN
of IN
genes NNS
. .
In IN
the DT
latest JJS
work NN
, ,
the DT
researchers NNS
found VBD
that IN
this DT
section NN
of IN
the DT
chromosome NN
was VBD
frequently RB
missing VBG
in IN
those DT
with IN
acute JJ
lymphoblastic JJ
leukemia NN
. .
However RB
, ,
they PRP
left VBD
open JJ
the DT
possibility NN
that IN
some DT
other JJ
gene NN
in IN
this DT
region NN
besides VBZ
those DT
that WDT
make VBP
interferon RP
could MD
also RB
be VB
the DT
tumor-suppressing JJ
gene NN
. .
Acute NNP
lymphoblastic JJ
leukemia NN
accounts NNS
for IN
about IN
one-quarter JJ
of IN
all DT
childhood NN
cancers NNS
. .
It PRP
strikes VBZ
one CD
in IN
every DT
30 CD
, ,
000 CD
children NNS
. .

<DOCNO> AP900215-0120
Researchers NNS
, ,
using VBG
an DT
intricate JJ
manipulation NN
of IN
genes NNS
and CC
transplantation NN
of IN
bone NN
marrow NN
, ,
have VBP
produced VBN
a DT
mouse NN
that WDT
suffers NNS
from IN
a DT
vicious JJ
form NN
of IN
human JJ
leukemia NN
, ,
giving VBG
scientists NNS
a DT
new JJ
way NN
to TO
test NN
therapies NNS
against IN
the DT
killer NN
disease NN
. .
In IN
a DT
report NN
to TO
be VB
published VBN
Friday NNP
in IN
the DT
magazine NN
Science NNP
, ,
researchers NNS
at IN
the DT
Whitehead NNP
Institute NNP
for IN
Biomedical NNP
Research NNP
said VBD
they PRP
have VBP
discovered VBN
a DT
way NN
to TO
give VB
chronic JJ
myelogenous JJ
leukemia NN
, ,
CML NNP
, ,
to TO
laboratory NN
mice NN
. .
CML NNP
is VBZ
a DT
form NN
of IN
leukemia NN
that IN
usually RB
attacks VBZ
adults NNS
and CC
is VBZ
only RB
rarely RB
cured VBN
. .
`` ``
With IN
this DT
new JJ
animal NN
model NN
, ,
experimental JJ
therapies NNS
that WDT
might MD
otherwise VB
be VB
tried VBN
in IN
human JJ
patients NNS
can MD
now RB
be VB
tested VBN
in IN
these DT
mice NN
, ,
'' ''
said VBD
George NNP
Daley NNP
, ,
lead VBP
researcher NN
in IN
the DT
study NN
at IN
Whitehead NNP
. .
`` ``
You PRP
obviously RB
can MD
do VB
more RBR
with IN
the DT
mice NN
than IN
you PRP
could MD
with IN
human JJ
patients NNS
. .
'' ''
Daley NNP
said VBD
the DT
study NN
also RB
proves VBZ
that IN
CML NNP
is VBZ
initiated VBN
by IN
the DT
fusion NN
of IN
parts NNS
from IN
two CD
broken VBN
chromosomes NNS
, ,
a DT
finding NN
that WDT
had VBD
been VBN
suggested VBN
by IN
earlier JJR
studies NNS
in IN
other JJ
laboratories NNS
. .
Those DT
parts NNS
have VBP
been VBN
identified VBN
as IN
the DT
so-called JJ
ABL NNP
gene NN
from IN
chromosome NN
9 CD
and CC
a DT
gene NN
called VBN
BCR NNP
from IN
chromosome NN
22 CD
. .
Cells NNS
containing VBG
this DT
hybrid NN
gene NN
produce NN
a DT
protein NN
, ,
called VBN
P210 NNP
, ,
that IN
changes NNS
healthy JJ
cells NNS
into IN
cancer NN
cells NNS
. .
Daley NNP
said VBD
his PRP$
study NN
showed VBD
that IN
transferring NN
the DT
BCR NNP
@ NNP
ABL NNP
gene NN
into IN
mouse NN
bone NN
marrow NN
and CC
then RB
putting VBG
these DT
infected JJ
cells NNS
into IN
healthy JJ
mice NN
could MD
produce VB
CML NNP
in IN
those DT
mice NN
. .
`` ``
It PRP
answers VBZ
a DT
question NN
of IN
basic JJ
science NN
, ,
that IN
is VBZ
, ,
what WP
causes NNS
the DT
disease NN
, ,
'' ''
said VBD
Daley NNP
. .
`` ``
We PRP
now RB
know VBP
that IN
the DT
BCR NNP
@ NNP
ABL NNP
gene NN
is VBZ
sufficient JJ
to TO
induce VB
the DT
leukemia NN
. .
'' ''
He PRP
said VBD
it PRP
is VBZ
still RB
not RB
known VBN
precisely RB
what WP
causes NNS
the DT
two CD
chromosomes NNS
to TO
break VB
and CC
create VB
the DT
hybrid JJ
gene NN
, ,
but CC
a DT
high JJ
exposure NN
to TO
radiation NN
is VBZ
thought VBN
to TO
be VB
a DT
factor NN
. .
Dr. NNP
George NNP
Canellos NNP
, ,
chief NN
of IN
medical JJ
oncology NN
at IN
the DT
Dana-Farber JJ
Institute NNP
in IN
Boston NNP
, ,
described VBD
the DT
Whitehead NNP
finding NN
as IN
`` ``
an DT
important JJ
advance NN
in IN
understanding NN
the DT
disease NN
. .
'' ''
He PRP
said VBD
the DT
new JJ
animal JJ
model NN
of IN
the DT
disease NN
possibly RB
may MD
help VB
scientists NNS
find VB
ways NNS
to TO
block VB
the DT
action NN
of IN
the DT
P210 NNP
protein NN
produced VBN
by IN
the DT
BCR NNP
@ NNP
ABL NNP
gene NN
, ,
thus RB
preventing VBG
the DT
disease NN
. .
Daley NNP
said VBD
that IN
the DT
mouse NN
can MD
be VB
used VBN
to TO
test NN
`` ``
biological JJ
inhibitors NNS
'' ''
that IN
would MD
prevent VB
the DT
P210 NNP
protein NN
from IN
transforming VBG
normal JJ
cells NNS
into IN
cancers NNS
. .
Such JJ
inhibitors NNS
formally RB
could MD
only RB
be VB
tested VBN
on IN
human JJ
patients NNS
, ,
a DT
process NN
that WDT
could MD
take VB
years NNS
. .
With IN
a DT
mouse NN
model NN
of IN
the DT
disease NN
, ,
experiments NNS
can MD
be VB
speeded VBN
up RP
and CC
can MD
be VB
more RBR
extensive JJ
. .
To TO
create VB
the DT
mouse NN
model NN
, ,
Daley NNP
said VBD
he PRP
and CC
his PRP$
collegues NNS
inserted VBD
the DT
human JJ
BCR NNP
@ NNP
ABL NNP
gene NN
into IN
a DT
virus JJ
. .
Normal JJ
mouse NN
bone NN
marrow NN
cells NNS
were VBD
then RB
exposed VBN
to TO
the DT
virus NN
, ,
which WDT
transferred VBN
the DT
gene NN
into IN
the DT
marrow NN
cells NNS
. .
Thirty NNP
healthy JJ
mice NN
were VBD
then RB
irradiated VBN
to TO
kill VB
their PRP$
bone NN
marrow NN
cells NNS
. .
The DT
bone NN
marrow NN
carrying VBG
the DT
BCR NNP
@ NNP
ABL NNP
gene NN
was VBD
then RB
transplanted VBN
into IN
the DT
30 CD
mice NN
. .
Within NNP
five CD
months NNS
, ,
13 CD
of IN
the DT
30 CD
mice NN
developed VBD
a DT
blood NN
disease NN
that WDT
mimicked VBD
human NN
chronic NN
myelogenous JJ
leukemia NN
. .
CML NNP
in IN
humans NNS
can MD
be VB
controlled VBN
by IN
chemotherpy NN
for IN
3 CD
to TO
5 CD
years NNS
. .
This DT
remission NN
period NN
usually RB
ends VBZ
with IN
the DT
sudden JJ
increase NN
in IN
abnormal JJ
cells NNS
, ,
a DT
disease NN
phase NN
called VBN
`` ``
blast JJ
crisis NN
'' ''
that WDT
usually RB
results VBZ
in IN
death NN
. .
The DT
only JJ
successful JJ
therapy NN
now RB
is VBZ
to TO
kill VB
the DT
diseased VBN
bone NN
marrow NN
in IN
the DT
patient NN
and CC
replace NN
it PRP
with IN
healthy JJ
bone NN
marrow NN
from IN
a DT
compatible JJ
donor NN
, ,
but CC
even RB
this DT
treatment NN
often RB
fails VBZ
. .
Daley NNP
said VBD
that IN
continued VBN
studies NNS
of IN
the DT
CML NNP
mice NN
shows VBZ
that IN
many JJ
of IN
the DT
laboratory NN
animals NNS
develop VB
the DT
`` ``
blast JJ
crisis NN
'' ''
phase NN
of IN
the DT
disease NN
. .
This DT
, ,
he PRP
said VBD
, ,
is VBZ
further JJ
verification NN
that WDT
the DT
course NN
of IN
the DT
disease NN
in IN
the DT
mice NN
is VBZ
similar JJ
to TO
CML NNP
in IN
humans NNS
. .
Co-authors NNS
of IN
the DT
study NN
with IN
Daley NNP
were VBD
Richard NNP
A DT
. .
Van NNP
Etten NNP
and CC
David NNP
Baltimore NNP
, ,
both DT
of IN
the DT
Whitehead NNP
Institute NNP
. .
Science NN
, ,
which WDT
published VBD
the DT
study NN
, ,
is VBZ
the DT
journal NN
of IN
the DT
American NNP
Association NNP
for IN
the DT
Advancement NNP
of IN
Science NNP
. .

<DOCNO> SJMN91-06040145
Frequent NNP
use VBP
of IN
hair NN
dryers NNS
and CC
black-and-white JJ
televisions NNS
also RB
slightly RB
increased VBN
the DT
risk NN
of IN
leukemia NN
, ,
although IN
the DT
exact JJ
increase NN
was VBD
not RB
released VBN
. .
; :
Dr. NNP
John NNP
Peters NNP
, ,
director NN
of IN
USC NNP
's POS
occupational JJ
health NN
division NN
at IN
the DT
University NNP
of IN
Southern NNP
California NNP
, ,
presented VBD
his PRP$
findings NNS
Thursday NNP
at IN
a DT
closed VBN
scientific JJ
meeting NN
in IN
Carmel NNP
. .
; :
Peters NNP
said VBD
, ,
through IN
a DT
spokesman NN
, ,
that IN
he PRP
would MD
not RB
release VB
his PRP$
data NNS
or CC
discuss NNS
his PRP$
findings NNS
in IN
public JJ
until IN
they PRP
have VBP
been VBN
reviewed VBN
and CC
accepted VBN
for IN
publication NN
in IN
a DT
scientific JJ
journal JJ
. .
But CC
in IN
a DT
departure NN
from IN
usual JJ
scientific JJ
procedure NN
, ,
summaries NNS
of IN
his PRP$
findings NNS
were VBD
distributed VBN
by IN
the DT
Electric NNP
Power NNP
Research NNP
Institute NNP
, ,
the DT
Palo NNP
Alto-based JJ
industry NN
group NN
that WDT
financed VBN
his PRP$
study NN
and CC
sponsored VBD
the DT
Carmel NNP
meeting NN
. .
; :
The DT
institute NN
acted VBD
on IN
its PRP$
own JJ
because IN
it PRP
assumed VBD
that IN
word NN
of IN
the DT
results NNS
would MD
leak VB
out RP
anyway RB
, ,
and CC
it PRP
wanted VBD
to TO
provide VB
as IN
thorough JJ
a DT
report NN
as IN
possible JJ
, ,
a DT
spokeswoman NN
said VBD
. .
; :
Electromagnetic JJ
fields NNS
are VBP
routinely RB
produced VBN
when WRB
electrical JJ
current JJ
passes NNS
through IN
a DT
wire NN
or CC
household NN
appliance NN
. .
; :
In IN
the DT
past JJ
decade NN
, ,
several JJ
inconclusive JJ
studies NNS
have VBP
suggested VBN
that IN
children NNS
living VBG
near IN
high-voltage JJ
lines NNS
have VBP
a DT
higher-than-normal JJ
chance NN
of IN
developing VBG
leukemia NN
. .
; :
No DT
one NN
has VBZ
proved VBN
that IN
the DT
power NN
lines NNS
are VBP
causing VBG
cancer NN
, ,
or CC
even RB
how WRB
they PRP
might MD
. .
But CC
the DT
Environmental NNP
Protection NNP
Agency NNP
, ,
in IN
a DT
recent JJ
draft NN
report NN
, ,
concluded VBD
that IN
there EX
was VBD
enough RB
evidence NN
of IN
a DT
possible JJ
link NN
to TO
warrant VB
new JJ
research NN
. .
; :
In IN
the DT
USC NNP
study NN
, ,
which WDT
began VBD
in IN
1986 CD
, ,
Peters NNP
examined VBD
the DT
lives NNS
of IN
464 CD
children NNS
under IN
the DT
age NN
of IN
10 CD
. .
Half NNP
had VBD
leukemia NNS
and CC
half DT
did VBD
not RB
. .
Each DT
leukemia NN
patient NN
was VBD
compared VBN
to TO
a DT
healthy JJ
child NN
of IN
the DT
same JJ
age NN
, ,
sex NN
, ,
race NN
and CC
geographic JJ
area NN
. .
; :
Parents NNS
were VBD
interviewed VBN
by IN
telephone NN
about IN
occupation NN
, ,
household NN
use NN
of IN
chemicals NNS
, ,
smoking VBG
, ,
drug NN
use NN
and CC
daily JJ
activities NNS
, ,
including VBG
exposure NN
to TO
electrical JJ
appliances NNS
. .
; :
Unlike NNP
those DT
who WP
conducted VBN
earlier JJR
studies NNS
, ,
Peters NNP
' POS
group NN
entered VBD
homes NNS
and CC
took VBD
direct JJ
measurements NNS
of IN
the DT
electric JJ
and CC
magnetic JJ
fields NNS
. .
A DT
recording NN
device NN
was VBD
placed VBN
in IN
each DT
child NN
's POS
bedroom NN
to TO
measure VB
such JJ
fields NNS
every DT
minute NN
for IN
24 CD
hours NNS
. .
; :
Power NNP
lines NNS
in IN
the DT
neighborhood NN
were VBD
examined VBN
, ,
as IN
well RB
as IN
the DT
thickness NN
of IN
the DT
wires NNS
and CC
their PRP$
distance NN
from IN
the DT
houses NNS
. .
; :
Like IN
previous JJ
researchers NNS
, ,
Peters NNP
found VBD
an DT
association NN
between IN
neighborhood NN
power NN
lines NNS
and CC
the DT
risk NN
for IN
childhood NN
leukemia NN
. .
The DT
normal JJ
risk NN
of IN
childhood NN
leukemia NN
is VBZ
1 CD
in IN
20 CD
, ,
000 CD
a DT
year NN
, ,
the DT
institute NN
said VBD
, ,
and CC
the DT
children NNS
with IN
the DT
greatest JJS
exposure NN
to TO
the DT
most JJS
powerful JJ
transmission NN
lines NNS
had VBD
a DT
risk NN
of IN
2.5 CD
in IN
20 CD
, ,
000. CD
; :
But CC
oddly RB
, ,
there EX
was VBD
little JJ
or CC
no DT
association NN
between IN
leukemia NN
and CC
measures VBZ
of IN
exposure NN
to TO
electric JJ
or CC
magnetic JJ
fields NNS
. .
; :
In IN
fact NN
, ,
children NNS
in IN
homes NNS
with IN
moderate JJ
magnetic JJ
field NN
exposures NNS
had VBD
a DT
lower JJR
cancer NN
risk NN
than IN
children NNS
in IN
homes NNS
with IN
the DT
least JJS
exposures NNS
. .
; :
The DT
study NN
also RB
found VBD
other JJ
factors NNS
associated VBN
with IN
leukemia NN
risk NN
: :
parents NNS
' POS
use NN
of IN
incense NN
, ,
pesticides VBZ
inside NN
the DT
house NN
and CC
men NNS
's POS
use NN
of IN
spray NN
paint NN
at IN
work NN
during IN
their PRP$
wives NNS
' POS
pregnancies NNS
. .

<DOCNO> AP880524-0168
The DT
natural JJ
protein NN
interferon NN
, ,
combined VBN
with IN
standard JJ
chemotherapy NN
drugs NNS
, ,
shows VBZ
promise NN
in IN
controlling NN
multiple NN
myeloma NN
, ,
a DT
lethal JJ
form NN
of IN
bone NN
cancer NN
, ,
researchers NNS
said VBD
Tuesday NNP
. .
`` ``
We PRP
finally RB
have VBP
a DT
leg NN
up RP
on IN
arresting NN
the DT
natural JJ
progression NN
of IN
the DT
disease NN
and CC
producing VBG
patients NNS
who WP
are VBP
alive JJ
at IN
five CD
years NNS
, ,
which WDT
has VBZ
been VBN
a DT
rarity NN
, ,
'' ''
said VBD
Dr. NNP
Martin NNP
M. NNP
Oken NNP
of IN
the DT
University NNP
of IN
Minnesota NNP
. .
His PRP$
research NN
is VBZ
part NN
of IN
a DT
new JJ
effort NN
by IN
scientists NNS
to TO
find VB
a DT
role NN
for IN
interferon NN
by IN
combining NN
it PRP
with IN
the DT
drugs NNS
that WDT
have VBP
long RB
been VBN
used VBN
to TO
attack VB
cancer NN
. .
Oken NNP
said VBD
interferon NN
might MD
provide VB
a DT
knockout NN
punch NN
after IN
cancer NN
has VBZ
been VBN
weakened VBN
, ,
but CC
not RB
destroyed VBN
, ,
by IN
medicines NNS
. .
The DT
work NN
may MD
also RB
represent VB
a DT
revival NN
of IN
the DT
fortunes NNS
of IN
interferon NN
, ,
which WDT
has VBZ
been VBN
on IN
a DT
roller NN
coaster NN
of IN
public JJ
acclaim NN
and CC
disdain NN
for IN
a DT
decade NN
. .
Interferon NNP
is VBZ
a DT
natural JJ
, ,
hormone-like JJ
substance NN
that WDT
, ,
among IN
other JJ
things NNS
, ,
helps NNS
regulate VBP
the DT
body NN
's POS
immune NN
system NN
. .
When WRB
the DT
human JJ
gene NN
that WDT
makes VBZ
this DT
chemical JJ
was VBD
isolated VBN
, ,
some DT
experts NNS
predicted VBD
many JJ
uses NNS
for IN
interferon NN
in IN
eliminating NN
cancer NN
and CC
infections NNS
. .
However RB
, ,
studies NNS
showed VBD
that IN
when WRB
used VBN
alone NN
, ,
interferon NN
had VBD
little JJ
major JJ
impact NN
on IN
any DT
cancer NN
except IN
an DT
exceedingly RB
rare JJ
malignancy NN
called VBN
hairy NN
cell NN
leukemia NN
, ,
for IN
which WDT
it PRP
has VBZ
become VBN
standard JJ
therapy NN
. .
In IN
the DT
latest JJS
research NN
, ,
presented VBD
at IN
the DT
annual JJ
meeting NN
of IN
the DT
American NNP
Association NNP
of IN
Clinical NNP
Oncology NNP
, ,
doctors NNS
found VBD
that IN
interferon NN
plus CC
chemotherapy NN
produced VBN
complete JJ
remissions NNS
in IN
30 CD
percent NN
of IN
the DT
54 CD
patients NNS
studied VBD
. .
Such JJ
remissions NNS
, ,
in IN
which WDT
all DT
signs NNS
of IN
the DT
disease NN
are VBP
gone VBN
, ,
are VBP
rare JJ
in IN
multiple NN
myeloma NN
, ,
and CC
they PRP
are VBP
the DT
first JJ
step NN
toward IN
curing VBG
the DT
disease NN
. .
In IN
all DT
, ,
41 CD
percent NN
of IN
the DT
patients NNS
had VBD
remissions NNS
that IN
were VBD
complete JJ
or CC
nearly RB
complete JJ
. .
In IN
an DT
earlier JJR
study NN
, ,
only RB
11 CD
percent NN
of IN
the DT
patients NNS
reached VBD
this DT
level NN
after IN
receiving VBG
chemotherapy NN
alone RB
. .
In IN
another DT
study NN
presented VBD
at IN
the DT
meeting NN
, ,
doctors NNS
from IN
the DT
University NNP
of IN
North NNP
Carolina NNP
showed VBD
promising VBG
early JJ
results NNS
of IN
testing NN
interferon NN
against IN
chronic JJ
myelogenous JJ
leukemia NN
. .
`` ``
These DT
are VBP
interesting VBG
results NNS
, ,
'' ''
said VBD
Dr. NNP
James NNP
Griffin NNP
of IN
the DT
Dana-Farber JJ
Cancer NNP
Institute NNP
in IN
Boston NNP
. .
`` ``
Response NN
rates NNS
can MD
be VB
improved VBN
and CC
toxicity NN
minimized VBD
by IN
these DT
recombinant JJ
proteins NNS
. .
'' ''
About IN
11 CD
, ,
000 CD
new JJ
cases NNS
of IN
multiple NN
myeloma NN
and CC
5 CD
, ,
000 CD
cases NNS
of IN
chronic JJ
myelogenous JJ
leukemia NN
are VBP
found VBN
each DT
year NN
. .
This DT
form NN
of IN
leukemia NN
can MD
be VB
effectively RB
treated VBN
with IN
bone NN
marrow NN
transplants NNS
. .
However RB
, ,
many JJ
victims NNS
do VBP
not RB
receive VB
transplants NNS
because IN
no DT
suitable JJ
narrow NN
donors NNS
are VBP
available JJ
. .
Dr. NNP
Howard NNP
Ozer NNP
and CC
his PRP$
colleagues NNS
at IN
the DT
University NNP
of IN
North NNP
Carolina NNP
found VBD
they PRP
could MD
reduce VB
the DT
outward NN
signs NNS
of IN
myelogenous JJ
leukemia NN
and CC
help VB
the DT
body NN
replace NN
defective NN
cells NNS
with IN
normal JJ
ones NNS
. .
`` ``
For IN
the DT
first JJ
time NN
, ,
there EX
is VBZ
a DT
drug NN
available JJ
that IN
potentially RB
keeps VBZ
the DT
abnormal JJ
( NN
cell NN
) :
clone NN
under IN
control NN
and CC
allows VBZ
the DT
normal JJ
clone NN
to TO
come VB
back RB
, ,
'' ''
Ozer NNP
said VBD
. .
His PRP$
team NN
tested VBD
interferon NN
on IN
112 CD
people NNS
with IN
this DT
form NN
of IN
cancer NN
. .
They PRP
found VBD
that IN
70 CD
percent NN
of IN
them PRP
improved VBN
, ,
although IN
it PRP
is VBZ
still RB
too RB
soon RB
to TO
know VB
how WRB
the DT
treatment NN
affects VBZ
long-term JJ
survival NN
. .
He PRP
said VBD
that IN
interferon NN
may MD
have VB
to TO
be VB
given VBN
for IN
several JJ
years NNS
to TO
keep VB
the DT
disease NN
under IN
control NN
. .
Oken NNP
said VBD
more JJR
study NN
will MD
be VB
needed VBN
as IN
well RB
to TO
see VB
how WRB
interferon NN
affects NNS
multiple VBP
myeloma NN
over IN
time NN
. .
However RB
, ,
he PRP
added VBD
, ,
`` ``
I PRP
think VBP
it PRP
's VBZ
a DT
real JJ
advance NN
. .
'' ''
Typically NNP
, ,
about IN
30 CD
percent NN
of IN
multiple NN
myeloma NN
patients NNS
survive VBP
for IN
five CD
years NNS
. .
Just RB
how WRB
interferon JJ
works NNS
against IN
cancer NN
is VBZ
unclear JJ
. .
Ozer NNP
speculates VBZ
that IN
it PRP
acts VBZ
as IN
a DT
sort NN
of IN
negative JJ
growth NN
regulator NN
, ,
shutting VBG
down IN
bone NN
marrow NN
cells NNS
that WDT
produce NN
cancerous VBZ
blood NN
cells NNS
. .
Interferon NNP
is VBZ
produced VBN
by IN
inserting NN
a DT
human NN
gene NN
into IN
bacteria NN
or CC
yeast JJ
, ,
which WDT
can MD
churn VB
out RP
the DT
substance NN
in IN
limitless NN
quantities NNS
. .
It PRP
is VBZ
just RB
one CD
of IN
several JJ
otherwise NN
rare NN
natural JJ
chemicals NNS
to TO
be VB
made VBN
through IN
genetic JJ
engineering NN
. .

<DOCNO> AP900216-0033
Researchers NNS
report VBP
today NN
they PRP
have VBP
succeeded VBN
in IN
giving NN
a DT
form NN
of IN
human JJ
leukemia NN
to TO
laboratory NN
mice NN
, ,
producing VBG
an DT
animal JJ
that IN
now RB
can MD
be VB
used VBN
to TO
test NN
therapies NNS
against IN
the DT
disease NN
. .
`` ``
With IN
this DT
new JJ
animal NN
model NN
, ,
experimental JJ
therapies NNS
that WDT
might MD
otherwise VB
be VB
tried VBN
in IN
human JJ
patients NNS
can MD
now RB
be VB
tested VBN
in IN
these DT
mice NN
, ,
'' ''
said VBD
George NNP
Daley NNP
, ,
lead VBP
researcher NN
in IN
the DT
study NN
conducted VBD
at IN
the DT
Whitehead NNP
Institute NNP
for IN
Biomedical NNP
Research NNP
in IN
Cambridge NNP
, ,
Mass NNP
. .
`` ``
You PRP
obviously RB
can MD
do VB
more RBR
with IN
the DT
mice NN
than IN
you PRP
could MD
with IN
human JJ
patients NNS
, ,
'' ''
he PRP
said VBD
. .
The DT
study NN
, ,
published VBD
today NN
in IN
Science NNP
, ,
says VBZ
the DT
Whitehead NNP
researchers NNS
used VBN
intricate JJ
genetic JJ
engineering NN
to TO
inject VB
into IN
the DT
bone NN
marrow NN
of IN
laboratory NN
mice NN
the DT
human NN
gene NN
linked VBD
to TO
chronic JJ
myelogenous JJ
leukemia NN
( :
CML NNP
) :
, ,
a DT
form NN
of IN
a DT
blood NN
cancer NN
that WDT
usually RB
attacks VBZ
adults NNS
and CC
is VBZ
only RB
rarely RB
cured VBN
. .
Daley NNP
said VBD
the DT
study NN
also RB
proves VBZ
CML NNP
is VBZ
initiated VBN
by IN
the DT
fusion NN
of IN
parts NNS
from IN
two CD
broken VBN
chromosomes NNS
, ,
a DT
finding NN
that WDT
was VBD
suggested VBN
by IN
earlier JJR
studies NNS
in IN
other JJ
laboratories NNS
. .
Those DT
parts NNS
have VBP
been VBN
identified VBN
as IN
the DT
so-called JJ
ABL NNP
gene NN
from IN
chromosome NN
9 CD
and CC
a DT
gene NN
called VBN
BCR NNP
from IN
chromosome NN
22 CD
. .
Cells NNS
containing VBG
this DT
hybrid NN
gene NN
produce NN
a DT
protein NN
, ,
called VBN
P210 NNP
, ,
that IN
changes NNS
healthy JJ
cells NNS
into IN
cancer NN
cells NNS
. .
Daley NNP
said VBD
his PRP$
study NN
showed VBD
that IN
transferring NN
the DT
BCR NNP
@ NNP
ABL NNP
gene NN
into IN
mouse NN
bone NN
marrow NN
and CC
then RB
putting VBG
these DT
infected JJ
cells NNS
into IN
healthy JJ
mice NN
could MD
produce VB
CML NNP
in IN
those DT
mice NN
. .
`` ``
It PRP
answers VBZ
a DT
question NN
of IN
basic JJ
science NN
, ,
that IN
is VBZ
, ,
what WP
causes NNS
the DT
disease NN
, ,
'' ''
said VBD
Daley NNP
. .
`` ``
We PRP
now RB
know VBP
that IN
the DT
BCR NNP
@ NNP
ABL NNP
gene NN
is VBZ
sufficient JJ
to TO
induce VB
the DT
leukemia NN
. .
'' ''
He PRP
said VBD
it PRP
is VBZ
still RB
not RB
known VBN
precisely RB
what WP
causes NNS
the DT
two CD
chromosomes NNS
to TO
break VB
and CC
create VB
the DT
hybrid JJ
gene NN
, ,
but CC
a DT
high JJ
exposure NN
to TO
radiation NN
is VBZ
thought VBN
to TO
be VB
a DT
factor NN
. .
Dr. NNP
George NNP
Canellos NNP
, ,
chief NN
of IN
medical JJ
oncology NN
at IN
the DT
Dana-Farber JJ
Institute NNP
in IN
Boston NNP
, ,
said VBD
the DT
Whitehead NNP
finding NN
is VBZ
`` ``
an DT
important JJ
advance NN
in IN
understanding NN
the DT
disease NN
. .
'' ''
He PRP
said VBD
the DT
new JJ
animal JJ
model NN
of IN
the DT
disease NN
may MD
help VB
scientists NNS
find VB
ways NNS
to TO
block VB
the DT
action NN
of IN
the DT
P210 NNP
protein NN
produced VBN
by IN
the DT
BCR NNP
@ NNP
ABL NNP
gene NN
, ,
thus RB
preventing VBG
the DT
disease NN
. .
`` ``
In IN
screening NN
biological JJ
substances NNS
, ,
it PRP
will MD
make VB
a DT
very RB
nice JJ
model NN
, ,
'' ''
said VBD
Canellos NNP
. .
Daley NNP
said VBD
the DT
mouse NN
can MD
be VB
used VBN
to TO
test NN
`` ``
biological JJ
inhibitors NNS
'' ''
that IN
would MD
prevent VB
the DT
P210 NNP
protein NN
from IN
transforming VBG
normal JJ
cells NNS
into IN
cancers NNS
. .
Such JJ
inhibitors NNS
formally RB
could MD
only RB
be VB
tested VBN
on IN
human JJ
patients NNS
, ,
a DT
process NN
that WDT
could MD
take VB
years NNS
. .
With IN
a DT
mouse NN
model NN
of IN
the DT
disease NN
, ,
experiments NNS
can MD
be VB
sped VBN
up RP
and CC
can MD
be VB
more RBR
extensive JJ
. .
To TO
create VB
the DT
mouse NN
model NN
, ,
Daley NNP
said VBD
he PRP
and CC
his PRP$
colleagues NNS
inserted VBD
the DT
human JJ
BCR NNP
@ NNP
ABL NNP
gene NN
into IN
a DT
virus JJ
. .
Normal JJ
mouse NN
bone NN
marrow NN
cells NNS
were VBD
then RB
exposed VBN
to TO
the DT
virus NN
, ,
which WDT
transferred VBN
the DT
gene NN
into IN
the DT
marrow NN
cells NNS
. .
Thirty NNP
healthy JJ
mice NN
were VBD
then RB
irradiated VBN
to TO
kill VB
their PRP$
bone NN
marrow NN
cells NNS
. .
Next JJ
, ,
the DT
bone NN
marrow NN
carrying VBG
the DT
BCR NNP
@ NNP
ABL NNP
gene NN
was VBD
transplanted VBN
into IN
the DT
30 CD
mice NN
. .
Within NNP
five CD
months NNS
, ,
13 CD
of IN
the DT
30 CD
mice NN
developed VBD
a DT
blood NN
disease NN
that WDT
mimicked VBD
human NN
chronic NN
myelogenous JJ
leukemia NN
. .
CML NNP
in IN
humans NNS
can MD
be VB
controlled VBN
by IN
chemotherapy NN
for IN
3 CD
to TO
5 CD
years NNS
. .
This DT
remission NN
period NN
usually RB
ends VBZ
with IN
the DT
sudden JJ
increase NN
in IN
abnormal JJ
cells NNS
, ,
a DT
disease NN
phase NN
called VBN
`` ``
blast JJ
crisis NN
'' ''
that WDT
usually RB
results VBZ
in IN
death NN
. .
The DT
only JJ
successful JJ
therapy NN
used VBN
now RB
is VBZ
to TO
kill VB
the DT
diseased VBN
bone NN
marrow NN
in IN
the DT
patient NN
and CC
replace NN
it PRP
with IN
healthy JJ
bone NN
marrow NN
from IN
a DT
compatible JJ
donor NN
, ,
but CC
even RB
this DT
treatment NN
often RB
fails VBZ
. .
Daley NNP
said VBD
that IN
continued VBN
studies NNS
of IN
the DT
CML NNP
mice NN
show NN
that IN
many JJ
of IN
the DT
laboratory NN
animals NNS
develop VB
the DT
`` ``
blast JJ
crisis NN
'' ''
phase NN
of IN
the DT
disease NN
. .
This DT
, ,
he PRP
said VBD
, ,
is VBZ
further JJ
verification NN
that WDT
the DT
course NN
of IN
the DT
disease NN
in IN
the DT
mice NN
mimics NNS
CML NNP
in IN
humans NNS
. .
Richard NNP
A DT
. .
Van NNP
Etten NNP
and CC
David NNP
Baltimore NNP
, ,
both DT
of IN
the DT
Whitehead NNP
Institute NNP
, ,
were VBD
coauthors NNS
of IN
the DT
study NN
with IN
Daley NNP
. .
Science NN
, ,
which WDT
published VBD
the DT
study NN
, ,
is VBZ
the DT
journal NN
of IN
the DT
American NNP
Association NNP
for IN
the DT
Advancement NNP
of IN
Science NNP
. .

<DOCNO> WSJ910208-0083
The DT
study NN
, ,
though IN
still RB
subject JJ
to TO
scientific JJ
peer NN
review NN
, ,
appears VBZ
to TO
support VB
growing VBG
evidence NN
of IN
ties NNS
between IN
electrical JJ
equipment NN
and CC
cancer NN
risks NNS
. .
A DT
recent JJ
Environmental NNP
Protection NNP
Agency NNP
report NN
said VBD
that IN
electro-magnetic JJ
fields NNS
from IN
electric JJ
power NN
lines NNS
are VBP
a DT
possible JJ
-- :
if IN
not RB
proven VBN
-- :
cause NN
of IN
cancer NN
. .
There EX
have VBP
been VBN
reports NNS
that IN
electrical JJ
workers NNS
may MD
be VB
more RBR
at IN
risk NN
of IN
brain NN
tumors NNS
and CC
leukemia NN
. .
And CC
frequently-cited JJ
studies NNS
of IN
Denver NNP
residents NNS
found VBD
correlations NNS
between IN
childhood NN
cancer NN
and CC
neighboring VBG
power NN
lines NNS
. .
Dr. NNP
Peters NNP
's POS
work NN
`` ``
adds VBZ
to TO
the DT
body NN
of IN
evidence NN
'' ''
that WDT
some DT
still-unexplained JJ
process NN
may MD
be VB
increasing VBG
the DT
risk NN
of IN
cancer NN
, ,
said VBD
George NNP
Hidy NNP
, ,
who WP
heads NNS
the DT
environment NN
division NN
of IN
the DT
Electric NNP
Power NNP
Research NNP
Institute NNP
, ,
an DT
industry-financed JJ
group NN
that WDT
paid VBN
for IN
the DT
study NN
. .
The DT
results NNS
of IN
the DT
University NNP
of IN
Southern NNP
California NNP
study NN
had VBD
been VBN
widely RB
awaited VBN
because IN
of IN
a DT
large JJ
sample NN
size NN
-- :
some DT
232 CD
children NNS
with IN
leukemia NN
and CC
an DT
equal JJ
number NN
of IN
healthy JJ
children NNS
-- :
as IN
well RB
as IN
detailed JJ
readings NNS
of IN
electrical JJ
and CC
magnetic JJ
fields NNS
that WDT
were VBD
a DT
part NN
of IN
the DT
research NN
's POS
design NN
. .
But CC
while IN
the DT
research NN
appeared VBD
to TO
offer VB
important JJ
affirmation NN
that WDT
physical JJ
proximity NN
to TO
electrical-transmission NN
equipment NN
may MD
increase VB
the DT
risk NN
of IN
leukemia NN
, ,
it PRP
did VBD
n't RB
answer VB
why WRB
. .
Its PRP$
careful JJ
readings NNS
of IN
magnetic JJ
and CC
electrical JJ
fields NNS
in IN
houses NNS
where WRB
the DT
children NNS
lived VBD
did VBD
n't RB
find VB
that IN
the DT
more RBR
intense JJ
fields NNS
of IN
bigger JJR
power NN
lines NNS
can MD
be VB
directly RB
identified VBN
with IN
increased VBN
likelihood NN
of IN
cancer NN
. .
This DT
initial JJ
failure NN
to TO
tie VB
magnetic JJ
fields NNS
to TO
cancer NN
is VBZ
perplexing VBG
. .
`` ``
We PRP
are VBP
obviously RB
missing VBG
something NN
in IN
this DT
work NN
, ,
'' ''
said VBD
Mr. NNP
Hidy NNP
. .
And CC
, ,
in IN
that DT
sense NN
, ,
the DT
findings NNS
of IN
the DT
latest JJS
study NN
may MD
focus VB
future JJ
research NN
, ,
he PRP
said VBD
. .
The DT
cancer NN
risks NNS
uncovered VBD
were VBD
relatively RB
low JJ
. .
The DT
overall JJ
frequency NN
of IN
childhood NN
leukemia NN
is VBZ
about IN
one CD
case NN
for IN
each DT
20 CD
, ,
000 CD
children NNS
, ,
and CC
an DT
increase NN
of IN
2.5 CD
times NNS
in IN
this DT
frequency NN
implies VBZ
2.5 CD
cases NNS
for IN
each DT
20 CD
, ,
000 CD
youngsters NNS
. .
Results NNS
of IN
the DT
research NN
were VBD
discussed VBN
yesterday NN
at IN
a DT
scientific JJ
conference NN
in IN
Carmel NNP
, ,
Calif. NNP
Sketchy NNP
conclusions NNS
were VBD
disclosed VBN
in IN
both DT
an DT
`` ``
executive JJ
summary NN
'' ''
written VBN
by IN
Dr. NNP
Peters NNP
and CC
in IN
material NN
prepared VBN
by IN
the DT
Electric NNP
Power NNP
Research NNP
Institute NNP
. .
However RB
, ,
Dr. NNP
Peters NNP
could MD
n't RB
be VB
reached VBN
for IN
comment NN
and CC
has VBZ
indicated VBN
that IN
he PRP
wo MD
n't RB
discuss VB
results NNS
of IN
the DT
study NN
outside IN
scientific JJ
circles NNS
until IN
they PRP
have VBP
received VBN
`` ``
peer NN
review NN
'' ''
by IN
fellow JJ
scientists NNS
and CC
been VBN
published VBN
. .
In IN
his PRP$
executive NN
summary NN
, ,
Dr. NNP
Peters NNP
noted VBD
`` ``
considerable JJ
'' ''
evidence NN
of IN
a DT
relationship NN
between IN
childrens NNS
' POS
use NN
of IN
electric JJ
appliances NNS
and CC
the DT
risk NN
of IN
leukemia NN
. .
According VBG
to TO
the DT
Electric NNP
Power NNP
Research NNP
Institute NNP
, ,
the DT
appliances NNS
found VBD
to TO
have VB
strong JJ
correlations NNS
were VBD
hair-dryers NNS
and CC
black-and-white JJ
television NN
sets NNS
. .
The DT
industry NN
research NN
group NN
questioned VBD
these DT
particular JJ
findings NNS
, ,
saying VBG
that IN
they PRP
depended VBD
on IN
parents NNS
' POS
memories NNS
of IN
appliance NN
use NN
and CC
thus RB
were VBD
less JJR
objective JJ
than IN
other JJ
elements NNS
of IN
Dr. NNP
Peters NNP
's POS
findings NNS
. .
The DT
apparent JJ
lack NN
of IN
correlation NN
between IN
careful JJ
measurements NNS
of IN
magnetic-field JJ
strength NN
and CC
cancer NN
could MD
be VB
reversed VBN
with IN
more JJR
statistical JJ
analysis NN
. .
The DT
study NN
, ,
begun NN
in IN
1986 CD
as IN
an DT
expansion NN
of IN
an DT
existing VBG
work NN
on IN
various JJ
potentially RB
leukemia-related JJ
environmental JJ
factors NNS
, ,
included VBD
a DT
wide JJ
range NN
of IN
factors NNS
such JJ
as IN
household NN
chemicals NNS
, ,
cigarette NN
smoke NN
and CC
parent NN
's POS
occupations NNS
. .
But CC
beyond IN
more JJR
statistical JJ
analysis NN
, ,
the DT
lack NN
of IN
a DT
link NN
between IN
magnetic-field JJ
strength NN
and CC
leukemia NN
risk NN
may MD
stem VB
from IN
a DT
24-hour CD
, ,
concentrated VBN
period NN
in IN
which WDT
magnetic JJ
readings NNS
were VBD
made VBN
in IN
houses NNS
. .
`` ``
Over IN
a DT
much JJ
longer NN
term NN
, ,
it PRP
may MD
be VB
that IN
we PRP
will MD
find VB
the DT
relationship NN
, ,
'' ''
said VBD
Mr. NNP
Hidy NNP
. .
Less RBR
plausibly RB
perhaps RB
, ,
the DT
relationship NN
between IN
wires NNS
and CC
cancer NN
could MD
stem VB
not RB
from IN
magnetic JJ
fields NNS
but CC
some DT
other JJ
nonelectrical JJ
environmental JJ
threat NN
. .

<DOCNO> WSJ870320-0168
THE DT
EPISODE NNP
WAS NNP
the DT
kind NN
that IN
makes VBZ
grist NN
for IN
novels NNS
and CC
movies NNS
. .
A DT
40-year-old JJ
man NN
suffering NN
a DT
severe JJ
liver NN
disease NN
had VBD
suddenly RB
developed VBN
a DT
life-threatening JJ
skin NN
condition NN
. .
`` ``
His PRP$
skin NN
was VBD
sloughing VBG
off RP
all DT
over IN
his PRP$
body NN
, ,
'' ''
recalls VBZ
Marshall NNP
M. NNP
Kaplan NNP
, ,
the DT
Tufts NNPS
University NNP
gastroenterologist NN
who WP
had VBD
been VBN
tending VBG
the DT
patient NN
's POS
liver NN
problems NNS
. .
Cortisone NNP
was VBD
n't RB
helping VBG
, ,
`` ``
so IN
the DT
question NN
came VBD
up RP
whether IN
methotrexate JJ
would MD
help VB
, ,
'' ''
Dr. NNP
Kaplan NNP
says VBZ
. .
Methotrexate NNP
is VBZ
an DT
old JJ
anti-cancer NN
drug NN
that WDT
had VBD
been VBN
found VBN
to TO
aid NN
certain JJ
other JJ
skin NN
conditions NNS
, ,
but CC
it PRP
also RB
has VBZ
a DT
dangerous JJ
side NN
effect NN
-- :
liver NN
damage NN
. .
The DT
idea NN
of IN
using VBG
this DT
drug NN
in IN
a DT
man NN
with IN
a DT
diseased VBN
liver NN
was VBD
`` ``
frightening NN
, ,
'' ''
Dr. NNP
Kaplan NNP
says VBZ
. .
`` ``
But CC
if IN
we PRP
did VBD
n't RB
use VB
it PRP
, ,
there EX
was VBD
a DT
good JJ
chance NN
he PRP
would MD
die VB
from IN
the DT
skin NN
condition NN
. .
`` ``
Balancing JJ
the DT
risks NNS
, ,
doctors NNS
began VBD
giving VBG
the DT
man NN
methotrexate NN
. .
`` ``
We PRP
watched VBD
his PRP$
blood NN
tests NNS
( :
for IN
signs NNS
of IN
liver NN
damage NN
) :
, ,
fully RB
expecting VBG
them PRP
to TO
get VB
worse NN
, ,
'' ''
Dr. NNP
Kaplan NNP
says VBZ
. .
Instead RB
, ,
not RB
only RB
did VBD
his PRP$
skin NN
condition NN
clear NN
up IN
, ,
but CC
to TO
the DT
doctors NNS
' POS
astonishment NN
, ,
his PRP$
liver NN
began VBD
to TO
improve VB
. .
Now RB
, ,
eight CD
years NNS
later RBR
, ,
he PRP
takes VBZ
maintenance NN
doses NNS
of IN
methotrexate JJ
, ,
and CC
both DT
his PRP$
skin NN
and CC
liver NN
are VBP
normal JJ
. .
THIS DT
EPISODE NNP
, ,
recently RB
published VBD
in IN
Annals NNP
of IN
Internal NNP
Medicine NNP
, ,
marks VBZ
another DT
serendipitous JJ
incident NN
in IN
the DT
strange NN
history NN
of IN
methotrexate NN
. .
In IN
these DT
days NNS
when WRB
genetic JJ
engineering NN
and CC
molecular JJ
manipulation NN
turn NN
up IN
new JJ
wonder NN
drugs NNS
almost RB
weekly JJ
, ,
methotrexate JJ
stands NNS
out IN
as RB
a DT
baffling NN
technological JJ
anomaly RB
. .
In IN
the DT
40 CD
years NNS
since IN
the DT
drug NN
was VBD
first JJ
synthesized VBN
, ,
it PRP
has VBZ
been VBN
alternately RB
lauded VBN
as IN
a DT
treatment NN
for IN
a DT
variety NN
of IN
human NN
scourges NNS
and CC
castigated VBD
as IN
a DT
poison NN
whose WP$
risks NNS
are VBP
greater JJR
than IN
the DT
diseases NNS
it PRP
's VBZ
being VBG
used VBN
to TO
treat VB
. .
Yet CC
no DT
one NN
is VBZ
quite RB
sure JJ
how WRB
or CC
why WRB
it PRP
does VBZ
what WP
it PRP
does VBZ
. .
The DT
methotrexate NN
story NN
begins VBZ
in IN
the DT
mid-1940s JJ
when WRB
the DT
late JJ
Sidney NNP
Farber NNP
and CC
his PRP$
colleagues NNS
at IN
Children NNP
's POS
Hospital NNP
in IN
Boston NNP
were VBD
attempting VBG
the DT
first JJ
use NN
of IN
chemicals NNS
in IN
the DT
treatment NN
of IN
acute NN
childhood NN
leukemia NN
, ,
then RB
an DT
invariably RB
fatal JJ
blood NN
cancer NN
. .
The DT
cancer NN
researchers NNS
, ,
according VBG
to TO
an DT
oft-told JJ
story NN
, ,
had VBD
noticed VBN
a DT
similarity NN
between IN
the DT
leukemia NN
and CC
a DT
certain JJ
anemia NN
which WDT
was VBD
due JJ
to TO
a DT
deficiency NN
of IN
the DT
vitamin NN
folic JJ
acid NN
. .
This DT
led VBN
them PRP
to TO
treat VB
the DT
leukemia NN
with IN
folic JJ
acid NN
. .
To TO
their PRP$
horror NN
, ,
the DT
folic JJ
acid NN
accelerated VBD
the DT
leukemia NN
instead RB
of IN
retarding VBG
it PRP
. .
This DT
near-disaster JJ
, ,
however RB
, ,
led VBN
them PRP
to TO
try VB
a DT
second JJ
chemical NN
, ,
called VBN
aminopterin NN
, ,
that IN
blocked VBN
the DT
cancer NN
cells NNS
' POS
use NN
of IN
folic JJ
acid NN
. .
In IN
1948 CD
, ,
in IN
an DT
historic JJ
research NN
paper NN
, ,
the DT
Boston NNP
researchers NNS
reported VBD
the DT
first JJ
remissions NNS
of IN
acute JJ
leukemia NN
through IN
chemotherapy NN
. .
Unfortunately RB
, ,
the DT
remissions NNS
lasted VBD
only RB
a DT
few JJ
weeks NNS
or CC
months NNS
. .
The DT
Boston NNP
discovery NN
led VBD
chemists NNS
at IN
Lederle NNP
Laboratories NNPS
, ,
the DT
pharmaceutical JJ
subsidiary NN
of IN
American NNP
Cyanamid NNP
Co. NNP
, ,
to TO
synthesize VB
an DT
improved VBN
version NN
of IN
aminopterin NN
they PRP
called VBD
a-methopterin JJ
, ,
to TO
which WDT
Lederle NNP
's POS
marketing NN
people NNS
affixed VBN
the DT
brand NN
name NN
, ,
Methotrexate NNP
( NNP
the DT
brand NN
name NN
has VBZ
since IN
slid JJ
into IN
generic JJ
use NN
) :
. .
METHOTREXATE NNP
PROVED VBD
even RB
better JJR
at IN
bringing VBG
about IN
remissions NNS
of IN
acute JJ
lymphoblastic JJ
leukemia NN
, ,
and CC
today NN
it PRP
is VBZ
one CD
of IN
the DT
drugs NNS
achieving VBG
cures NNS
of IN
leukemia NN
in IN
about IN
50 CD
% NN
of IN
afflicted VBN
children NNS
. .
By IN
1956 CD
, ,
cancer NN
researchers NNS
reported VBD
another DT
first JJ
: :
Women NNS
developing VBG
an DT
unusual JJ
cancer NN
of IN
the DT
placenta NN
during IN
pregnancy NN
had VBD
been VBN
permanently RB
cured VBN
by IN
methotrexate NN
, ,
the DT
first JJ
cancer NN
ever RB
cured VBN
by IN
chemotherapy NN
. .
In IN
the DT
early JJ
1960s CD
, ,
serendipity NN
struck NN
again RB
. .
A DT
New NNP
York NNP
dermatologist NN
reported VBD
instances NNS
of IN
some DT
patients NNS
being VBG
relieved VBN
of IN
psoriasis NN
, ,
a DT
chronic JJ
and CC
severely RB
disturbing VBG
skin NN
disease NN
, ,
when WRB
treated VBN
with IN
methotrexate JJ
. .
This DT
led VBN
William NNP
O'Brien NNP
and CC
Roger NNP
Black NNP
at IN
the DT
National NNP
Institutes NNPS
of IN
Health NNP
to TO
run VB
a DT
controlled JJ
trial NN
on IN
21 CD
psoriasis NN
patients NNS
. .
Not RB
only RB
did VBD
the DT
skin NN
disorder NN
clear NN
up IN
in IN
several JJ
patients NNS
but CC
so RB
did VBD
a DT
type NN
of IN
arthritis NNS
that WDT
often RB
accompanies VBZ
psoriasis NN
. .
The DT
scientists NNS
then RB
reported VBD
a DT
second JJ
trial NN
showing VBG
that IN
methotrexate JJ
produced VBN
remissions NNS
in IN
some DT
patients NNS
with IN
rheumatoid JJ
arthritis NNS
, ,
the DT
most RBS
common JJ
form NN
of IN
the DT
crippling NN
disorder NN
. .
But CC
, ,
in IN
treating NN
psoriasis NN
patients NNS
, ,
the DT
dangers NNS
of IN
methotrexate JJ
became NN
apparent NN
. .
In IN
high JJ
doses NNS
and CC
daily JJ
use NN
, ,
the DT
drug NN
can MD
cause VB
severe JJ
liver NN
damage NN
and CC
sometimes RB
a DT
lung NN
disorder NN
. .
IN IN
SOME DT
CANCER NN
PATIENTS NNS
, ,
doctors NNS
have VBP
worked VBN
out RP
a DT
unique JJ
`` ``
rescue NN
'' ''
concept NN
, ,
giving VBG
a DT
patient NN
dangerously RB
high JJ
doses NNS
of IN
methotrexate JJ
to TO
kill VB
cancer NN
cells NNS
and CC
then RB
shortly RB
afterward RB
administering VBG
an DT
antidote NN
to TO
save VB
normal JJ
tissues NNS
from IN
its PRP$
poisonous JJ
effects NNS
. .
Methotrexate NNP
's POS
use NN
in IN
arthritis NN
, ,
at IN
least JJS
for IN
patients NNS
whose WP$
disease NN
is VBZ
n't RB
helped VBN
by IN
any DT
other JJ
drug NN
, ,
is VBZ
now RB
being VBG
revived VBN
. .
Researchers NNS
have VBP
treated VBN
several JJ
hundred CD
arthritis NNS
patients NNS
with IN
low JJ
doses NNS
of IN
methotrexate JJ
given VBN
only RB
once RB
a DT
week NN
. .
Anywhere RB
from IN
half DT
to TO
two-thirds NNS
of IN
these DT
patients NNS
improve VBP
; :
some DT
have VBP
remissions NNS
of IN
their PRP$
arthritis NNS
. .
But CC
while IN
many JJ
arthritis NNS
specialists NNS
are VBP
using VBG
methotrexate NN
in IN
`` ``
refractory NN
'' ''
patients NNS
, ,
others NNS
shun VBP
it PRP
. .
One CD
is VBZ
Dr. NNP
O'Brien NNP
, ,
who WP
did VBD
the DT
first JJ
trial NN
of IN
methotrexate NN
in IN
arthritis NN
and CC
who WP
is VBZ
now RB
a DT
professor NN
at IN
the DT
University NNP
of IN
Virginia NNP
. .
Because IN
of IN
its PRP$
toxicity NN
, ,
he PRP
says VBZ
, ,
`` ``
we PRP
do VBP
n't RB
use VB
it PRP
anymore JJR
here RB
in IN
Charlottesville NNP
. .
`` ``
Meanwhile RB
, ,
in IN
Boston NNP
, ,
Dr. NNP
Kaplan NNP
and CC
his PRP$
colleagues NNS
say VBP
they PRP
had VBD
a DT
second JJ
patient NN
with IN
the DT
same JJ
severe NN
liver NN
disease NN
as IN
the DT
first JJ
but CC
without IN
the DT
skin NN
problem NN
. .
`` ``
He PRP
was VBD
at IN
his PRP$
wits NNS
' POS
end NN
, ,
'' ''
Dr. NNP
Kaplan NNP
says VBZ
. .
`` ``
I PRP
thought VBD
of IN
that DT
first JJ
patient NN
and CC
said VBD
, ,
'If JJ
you PRP
're VBP
a DT
gambler NN
and CC
you PRP
want VBP
to TO
try NN
methotrexate NN
, ,
we PRP
'll MD
do VB
it PRP
. .
' POS
'' ''
The DT
patient NN
's POS
liver NN
is VBZ
now RB
normal JJ
. .
A DT
clinical JJ
trial NN
of IN
methotrexate NN
in IN
the DT
liver NN
disease NN
, ,
called VBN
primary JJ
sclerosis NN
cholangitis NNS
, ,
is VBZ
now RB
under IN
way NN
. .

<DOCNO> SJMN91-06080197
`` ``
I PRP
think VBP
it PRP
's VBZ
disturbing VBG
, ,
'' ''
said VBD
Steve NNP
Wing NNP
, ,
a DT
University NNP
of IN
North NNP
Carolina NNP
epidemiologist NN
who WP
was VBD
the DT
principal JJ
author NN
of IN
the DT
study NN
. .
`` ``
We PRP
have VBP
seen VBN
an DT
association NN
between IN
cancer NN
mortality NN
and CC
radiation NN
doses NNS
at IN
a DT
very RB
low JJ
level NN
. .
. .
. .
. .
Many JJ
people NNS
have VBP
assumed VBN
that IN
there EX
is VBZ
no DT
safe NN
level NN
of IN
exposure NN
, ,
but CC
it PRP
has VBZ
been VBN
assumed VBN
that IN
the DT
chances NNS
of IN
finding VBG
an DT
effect NN
of IN
exposures NNS
at IN
this DT
level NN
would MD
be VB
like IN
a DT
few JJ
drops NNS
of IN
water NN
in IN
a DT
swimming NN
pool NN
, ,
not RB
enough RB
to TO
be VB
measurable JJ
. .
Now RB
we PRP
see VBP
it PRP
looks VBZ
like IN
it PRP
's VBZ
not RB
just RB
a DT
few JJ
drops NNS
, ,
and CC
that's NNP
disturbing NN
. .
`` ``
; :
The DT
report NN
does VBZ
not RB
say VB
there EX
is VBZ
a DT
cause-and-effect JJ
relationship NN
between IN
the DT
low-exposure JJ
levels NNS
and CC
the DT
increased VBN
leukemia NN
rate NN
. .
Nor NNP
does VBZ
it PRP
suggest VBP
that IN
there EX
is VBZ
any DT
danger NN
to TO
residents NNS
of IN
communities NNS
surrounding VBG
nuclear JJ
facilities NNS
. .
On IN
the DT
contrary NN
, ,
a DT
previously RB
publicized VBN
study NN
, ,
published VBD
in IN
the DT
same JJ
issue NN
, ,
says VBZ
`` ``
deaths NNS
due JJ
to TO
leukemia VB
or CC
other JJ
cancers NNS
'' ''
in IN
107 CD
counties NNS
where WRB
such JJ
facilities NNS
are VBP
located VBN
were VBD
not RB
more RBR
frequent JJ
than IN
elsewhere RB
. .
; :
Wing NNP
and CC
his PRP$
colleagues NNS
examined VBD
the DT
records NNS
of IN
8 CD
, ,
318 CD
white JJ
men NNS
who WP
worked VBD
at IN
Oak NNP
Ridge NNP
from IN
1943 CD
to TO
1972 CD
. .
Because IN
they PRP
came VBD
from IN
a DT
generally RB
well-educated JJ
and CC
prosperous JJ
segment NN
of IN
the DT
population NN
, ,
the DT
researchers NNS
said VBD
, ,
the DT
workers NNS
had VBD
lower-than-expected JJ
death NN
rates NNS
from IN
all DT
causes NNS
, ,
including VBG
cancers NNS
other JJ
than IN
leukemia NN
. .
; :
But CC
of IN
the DT
1 CD
, ,
524 CD
who WP
are VBP
known VBN
to TO
have VB
died VBN
, ,
28 CD
died VBD
of IN
leukemia NN
, ,
and CC
two CD
others NNS
had VBD
leukemia NNS
among IN
other JJ
illnesses NNS
, ,
a DT
rate NN
`` ``
63 CD
percent NN
higher JJR
than IN
expected VBN
, ,
'' ''
the DT
researchers NNS
found VBD
. .
; :
Wing NNP
's POS
study NN
was VBD
financed VBN
by IN
the DT
Energy NNP
Department NNP
, ,
which WDT
operates VBZ
Oak NNP
Ridge NNP
, ,
as IN
part NN
of IN
a DT
long-term JJ
study NN
begun NN
in IN
1943 CD
of IN
the DT
effects NNS
on IN
workers NNS
and CC
nearby JJ
residents NNS
of IN
the DT
nuclear JJ
weapons NNS
manufacturing VBG
operations NNS
. .
; :
Assistant NNP
Energy NNP
Secretary NNP
Paul NNP
Ziemer NNP
, ,
a DT
former JJ
health NN
physicist NN
at IN
Oak NNP
Ridge NNP
, ,
said VBD
Wing NNP
's POS
report NN
was VBD
`` ``
clearly RB
a DT
real JJ
finding NN
, ,
'' ''
but CC
he PRP
said VBD
it PRP
would MD
be VB
premature NN
to TO
decrease VB
the DT
permissible-exposure JJ
standard JJ
on IN
that DT
basis NN
alone NN
. .
; :
International NNP
agencies NNS
that WDT
set VBN
exposure NN
limits NNS
are VBP
constantly RB
re-evaluating JJ
available JJ
data NNS
and CC
will MD
consider VB
Wing NNP
's POS
findings NNS
among IN
others NNS
in IN
deciding NN
whether IN
to TO
recommend VB
that IN
limits NNS
be VB
tightened VBN
, ,
Ziemer NNP
said VBD
. .

<DOCNO> AP880609-0061
The DT
rate NN
of IN
leukemia NN
among IN
young JJ
people NNS
living VBG
near IN
a DT
nuclear JJ
complex NN
in IN
a DT
barren NN
area NN
of IN
northern JJ
Scotland NNP
is VBZ
nearly RB
twice NN
Britain NNP
's POS
national JJ
rate NN
, ,
a DT
report NN
published VBD
today NN
says VBZ
. .
The DT
report NN
by IN
the DT
government-sponsored JJ
Committee NNP
on IN
Medical NNP
Aspects NNP
of IN
Radiation NNP
in IN
the DT
Environment NNP
says VBZ
six CD
known VBN
cases NNS
of IN
leukemia NN
were VBD
diagnosed VBN
among IN
young JJ
people NNS
under IN
24 CD
who WP
lived VBN
within IN
15 CD
miles NNS
of IN
the DT
plant NN
in IN
Dounreay NNP
between IN
1968 CD
and CC
1984 CD
. .
`` ``
This DT
is VBZ
twice NN
the DT
number NN
expected VBN
on IN
the DT
basis NN
of IN
the DT
national JJ
rate NN
, ,
'' ''
the DT
report NN
says VBZ
, ,
adding VBG
that IN
the DT
likelihood NN
of IN
such JJ
a DT
high JJ
rate NN
occurring VBG
by IN
chance NN
is VBZ
about IN
one CD
in IN
12 CD
. .
Five CD
of IN
the DT
victims NNS
lived VBD
within IN
7.8 CD
miles NNS
of IN
the DT
nuclear JJ
complex NN
, ,
the DT
center NN
for IN
Britain NNP
's POS
fast-breeder JJ
reactor NN
research NN
program NN
, ,
the DT
study NN
says VBZ
. .
The DT
report NN
says VBZ
the DT
reason NN
for IN
the DT
number NN
of IN
leukemia NN
cases NNS
is VBZ
not RB
known VBN
, ,
though IN
the DT
findings NNS
echo VBP
a DT
1986 CD
government NN
investigation NN
showing VBG
the DT
childhood NN
leukemia NN
rate NN
near IN
the DT
Sellafield NNP
nuclear JJ
reprocessing NN
plant NN
in IN
Cumbria NNP
, ,
northwest JJS
England NNP
, ,
to TO
be VB
four CD
times NNS
the DT
national JJ
average NN
. .
`` ``
It PRP
is VBZ
hard RB
to TO
imagine VB
that IN
you PRP
could MD
see VB
an DT
excess NN
around IN
Dounreay NNP
and CC
an DT
excess NN
around IN
Sellafield NNP
, ,
and CC
it PRP
is VBZ
just RB
bad JJ
luck NN
, ,
'' ''
said VBD
commission NN
chairman NN
Martin NNP
Bobrow NNP
. .
The DT
committee NN
said VBD
it PRP
was VBD
`` ``
conceivable JJ
that DT
minute NN
amounts VBZ
of IN
radioactive JJ
material NN
carried VBD
home NN
may MD
accumulate VB
and CC
lead VB
to TO
exposure VB
of IN
infants NNS
in IN
some DT
unforeseen NN
way NN
. .
'' ''
But CC
it PRP
said VBD
the DT
level NN
of IN
leukemia NN
might MD
also RB
be VB
due JJ
to TO
exposure VB
to TO
chemicals NNS
, ,
viruses NNS
or CC
even RB
chance NN
. .
Scottish JJ
Health NNP
Minister NNP
Michael NNP
Forsyth NNP
said VBD
the DT
government NN
had VBD
accepted VBN
the DT
committee NN
's POS
recommendation NN
to TO
hold VB
an DT
investigation NN
into IN
the DT
high JJ
rates NNS
, ,
despite IN
the DT
`` ``
small JJ
number NN
of IN
cases NNS
involved VBN
. .
'' ''
However NNP
, ,
union NN
spokesman NN
Bryan NNP
Durrans NNP
of IN
the DT
Institute NNP
of IN
Professional NNP
Civil NNP
Servants NNP
called VBD
the DT
report NN
`` ``
inconclusive JJ
. .
'' ''
`` ``
If IN
most JJS
of IN
us PRP
thought VBD
anything NN
was VBD
likely JJ
to TO
happen VB
to TO
our PRP$
children NNS
or CC
families NNS
, ,
we PRP
would MD
not RB
be VB
here RB
. .
'' ''
he PRP
said VBD
. .
The DT
Dounreay NNP
complex NN
employs VBZ
2 CD
, ,
100 CD
workers NNS
in IN
a DT
barren NN
area NN
of IN
Northern NNP
Scotland NNP
that IN
offers NNS
little RB
alternative JJ
employment NN
. .
The DT
environmental JJ
group NN
Friends NNPS
of IN
the DT
Earth NNP
lauded VBD
the DT
report NN
as IN
the DT
first JJ
government NN
admission NN
of IN
a DT
link NN
between IN
leukemia NN
and CC
nuclear JJ
emissions NNS
, ,
and CC
called VBN
for IN
an DT
immediate JJ
closure NN
of IN
both DT
the DT
Dounreay NNP
and CC
Sellafield NNP
plants NNS
. .
`` ``
The DT
nuclear JJ
industry NN
has VBZ
finally RB
been VBN
implicated VBN
in IN
causing NN
cancers NNS
_ NNP
something NN
it PRP
has VBZ
denied VBN
for IN
years NNS
, ,
'' ''
said VBD
spokesman NN
Stewart NNP
Boyle NNP
. .
Leukemia NNP
clusters NNS
_ NNP
occurrences NNS
of IN
the DT
disease NN
statistically RB
higher JJR
than IN
normal JJ
_ NNP
have VBP
also RB
been VBN
found VBN
in IN
southern NN
England NNP
near IN
the DT
Atomic NNP
Weapons NNP
Research NNP
Establishment NNP
, ,
the DT
Royal NNP
Ordnance NNP
Factory NNP
and CC
the DT
U.K. NNP
Atomic NNP
Energy NNP
Authority NNP
. .
In IN
each DT
case NN
, ,
scientists NNS
in IN
the DT
nuclear JJ
industry NN
argued VBD
that IN
recorded VBN
emissions NNS
of IN
radiation NN
were VBD
not RB
high JJ
enough RB
to TO
account VB
for IN
higher JJR
rates NNS
of IN
the DT
radiation-linked JJ
disease NN
. .
The DT
national JJ
leukemia NN
rate NN
is VBZ
eight CD
cases NNS
per IN
100 CD
, ,
000 CD
people NNS
. .

<DOCNO> AP880909-0135
The DT
death NN
rate NN
from IN
leukemia NN
was VBD
nearly RB
60 CD
percent NN
higher JJR
among IN
smokers NNS
of IN
more JJR
than IN
10 CD
cigarettes NNS
a DT
day NN
than IN
among IN
non-smokers NNS
, ,
according VBG
to TO
a DT
study NN
published VBN
Friday NNP
. .
While IN
no DT
direct JJ
link NN
has VBZ
been VBN
established VBN
between IN
smoking NN
and CC
leukemia NN
, ,
research NN
published VBD
in IN
the DT
British JJ
Medical JJ
Journal NNP
showed VBD
that IN
the DT
leukemia NN
death NN
rate NN
among IN
people NNS
who WP
smoked VBN
fewer JJR
than IN
10 CD
cigarettes NNS
a DT
day NN
was VBD
34 CD
percent NN
higher JJR
than IN
among IN
non-smokers NNS
. .
For IN
smokers NNS
of IN
10 CD
to TO
20 CD
cigarettes NNS
a DT
day NN
it PRP
was VBD
57 CD
percent NN
, ,
and CC
for IN
smokers NNS
of IN
21 CD
or CC
more JJR
cigarettes NNS
63 CD
percent NN
, ,
the DT
study NN
showed VBD
. .
`` ``
If IN
the DT
findings NNS
in IN
our PRP$
study NN
represented VBD
a DT
direct JJ
relationship NN
between IN
smoking NN
and CC
leukemia NN
, ,
then RB
it PRP
must MD
follow VB
that IN
smoking NN
is VBZ
responsible JJ
for IN
more RBR
cases NNS
of IN
leukemia NN
than IN
all DT
the DT
hitherto NN
established VBD
causes NNS
combined VBN
, ,
'' ''
said VBD
Dr. NNP
Leo NNP
Kinlen NNP
, ,
director NN
of IN
the DT
Cancer NNP
Epidemiology NNP
Unit NNP
at IN
the DT
University NNP
of IN
Edinburgh NNP
. .
Kinlen NNP
conducted VBD
the DT
study NN
of IN
248 CD
, ,
000 CD
U.S. NNP
military JJ
veterans NNS
with IN
E. NNP
Rogot NNP
, ,
a DT
statistician JJ
at IN
the DT
National NNP
Heart NNP
, ,
Lung NNP
and CC
Blood NNP
Institute NNP
of IN
the DT
National NNP
Institutes NNPS
of IN
Health NNP
in IN
Bethesda NNP
, ,
Maryland NNP
. .
They PRP
wrote VBD
that IN
it PRP
was VBD
`` ``
the DT
largest JJS
study NN
of IN
leukemia NN
and CC
smoking NN
habits NNS
to TO
date NN
( :
and CC
) :
represents NNS
additional JJ
evidence NN
that IN
leukemia NN
is VBZ
a DT
smoking-related JJ
disease NN
. .
'' ''
In IN
an DT
editorial NN
in IN
the DT
prestigious JJ
weekly JJ
, ,
Professor NNP
Nicholas NNP
Wald NNP
of IN
St. NNP
Bartholemew NNP
's POS
Hospital NNP
in IN
London NNP
cautioned VBD
that IN
no DT
cause-and-effect JJ
relationship NN
had VBD
been VBN
established VBN
. .
But CC
he PRP
added VBD
: :
`` ``
Whatever RB
the DT
mechanism NN
, ,
the DT
balance NN
of IN
evidence NN
suggests VBZ
that IN
smoking NN
may MD
cause VB
leukemia NN
. .
'' ''
It PRP
should MD
therefore VB
be VB
added VBN
to TO
the DT
World NNP
Heath NNP
Organization's NNP
list NN
of IN
tobacco-related JJ
causes NNS
of IN
death NN
, ,
he PRP
wrote VBD
. .
The DT
study NN
was VBD
conducted VBN
on IN
data NNS
collected VBN
from IN
248 CD
, ,
000 CD
veterans NNS
between IN
1954 CD
and CC
1969 CD
, ,
the DT
researchers NNS
wrote VBD
. .
During IN
that DT
period NN
723 CD
died VBD
of IN
leukemia NN
. .
Of IN
these DT
330 CD
were VBD
cigarette JJ
smokers NNS
, ,
185 CD
were VBD
ex-smokers NNS
, ,
46 CD
smoked VBD
cigars NNS
or CC
and CC
162 CD
were VBD
non-smokers NNS
. .
The DT
study NN
found VBD
that IN
in IN
some DT
types NNS
of IN
leukemia NN
, ,
the DT
death NN
rate NN
among IN
smokers NNS
was VBD
sharply RB
higher JJR
than IN
the DT
average NN
. .
Thus RB
for IN
monocytic JJ
and CC
myeloid JJ
leukemias NNS
, ,
the DT
rate NN
among IN
smokers NNS
of IN
more JJR
than IN
20 CD
cigarettes NNS
a DT
day NN
was VBD
93 CD
percent NN
higher JJR
, ,
compared VBN
with IN
48 CD
percent NN
for IN
lymphatic JJ
leukemias NNS
. .
For IN
smokers NNS
of IN
10 CD
to TO
20 CD
cigarettes NNS
a DT
day NN
the DT
rate NN
of IN
death NN
from IN
lymphatic JJ
leukemia NN
was VBD
76 CD
percent NN
higher JJR
, ,
and CC
for IN
one CD
to TO
10 CD
cigarettes NNS
, ,
40 CD
percent NN
higher JJR
. .
When WRB
the DT
data NNS
was VBD
broken VBN
down RP
into IN
smokers NNS
and CC
ex-smokers NNS
, ,
it PRP
suggested VBD
that IN
ex-smokers NNS
also RB
are VBP
significantly RB
more RBR
at IN
risk NN
. .
The DT
death NN
rate NN
among IN
smokers NNS
was VBD
53 CD
percent NN
higher JJR
, ,
and CC
among IN
ex-smokers NNS
39 CD
percent NN
. .

<DOCNO> WSJ910516-0166
Because IN
of IN
the DT
way NN
the DT
acne NN
drug NN
is VBZ
thought VBN
to TO
work VB
, ,
the DT
results NNS
support NN
a DT
new JJ
concept NN
of IN
cancer NN
chemotherapy NN
. .
In IN
the DT
type NN
of IN
leukemia NN
suffered VBD
by IN
the DT
patients NNS
, ,
white JJ
blood NN
cells NNS
have VBP
turned VBN
malignant JJ
at IN
an DT
immature NN
stage NN
of IN
cell NN
development NN
. .
Their PRP$
arrested VBN
development NN
is VBZ
what WP
renders NNS
them PRP
practically RB
immortal JJ
and CC
dangerous JJ
. .
The DT
acne NN
drug NN
is VBZ
believed VBN
to TO
trigger JJR
these DT
immature NN
but CC
malignant JJ
cells NNS
to TO
divide VB
and CC
mature VB
and CC
then RB
die VB
essentially RB
a DT
natural JJ
death NN
. .
This DT
new JJ
concept NN
of IN
triggering VBG
cancer NN
cells NNS
to TO
mature VB
and CC
die VB
contrasts NNS
with IN
the DT
conventional JJ
concept NN
of IN
chemotherapy NN
, ,
in IN
which WDT
drugs NNS
simply RB
poison NN
malignant NN
cells NNS
. .
The DT
drug NN
used VBD
in IN
the DT
experimental JJ
treatment NN
is VBZ
known VBN
as IN
tretinoin NN
, ,
which WDT
belongs NNS
to TO
a DT
class NN
of IN
chemicals NNS
called VBN
retinoic JJ
acids NNS
that WDT
are VBP
related VBN
to TO
vitamin VB
A. NNP
Tretinoin NNP
is VBZ
sold VBN
in IN
ointment NN
form NN
as IN
Retin-A NNP
, ,
the DT
acne NN
medication NN
produced VBN
by IN
Johnson NNP
& CC
amp VB
; :
Johnson NNP
's POS
Ortho NNP
Pharmaceutical NNP
division NN
. .
The DT
tretinoin NN
used VBD
in IN
the DT
leukemia NN
patients NNS
, ,
however RB
, ,
is VBZ
a DT
pill NN
that WDT
was VBD
prepared VBN
for IN
the DT
experiment NN
by IN
chemists NNS
at IN
Hoffmann-La NNP
Roche NNP
Inc. NNP
, ,
the DT
U.S. NNP
arm NN
of IN
Roche NNP
Holding NNP
Ltd. NNP
of IN
Switzerland NNP
. .
Roche NNP
, ,
which WDT
has VBZ
a DT
long JJ
history NN
of IN
making VBG
retinoic JJ
acids NNS
, ,
sells NNS
one CD
of IN
its PRP$
acids NNS
as IN
Accutane NNP
, ,
a DT
pill NN
for IN
treating NN
severe RB
acne NN
. .
The DT
particular JJ
form NN
of IN
leukemia NN
that IN
appears NNS
to TO
respond VB
readily RB
to TO
the DT
acne-drug NN
type NN
of IN
treatment NN
is VBZ
called VBN
acute JJ
promyelocytic JJ
leukemia NN
. .
It PRP
is VBZ
an DT
uncommon NN
cancer NN
, ,
afflicting VBG
about IN
1 CD
, ,
000 CD
Americans NNS
a DT
year NN
, ,
in IN
which WDT
certain JJ
cells NNS
in IN
the DT
bone NN
marrow NN
become NN
malignant NN
before IN
they PRP
have VBP
matured VBN
into IN
fully RB
functioning VBG
white JJ
blood NN
cells NNS
. .
The DT
malignant NN
, ,
immature NN
white NN
cells NNS
( :
known VBN
as IN
myelocytes NNS
) :
flood NN
the DT
blood NN
stream NN
, ,
producing VBG
fatigue NN
, ,
fever RB
, ,
weight RB
loss NN
and CC
bleeding VBG
. .
Until IN
now RB
, ,
chemotherapy NN
with IN
standard JJ
anti-cancer NN
drugs NNS
has VBZ
been VBN
the DT
only JJ
effective JJ
treatment NN
for IN
acute NN
promyelocyltic JJ
leukemia NN
, ,
but CC
it PRP
produces VBZ
cures NNS
in IN
only RB
about IN
a DT
third JJ
of IN
patients NNS
. .
The DT
tip-off JJ
that IN
an DT
tretinoin-like JJ
drug NN
might MD
be VB
effective JJ
in IN
treating NN
the DT
leukemia NN
came VBD
from IN
a DT
genetic JJ
finding NN
, ,
Dr. NNP
Raymond NNP
P. NNP
Warrell NNP
Jr. NNP
of IN
Memorial NNP
Sloan-Kettering JJ
and CC
his PRP$
colleagues NNS
in IN
New NNP
York NNP
and CC
at IN
M.D JJ
. .
Anderson NNP
Cancer NNP
Center NNP
in IN
Houston NNP
reported VBD
in IN
this DT
week NN
's POS
New NNP
England NNP
Journal NNP
of IN
Medicine NNP
. .
Most JJS
patients NNS
with IN
promyleocytic JJ
leukemia NNS
apparently RB
have VBP
the DT
same JJ
defect NN
in IN
two CD
of IN
their PRP$
23 CD
chromosomes NNS
, ,
the DT
structures NNS
in IN
the DT
cell NN
that IN
contain NN
all DT
the DT
genes NNS
. .
A DT
piece NN
of IN
chromosome NN
number NN
17 CD
appears NNS
to TO
have VB
broken VBN
loose JJ
and CC
become VB
a DT
part NN
of IN
chromosome NN
number NN
15 CD
. .
Last JJ
year NN
, ,
molecular JJ
geneticists NNS
identified VBD
one CD
of IN
the DT
genes NNS
in IN
chromosome NN
17 CD
that WDT
was VBD
damaged VBN
when WRB
the DT
chunk NN
of IN
the DT
chromosome NN
broke NN
loose NN
. .
The DT
damaged VBN
gene NN
, ,
it PRP
turned VBD
out RP
, ,
ordinarily RB
made VBD
a DT
protein NN
-- :
a DT
receptor NN
-- :
that IN
grabbed JJ
hold NN
of IN
retinoic JJ
acid NN
. .
This DT
and CC
other JJ
laboratory NN
findings NNS
suggested VBD
that IN
the DT
immaturity NN
of IN
the DT
leukemic JJ
white JJ
blood NN
cells NNS
might MD
somehow VB
be VB
related VBN
to TO
a DT
foul-up JJ
in IN
the DT
way NN
the DT
cells NNS
handled VBD
or CC
failed VBN
to TO
handle VB
retinoic JJ
acid NN
. .
The DT
nature NN
of IN
the DT
genetic JJ
damage NN
also RB
hinted VBD
that IN
doses NNS
of IN
retinoic JJ
acids NNS
might MD
prod VB
the DT
immature NN
malignant NN
cells NNS
to TO
proceed VB
to TO
maturity NN
and CC
then RB
die VB
as IN
normal JJ
white JJ
blood NN
cells NNS
do VBP
. .
`` ``
We PRP
're VBP
now RB
the DT
third JJ
group NN
to TO
show VB
remissions NNS
{ :
with IN
tretinoin NN
} :
in IN
this DT
leukemia NN
, ,
'' ''
following VBG
Chinese NNP
and CC
French NNP
researchers NNS
, ,
Dr. NNP
Warrell NNP
said VBD
. .
But CC
, ,
he PRP
added VBD
, ,
the DT
U.S. NNP
group NN
is VBZ
the DT
first JJ
to TO
show VB
that IN
the DT
drug NN
works VBZ
by IN
triggering NN
the DT
immature NN
cancer NN
cells NNS
to TO
mature VB
, ,
or CC
to TO
`` ``
differentiate VB
, ,
'' ''
in IN
the DT
biologists NNS
jargon VBP
. .
`` ``
We PRP
've VBP
documented VBN
conclusively RB
that IN
differentiation NN
as IN
a DT
method NN
of IN
cancer NN
therapy NN
in IN
humans NNS
is VBZ
a DT
reality NN
, ,
'' ''
he PRP
said VBD
. .

<DOCNO> WSJ870120-0009
Researchers NNS
are VBP
quietly RB
conducting VBG
a DT
large-scale JJ
sampling NN
of IN
the DT
nation NN
's POS
blood NN
supply NN
to TO
see VB
if IN
a DT
rare NN
virus NN
capable JJ
of IN
causing VBG
cancer NN
and CC
, ,
possibly RB
, ,
a DT
mysterious JJ
nerve NN
disease NN
is VBZ
being VBG
spread VBN
among IN
Americans NNPS
. .
The DT
virus NN
, ,
until IN
now RB
, ,
has VBZ
been VBN
confined VBN
to TO
small JJ
areas NNS
of IN
Japan NNP
, ,
the DT
Caribbean NNP
and CC
the DT
Mediterranean NNP
. .
It PRP
is VBZ
, ,
however RB
, ,
similar JJ
to TO
the DT
virus NN
that IN
causes NNS
acquired VBD
immune JJ
deficiency NN
syndrome NN
, ,
or CC
AIDS NNP
. .
Now RB
, ,
scientists NNS
are VBP
increasingly RB
concerned VBN
that IN
the DT
virus NN
, ,
which WDT
can MD
cause VB
a DT
form NN
of IN
adult NN
leukemia NN
, ,
is VBZ
being VBG
transmitted VBN
like IN
AIDS NNP
: :
through IN
an DT
exchange NN
of IN
blood NN
by IN
hypodermic JJ
syringes NNS
, ,
sexual JJ
practices NNS
or CC
transfusions NNS
. .
Although IN
it PRP
is VBZ
far RB
too RB
early RB
to TO
tell VB
how WRB
many JJ
people NNS
have VBP
been VBN
infected VBN
and CC
how WRB
many JJ
will MD
actually RB
develop VB
cancer NN
or CC
the DT
nerve NN
disease NN
, ,
evidence NN
already RB
suggests VBZ
that IN
many JJ
drug NN
addicts NNS
in IN
the DT
U.S. NNP
have VBP
been VBN
exposed VBN
to TO
the DT
virus NN
. .
And CC
there EX
is VBZ
at IN
least JJS
one CD
cluster NN
of IN
cases NNS
of IN
the DT
rare NN
leukemia NN
in IN
New NNP
York NNP
's POS
Bedford-Stuyvesant JJ
neighborhood NN
, ,
although IN
doctors NNS
do VBP
n't RB
know VB
how WRB
the DT
victims NNS
acquired VBD
the DT
virus NN
. .
In IN
an DT
unannounced VBN
move NN
, ,
the DT
American NNP
Red NNP
Cross NNP
late RB
last JJ
week NN
began VBD
testing NN
for IN
evidence NN
of IN
the DT
virus NN
in IN
blood NN
donated VBN
by IN
30 CD
, ,
000 CD
people NNS
in IN
six CD
unidentified VBN
cities NNS
around IN
the DT
country NN
. .
The DT
effort NN
follows VBZ
the DT
federal JJ
government NN
's POS
approval NN
of IN
an DT
experimental JJ
test NN
kit NN
to TO
detect VB
antibodies NNS
to TO
the DT
virus NN
. .
The DT
sampling NN
, ,
while IN
technically RB
a DT
trial NN
of IN
the DT
accuracy NN
of IN
the DT
new JJ
blood NN
test NN
, ,
should MD
also RB
indicate VB
whether IN
the DT
cancer NN
virus VBZ
is VBZ
enough RB
of IN
a DT
threat NN
for IN
blood NN
banks NNS
to TO
begin VB
routine JJ
screening NN
of IN
donated VBN
blood NN
as IN
is VBZ
now RB
done VBN
for IN
AIDS NNP
and CC
hepatitis VBZ
. .
`` ``
We PRP
have VBP
evidence NN
now RB
that IN
a DT
virus NN
spread NN
by IN
blood NN
and CC
associated VBN
with IN
a DT
very RB
serious JJ
disease NN
has VBZ
been VBN
detected VBN
in IN
the DT
U.S. NNP
, ,
'' ''
says VBZ
S. NNP
Gerald NNP
Sandler NNP
, ,
medical JJ
director NN
of IN
the DT
Red NNP
Cross NNP
. .
`` ``
Since IN
this DT
is VBZ
happening VBG
, ,
it PRP
is VBZ
the DT
responsibility NN
of IN
the DT
American NNP
Red NNP
Cross NNP
to TO
be VB
at IN
the DT
head NN
of IN
a DT
scientific JJ
investigation NN
to TO
quantify VB
the DT
incidence NN
of IN
the DT
virus NN
's POS
presence NN
and CC
spread NN
. .
`` ``
Adds VBZ
Bernard NNP
Poiesz NNP
, ,
head NN
of IN
the DT
division NN
of IN
hematology-oncology NN
at IN
the DT
State NNP
University NNP
of IN
New NNP
York NNP
in IN
Syracuse NNP
: :
`` ``
Incidence NN
of IN
the DT
virus NN
in IN
the DT
U.S. NNP
has VBZ
been VBN
sporadic JJ
, ,
but CC
it PRP
is VBZ
increasing VBG
now RB
. .
We PRP
are VBP
now RB
beginning VBG
to TO
realize VB
that IN
the DT
virus NN
is VBZ
causing VBG
a DT
real JJ
health NN
problem NN
in IN
this DT
country NN
. .
`` ``
The DT
virus NN
poses VBZ
an DT
unusual JJ
threat NN
because IN
of IN
its PRP$
long JJ
latency NN
period NN
. .
People NNS
infected VBD
with IN
the DT
virus NNS
may MD
not RB
develop VB
leukemia NN
for IN
several JJ
years NNS
. .
Thus RB
, ,
if IN
the DT
virus NN
is VBZ
spreading VBG
now RB
, ,
it PRP
may MD
be VB
a DT
decade NN
before IN
enough JJ
leukemia NN
cases NNS
develop VB
to TO
trigger VB
the DT
nation NN
's POS
epidemic JJ
alarm NN
system NN
. .
No DT
one NN
knows VBZ
what WP
percentage NN
of IN
infected VBN
individuals NNS
will MD
develop VB
leukemia NN
or CC
the DT
nerve NN
disease NN
. .
Although IN
the DT
cancer NN
threat NN
alone NN
has VBZ
worried VBN
health NN
officials NNS
for IN
several JJ
months NNS
, ,
those DT
concerns NNS
have VBP
increased VBN
following VBG
reports NNS
that IN
link NN
the DT
virus NN
with IN
a DT
nerve NN
condition NN
known VBN
as IN
tropical JJ
spastic JJ
paraparesis NN
or CC
TSP NNP
, ,
explains VBZ
William NNP
A. NNP
Blattner NNP
of IN
the DT
environmental JJ
epidemiology NN
branch NN
of IN
the DT
National NNP
Cancer NNP
Institute NNP
. .
The DT
nerve NN
disease NN
is VBZ
similar JJ
to TO
multiple VB
sclerosis NN
and CC
afflicts NNS
muscle NN
function NN
. .
It PRP
was VBD
first JJ
identified VBN
in IN
the DT
1960s CD
in IN
Jamaica NNP
. .
Last JJ
fall NN
, ,
however RB
, ,
French JJ
researchers NNS
in IN
Martinique NNP
linked VBD
the DT
nerve NN
disease NN
to TO
the DT
virus NN
after IN
finding NN
that IN
many JJ
TSP NNP
victims NNS
had VBD
been VBN
infected VBN
with IN
the DT
leukemia NN
virus VBZ
. .
Subsequently RB
, ,
Japanese JJ
researchers NNS
found VBD
that IN
many JJ
TSP NNP
victims NNS
in IN
Japan NNP
had VBD
previously RB
had VBD
blood VBN
transfusions NNS
. .
Although IN
the DT
incidence NN
of IN
TSP NNP
in IN
the DT
U.S. NNP
is VBZ
n't RB
known VBN
, ,
the DT
links NNS
between IN
the DT
leukemia NN
virus VBZ
, ,
the DT
nerve NN
disease NN
and CC
blood NN
transfusions NNS
have VBP
apparently RB
spurred VBN
the DT
preliminary JJ
screening NN
of IN
blood NN
supplies NNS
by IN
the DT
Red NNP
Cross NNP
. .
The DT
virus NN
is VBZ
known VBN
as IN
human JJ
T-cell NN
leukemia NN
virus VBZ
one CD
, ,
or CC
HTLV-I NNP
. .
The DT
T NNP
cell NN
is VBZ
a DT
particular JJ
type NN
of IN
white JJ
blood NN
cell NN
that WDT
is VBZ
infected VBN
and CC
turned VBD
malignant JJ
by IN
the DT
virus NN
. .
Less RBR
than IN
a DT
decade NN
ago IN
, ,
U.S. NNP
and CC
Japanese JJ
scientists NNS
proved VBD
that IN
HTLV-I JJ
was VBD
responsible JJ
for IN
a DT
type NN
of IN
leukemia NN
seen VBN
in IN
southern NN
Japan NNP
. .
The DT
virus NN
thus RB
became VBD
the DT
first JJ
virus NN
proved VBD
to TO
cause VB
a DT
human JJ
cancer NN
. .
So IN
far RB
, ,
it PRP
is VBZ
the DT
only JJ
proven CD
human NN
cancer NN
virus VBZ
, ,
although IN
many JJ
patients NNS
infected VBN
with IN
the DT
AIDS NNP
virus VBZ
develop VB
a DT
previously RB
rare JJ
type NN
of IN
skin NN
cancer NN
. .
The DT
rare NN
leukemia NN
, ,
once RB
it PRP
develops VBZ
, ,
is VBZ
devastating VBG
. .
`` ``
The DT
median JJ
survival NN
is VBZ
three CD
months NNS
, ,
'' ''
says VBZ
Harvey NNP
Dosik NNP
, ,
director NN
of IN
medicine NN
at IN
the DT
Interfaith NNP
Medical NNP
Center NNP
in IN
Brooklyn NNP
, ,
N.Y. NNP
Dr. NNP
Dosik NNP
and CC
his PRP$
colleagues NNS
have VBP
seen VBN
15 CD
cases NNS
of IN
the DT
leukemia NN
in IN
the DT
past JJ
two CD
years NNS
. .
`` ``
Only RB
one CD
of IN
the DT
15 CD
is VBZ
still RB
alive JJ
, ,
'' ''
he PRP
says VBZ
. .
The DT
15 CD
cases NNS
constitute VBP
the DT
largest JJS
cluster NN
of IN
the DT
leukemia NN
in IN
the DT
U.S JJ
. .
The DT
victims NNS
were VBD
all DT
blacks NNS
who WP
moved VBN
into IN
the DT
Bedford-Stuyvesant JJ
ghetto NN
in IN
Brooklyn NNP
from IN
the DT
Carribbean NNP
and CC
the DT
southern NN
U.S. NNP
, ,
areas NNS
where WRB
the DT
presence NN
of IN
the DT
virus NN
has VBZ
been VBN
known VBN
for IN
some DT
time NN
. .
None NN
of IN
the DT
15 CD
victims NNS
was VBD
known VBN
to TO
be VB
an DT
intravenous JJ
drug NN
user NN
, ,
Dr. NNP
Dosik NNP
says VBZ
. .
Mainly RB
because IN
of IN
the DT
lack NN
of IN
funds NNS
, ,
researchers NNS
have VBP
been VBN
unable JJ
to TO
explore VB
the DT
victims NNS
' POS
backgrounds NNS
to TO
discover VB
what WP
they PRP
might MD
have VB
in IN
common JJ
that IN
would MD
account VB
for IN
the DT
disease NN
, ,
Dr. NNP
Dosik NNP
says VBZ
. .
Evidence NN
of IN
the DT
virus NN
's POS
spread NN
among IN
Americans NNPS
comes VBZ
largely RB
from IN
tests NNS
of IN
drug NN
addicts NNS
. .
In IN
1984 CD
, ,
British NNP
health NN
officials NNS
, ,
while IN
screening NN
for IN
AIDS NNP
, ,
first JJ
noted VBD
that IN
about IN
4 CD
% NN
of IN
addicts NNS
there EX
had VBD
developed VBN
antibodies NNS
to TO
HTLV-I NNP
, ,
evidence NN
that IN
they PRP
had VBD
been VBN
exposed VBN
to TO
the DT
virus NN
. .
Earlier JJR
this DT
year NN
, ,
a DT
team NN
from IN
the DT
U.S. NNP
National NNP
Institutes NNPS
of IN
Health NNP
checked VBD
blood NN
samples NNS
taken VBN
five CD
years NNS
ago RB
from IN
56 CD
drug NN
addicts NNS
in IN
the DT
Queens NNP
section NN
of IN
New NNP
York NNP
. .
The DT
results NNS
indicated VBD
that IN
as IN
early JJ
as IN
1981 CD
as IN
many JJ
as IN
9 CD
% NN
of IN
the DT
intravenous JJ
drug NN
addicts NNS
had VBD
been VBN
exposed VBN
to TO
HTLV-I NNP
. .
If IN
the DT
spread NN
of IN
the DT
AIDS NNP
virus VBZ
since IN
then RB
is VBZ
any DT
kind NN
of IN
index NN
for IN
the DT
growth NN
of IN
HTLV-I NNP
, ,
the DT
virus NN
is VBZ
presumably RB
even RB
more RBR
widespread JJ
now RB
. .
Some DT
researchers NNS
are VBP
also RB
worried VBN
that IN
blood NN
screening VBG
such JJ
as IN
that DT
being VBG
done NN
by IN
the DT
Red NNP
Cross NNP
may MD
not RB
give VB
a DT
broad JJ
enough RB
picture NN
of IN
the DT
prevalence NN
of IN
HTLV-I NNP
. .
Blood NNP
banks NNS
have VBP
been VBN
carefully RB
excluding VBG
donors NNS
who WP
are VBP
at IN
risk NN
of IN
developing VBG
AIDS NNP
-- :
but CC
those DT
are VBP
the DT
people NNS
who WP
are VBP
also RB
most JJS
likely JJ
to TO
have VB
been VBN
exposed VBN
to TO
HTLV-I NNP
. .
Thus RB
, ,
sampling VBG
only RB
donated VBN
blood NN
might MD
result VB
in IN
underestimating NN
the DT
true JJ
extent NN
of IN
the DT
virus NN
. .
The DT
Red NNP
Cross NNP
screening NN
program NN
was VBD
made VBN
possible JJ
by IN
the DT
development NN
of IN
test NN
kits NNS
by IN
Cellular NNP
Products NNPS
Co. NNP
, ,
a DT
Buffalo NNP
, ,
N.Y. NNP
, ,
biotechnology NN
company NN
, ,
and CC
by IN
Du NNP
Pont NNP
Co. NNP
in IN
Wilmington NNP
, ,
Del NNP
. .
Both DT
companies NNS
already RB
produce VB
tests NNS
to TO
detect VB
the DT
AIDS NNP
virus VBZ
, ,
and CC
the DT
new JJ
tests NNS
use VBP
the DT
same JJ
technology NN
. .
Cellular JJ
Products NNS
began VBD
working VBG
on IN
a DT
test NN
at IN
the DT
`` ``
insistence NN
of IN
Dr. NNP
Poiesz NNP
'' ''
in IN
Syracuse NNP
, ,
`` ``
who WP
told VBD
us PRP
he PRP
was VBD
seeing VBG
enough RB
instances NNS
in IN
his PRP$
lab NN
to TO
warrant VB
nationwide JJ
screening NN
soon RB
, ,
'' ''
says VBZ
Richard NNP
Montagna NNP
, ,
Cellular NNP
's POS
president NN
. .
Dr. NNP
Poiesz NNP
, ,
a DT
scientific JJ
adviser NN
to TO
Cellular NNP
, ,
is VBZ
an DT
expert NN
on IN
the DT
HTLV-I NNP
virus VBZ
; :
he PRP
helped VBD
identify VB
the DT
virus NN
in IN
the DT
laboratory NN
of IN
Dr. NNP
Robert NNP
Gallo NNP
at IN
the DT
National NNP
Cancer NNP
Institute NNP
in IN
1978 CD
. .
Dr. NNP
Poiesz NNP
's POS
lab NN
has VBZ
been VBN
testing VBG
blood NN
samples NNS
from IN
around IN
the DT
world NN
, ,
but CC
the DT
lab NN
's POS
test NN
is VBZ
n't RB
simple JJ
enough RB
for IN
use NN
by IN
blood NN
banks NNS
. .
A DT
Du NNP
Pont NNP
spokesman NN
says VBZ
the DT
company NN
is VBZ
gearing VBG
up RP
to TO
produce VB
six CD
million CD
test NN
kits NNS
a DT
year NN
, ,
based VBN
on IN
Du NNP
Pont NNP
's POS
own JJ
studies NNS
of IN
the DT
spread NN
of IN
the DT
virus NN
. .
Based VBN
on IN
these DT
studies NNS
, ,
he PRP
adds VBZ
, ,
the DT
company NN
believes VBZ
there EX
will MD
be VB
a DT
need NN
within IN
a DT
few JJ
years NNS
for IN
about IN
50 CD
million CD
to TO
75 CD
million CD
test NN
kits NNS
, ,
about IN
the DT
same JJ
number NN
currently RB
used VBN
to TO
screen VB
for IN
the DT
AIDS NNP
virus VBZ
. .

<DOCNO> LA121190-0080
Cigarette NNP
smoking NN
appears VBZ
to TO
be VB
a DT
major JJ
risk NN
factor NN
for IN
the DT
development NN
of IN
leukemia NN
and CC
may MD
be VB
responsible JJ
for IN
more RBR
than IN
1 CD
in IN
5 CD
cases NNS
of IN
the DT
feared VBN
blood NN
cancer NN
, ,
according VBG
to TO
a DT
study NN
by IN
Loma NNP
Linda NNP
University NNP
researchers NNS
. .
The DT
researchers NNS
consider VBP
the DT
findings NNS
particularly RB
significant JJ
because IN
almost RB
all DT
of IN
the DT
34 CD
, ,
000 CD
Seventh-day JJ
Adventists NNS
studied VBD
who WP
had VBD
smoked VBN
had VBN
stopped VBN
years NNS
earlier JJR
, ,
suggesting VBG
that IN
some DT
of IN
the DT
adverse NN
effects NNS
may MD
not RB
be VB
reversible JJ
. .
The DT
report NN
increases NNS
the DT
credence NN
of IN
other JJ
recent JJ
studies NNS
that WDT
have VBP
suggested VBN
a DT
link NN
between IN
smoking NN
and CC
leukemia NN
. .
The DT
results NNS
, ,
being VBG
published VBN
this DT
month NN
in IN
the DT
Journal NNP
of IN
the DT
National NNP
Cancer NNP
Institute NNP
, ,
add VBD
to TO
a DT
growing VBG
list NN
of IN
cancers NNS
that WDT
have VBP
been VBN
linked VBN
to TO
cigarette VB
smoking NN
. .
The DT
list NN
includes VBZ
cancers NNS
of IN
the DT
lung NN
, ,
bladder NN
, ,
pancreas VBZ
, ,
esophagus VBZ
, ,
throat JJ
and CC
perhaps RB
the DT
cervix NN
. .
The DT
study NN
is VBZ
part NN
of IN
the DT
ongoing JJ
Adventist NNP
Health NNP
Study NNP
, ,
a DT
major JJ
epidemiological JJ
investigation NN
of IN
the DT
causes NNS
of IN
various JJ
cancers NNS
among IN
California NNP
residents NNS
. .
Although IN
the DT
vast JJ
majority NN
of IN
Adventists NNPS
do VBP
not RB
smoke VB
by IN
church NN
proscription NN
, ,
many JJ
are VBP
adult VBN
converts NNS
to TO
the DT
religion NN
who WP
smoked VBN
cigarettes VBZ
prior RB
to TO
their PRP$
baptism NN
into IN
the DT
church NN
. .
The DT
researchers NNS
found VBD
that IN
the DT
Adventist NNP
ex-smokers NNP
had VBD
twice NN
the DT
risk NN
of IN
developing VBG
leukemia NN
than IN
similar JJ
individuals NNS
who WP
never RB
had VBD
smoked VBN
. .
The DT
results NNS
are VBP
`` ``
very RB
discouraging VBG
, ,
'' ''
said VBD
Paul NNP
K. NNP
Mills NNP
, ,
an DT
assistant JJ
professor NN
of IN
preventive JJ
medicine NN
at IN
Loma NNP
Linda NNP
and CC
principal JJ
author NN
of IN
the DT
study NN
. .
`` ``
We PRP
saw VBD
a DT
strong JJ
association NN
between IN
prior RB
cigarette JJ
smoking NN
and CC
the DT
risk NN
of IN
developing VBG
leukemia NN
. .
`` ``
The DT
findings NNS
`` ``
obviously RB
strengthen RB
the DT
gathering NN
impression NN
that IN
cigarette NN
smoking NN
is VBZ
related VBN
to TO
leukemia VB
risk NN
and CC
that IN
the DT
association NN
is VBZ
likely JJ
to TO
be VB
causal JJ
, ,
'' ''
Dr. NNP
Clark NNP
W. NNP
Heath NNP
Jr. NNP
, ,
a DT
vice NN
president NN
of IN
the DT
American NNP
Cancer NNP
Society NNP
, ,
wrote VBD
in IN
an DT
editorial NN
published VBD
in IN
the DT
medical JJ
journal JJ
along IN
with IN
the DT
study NN
. .
The DT
risk NN
of IN
developing VBG
leukemia NN
was VBD
also RB
increased VBN
by IN
a DT
greater JJR
number NN
of IN
cigarettes NNS
smoked VBN
daily JJ
and CC
a DT
longer NN
duration NN
of IN
smoking NN
, ,
which WDT
Mills NNP
said VBD
was VBD
'' ''
important JJ
evidence NN
of IN
a DT
causal NN
relationship NN
. .
`` ``
Individuals NNS
who WP
regularly RB
smoked VBD
more JJR
than IN
25 CD
cigarettes NNS
a DT
day NN
had VBD
a DT
threefold NN
increased VBN
risk NN
of IN
developing VBG
leukemia NN
. .
The DT
Adventists NNPS
who WP
had VBD
smoked VBN
for IN
more JJR
than IN
15 CD
years NNS
had VBD
a DT
2 CD
1/2-fold JJ
increased VBN
leukemia NN
risk NN
. .
Leukemia NNP
is VBZ
a DT
bone-marrow JJ
cancer NN
in IN
which WDT
the DT
marrow NN
is VBZ
replaced VBN
by IN
immature NN
, ,
abnormal JJ
white JJ
blood NN
cells NNS
. .
Leukemia NNP
is VBZ
a DT
relatively RB
uncommon JJ
tumor NN
compared VBN
to TO
breast VB
, ,
colon NN
or CC
lung JJ
cancer NN
. .
Each DT
year NN
, ,
there EX
are VBP
about IN
27 CD
, ,
000 CD
newly RB
diagnosed VBN
cases NNS
and CC
18 CD
, ,
000 CD
deaths NNS
attributed VBD
to TO
leukemia VB
in IN
the DT
United NNP
States NNPS
. .
According VBG
to TO
Heath NNP
, ,
until IN
1986 CD
it PRP
was VBD
generally RB
accepted VBN
that IN
tobacco NN
use NN
was VBD
not RB
a DT
significant JJ
cause NN
of IN
leukemia NN
. .
Since IN
1988 CD
, ,
several JJ
studies NNS
, ,
including VBG
a DT
large JJ
study NN
of IN
U.S. NNP
military JJ
veterans NNS
and CC
two CD
American JJ
Cancer NNP
Society NNP
studies NNS
, ,
had VBD
provided VBN
preliminary JJ
evidence NN
of IN
a DT
link NN
. .
The DT
causes NNS
of IN
leukemia NN
are VBP
largely RB
unknown VBN
. .
Those DT
that DT
have VBP
been VBN
identified VBN
, ,
such JJ
as IN
the DT
chemical JJ
benzene NN
and CC
ionizing VBG
radiation NN
, ,
appear VBP
to TO
account NN
for IN
only RB
a DT
small JJ
percentage NN
of IN
cases NNS
, ,
according VBG
to TO
Heath NNP
. .
The DT
Loma NNP
Linda NNP
study NN
calculated VBD
that IN
about IN
20 CD
% NN
of IN
leukemia NN
cases NNS
were VBD
associated VBN
with IN
prior RB
smoking VBG
. .
In IN
all DT
, ,
there EX
were VBD
46 CD
new JJ
cases NNS
of IN
leukemia NN
diagnosed VBN
during IN
the DT
six-year JJ
study NN
period NN
. .
On IN
the DT
basis NN
of IN
this DT
and CC
earlier JJR
preliminary JJ
studies NNS
, ,
Heath NNP
estimated VBD
that IN
from IN
20 CD
% NN
to TO
30 CD
% NN
of IN
leukemia NN
cases NNS
may MD
be VB
linked VBN
to TO
smoking NN
. .
Because IN
cigarette NN
smoking VBG
is VBZ
very RB
common JJ
in IN
the DT
general JJ
population NN
-- :
more RBR
than IN
25 CD
% NN
of IN
adults NNS
smoke VBP
-- :
the DT
proportion NN
of IN
total JJ
leukemia NN
risk NN
that WDT
may MD
be VB
attributed VBN
to TO
cigarette VB
smoking NN
is VBZ
significant JJ
, ,
according VBG
to TO
the DT
researchers NNS
. .
In IN
a DT
related JJ
finding NN
, ,
the DT
Loma NNP
Linda NNP
researchers NNS
found VBD
that IN
ex-smokers NNS
among IN
the DT
Adventists NNPS
had VBD
a DT
threefold NN
increased VBN
risk NN
of IN
developing VBG
myeloma NN
, ,
another DT
bone-marrow NN
tumor NN
, ,
as IN
compared VBN
to TO
individuals NNS
who WP
had VBD
never RB
smoked VBN
. .
Mills NNS
cautioned VBD
that IN
this DT
result NN
should MD
be VB
considered VBN
`` ``
preliminary JJ
'' ''
because IN
it PRP
was VBD
based VBN
on IN
23 CD
cases NNS
. .
Previously RB
, ,
this DT
association NN
has VBZ
not RB
been VBN
closely RB
examined VBN
. .
The DT
Adventist NNP
Health NNP
Study NNP
began VBD
in IN
1974 CD
. .
Participants NNS
in IN
the DT
current JJ
study NN
completed VBN
a DT
questionnaire NN
about IN
their PRP$
lifestyle NN
in IN
1976 CD
and CC
were VBD
followed VBN
for IN
the DT
development NN
of IN
new JJ
cancers NNS
through IN
the DT
end NN
of IN
1982 CD
. .

<DOCNO> SJMN91-06024248
Because IN
no DT
one NN
knows VBZ
how WRB
dioxin NN
causes NNS
cancer NN
, ,
`` ``
one CD
can MD
never RB
say VB
there EX
is VBZ
no DT
risk NN
. .
It PRP
would MD
appear VB
that IN
for IN
groups NNS
with IN
lower JJR
exposure NN
, ,
the DT
risk NN
is VBZ
lower JJR
, ,
but CC
it PRP
does VBZ
n't RB
say VB
there EX
is VBZ
no DT
risk NN
, ,
'' ''
said VBD
Dr. NNP
Marilyn NNP
A. NNP
Fingerhut NNP
, ,
an DT
epidemiologist NN
who WP
led VBN
the DT
study NN
. .
; :
The DT
cancer-causing JJ
potential NN
of IN
dioxin NN
is VBZ
of IN
concern NN
, ,
in IN
part NN
, ,
because IN
it PRP
was VBD
a DT
contaminant JJ
of IN
Agent NNP
Orange NNP
, ,
a DT
tree-killing JJ
chemical NN
used VBN
widely RB
during IN
the DT
Vietnam NNP
War NNP
. .
Soldiers NNS
who WP
were VBD
sprayed VBN
with IN
it PRP
regularly RB
had VBD
far RB
less JJR
exposure NN
than IN
most JJS
of IN
the DT
chemical JJ
workers NNS
studied VBD
. .
; :
PARENTS NNS
' POS
SMOKING NN
LINKED NNP
TO TO
CHILDREN NNP
'S POS
HEALTH NNP
RISK NNP
; :
Fathers NNP
who WP
smoke NN
have VBP
an DT
increased VBN
risk NN
of IN
having VBG
children NNS
with IN
brain NN
cancer NN
and CC
leukemia NN
, ,
suggesting VBG
that IN
smoking NN
might MD
have VB
damaged VBN
the DT
fathers NNS
' POS
sperm NN
, ,
researchers NNS
said VBD
Wednesday NNP
. .
; :
That DT
conclusion NN
is VBZ
speculative JJ
, ,
said VBD
one CD
of IN
the DT
study NN
's POS
authors NNS
, ,
Dale NNP
P. NNP
Sandler NNP
of IN
the DT
National NNP
Institute NNP
of IN
Environmental NNP
Health NNP
Sciences NNPS
in IN
Research NNP
Triangle NNP
Park NNP
, ,
N.C NNP
. .
But CC
the DT
study NN
points NNS
to TO
the DT
possibility NN
of IN
an DT
effect NN
on IN
sperm NN
, ,
`` ``
and CC
another DT
study NN
with IN
bigger JJR
numbers NNS
ought MD
to TO
look VB
at IN
it PRP
carefully RB
, ,
'' ''
she PRP
said VBD
. .
; :
In IN
a DT
separate JJ
study NN
, ,
doctors NNS
found VBD
that IN
children NNS
whose WP$
parents NNS
smoke VBP
are VBP
three CD
to TO
four CD
times NNS
as RB
likely JJ
as IN
other JJ
children NNS
to TO
develop VB
serious JJ
infectious JJ
diseases NNS
requiring VBG
hospitalization NN
. .
; :
`` ``
I PRP
do VBP
n't RB
think VB
anyone NN
before IN
has VBZ
demonstrated VBN
that IN
the DT
association NN
is VBZ
not RB
just RB
for IN
mild NN
illnesses NNS
but CC
for IN
really RB
serious JJ
infections NNS
as IN
well RB
, ,
'' ''
said VBD
Anne NNP
T. NNP
Berg NNP
of IN
the DT
Yale NNP
University NNP
School NNP
of IN
Medicine NNP
, ,
the DT
principal JJ
author NN
of IN
the DT
study NN
. .
; :
SYNTHETIC NNP
GENE NNP
MAY NNP
AID NNP
MUSCULAR NNP
DYSTROPHY NNP
WAR NNP
; :
Scientists NNP
have VBP
made VBN
a DT
synthetic JJ
form NN
of IN
the DT
gene NN
linked VBD
to TO
the DT
most JJS
severe JJ
kind NN
of IN
muscular JJ
dystrophy NN
, ,
a DT
`` ``
milestone NN
'' ''
step VB
toward IN
gene NN
therapy NN
for IN
the DT
disease NN
. .
; :
The DT
gene NN
, ,
made VBN
from IN
mouse NN
genetic JJ
material NN
, ,
was VBD
shown VBN
to TO
work VB
in IN
experimental JJ
cells NNS
. .
; :
Scientists NNS
said VBD
the DT
accomplishment NN
boosts VBZ
prospects NNS
for IN
treating VBG
Duchenne NNP
dystrophy NN
, ,
the DT
most RBS
devastating JJ
and CC
common JJ
form NN
, ,
by IN
supplying NN
muscle NN
cells NNS
with IN
a DT
functioning VBG
version NN
of IN
the DT
gene NN
. .
Duchenne NNP
appears VBZ
when WRB
people NNS
lack VBP
a DT
functioning NN
version NN
. .
; :
But CC
creating VBG
the DT
gene NN
is VBZ
still RB
`` ``
a DT
long JJ
way NN
from IN
putting VBG
it PRP
into IN
a DT
patient NN
, ,
'' ''
cautioned VBD
Louis NNP
Kunkel NNP
of IN
Children NNP
's POS
Hospital NNP
in IN
Boston NNP
, ,
Harvard NNP
Medical NNP
School NNP
and CC
the DT
Hughes NNPS
institute NN
there RB
. .
; :
AIDS-TYPE JJ
FUNGUS NNP
HITS NNP
PEOPLE NNP
WITHOUT NNP
DISEASE NNP
; :
A DT
fungus NN
that WDT
is VBZ
the DT
leading VBG
cause NN
of IN
fatal JJ
infections NNS
among IN
AIDS NNP
patients NNS
has VBZ
afflicted VBN
a DT
small JJ
number NN
of IN
elderly RB
New NNP
Yorkers NNPS
without IN
AIDS NNP
, ,
and CC
experts NNS
do VBP
not RB
know VB
why WRB
, ,
according VBG
to TO
a DT
report NN
published VBD
today NN
. .
; :
The DT
fungus NN
, ,
pneumocystis VBZ
carinii NN
, ,
causes NNS
pneumocystis VBZ
pneumonia NN
, ,
or CC
PCP NNP
, ,
which WDT
rarely RB
has VBZ
struck NN
people NNS
with IN
a DT
healthy JJ
immune NN
system NN
. .
Yet CC
none NN
of IN
the DT
five CD
elderly RB
patients NNS
reported VBD
with IN
PCP NNP
had VBD
a DT
faulty NN
immune NN
system NN
. .

<DOCNO> AP880519-0175
People NNS
infected VBD
by IN
the DT
AIDS NNP
virus VBZ
may MD
be VB
more RBR
likely JJ
to TO
go VB
on IN
to TO
develop VB
the DT
deadly RB
disease NN
if IN
they PRP
also RB
are VBP
infected VBN
by IN
a DT
related JJ
virus NN
that WDT
can MD
cause VB
a DT
particularly RB
fatal JJ
form NN
of IN
leukemia NN
, ,
a DT
study NN
says VBZ
. .
`` ``
These DT
laboratory NN
results NNS
suggest VBP
that IN
doubly RB
infected VBN
individuals NNS
have VBP
a DT
worse NN
prognosis NN
for IN
developing VBG
AIDS NNP
'' ''
than IN
those DT
who WP
are VBP
infected VBN
only RB
by IN
the DT
AIDS NNP
virus VBZ
, ,
said VBD
molecular JJ
virologist NN
Irvin NNP
S.Y NNP
. .
Chen NNP
, ,
who WP
published VBD
his PRP$
study NN
in IN
Friday NNP
's POS
issue NN
of IN
the DT
journal NN
Science NNP
. .
`` ``
The DT
chances NNS
of IN
any DT
individual JJ
being VBG
infected VBN
by IN
both DT
viruses NNS
are VBP
very RB
slim JJ
, ,
but CC
among IN
selected VBN
populations NNS
, ,
such JJ
as IN
intravenous JJ
drug NN
abusers NNS
, ,
the DT
chances NNS
are VBP
quite RB
high JJ
, ,
'' ''
said VBD
Chen NNP
, ,
of IN
the DT
University NNP
of IN
California NNP
, ,
Los NNP
Angeles NNP
. .
Except IN
among IN
IV NNP
drug NN
abusers NNS
, ,
the DT
leukemia NN
virus VBZ
is VBZ
quite RB
rare JJ
in IN
the DT
United NNP
States NNPS
. .
It PRP
is VBZ
fairly RB
common JJ
in IN
southern NN
Japan NNP
, ,
the DT
Caribbean NNP
and CC
parts NNS
of IN
Africa NNP
, ,
Chen NNP
said VBD
. .
So IN
the DT
study NN
suggests VBZ
that IN
people NNS
in IN
those DT
areas NNS
may MD
be VB
more RBR
likely JJ
to TO
develop VB
full-fledged JJ
AIDS NNS
if IN
they PRP
are VBP
exposed VBN
to TO
the DT
AIDS NNP
virus VBZ
. .
But CC
more RBR
study JJ
of IN
people NNS
infected VBN
by IN
both DT
viruses NNS
must MD
be VB
done VBN
to TO
confirm VB
the DT
suspicion NN
raised VBD
by IN
laboratory NN
studies NNS
, ,
said VBD
Dr. NNP
Stanley NNP
H. NNP
Weiss NNP
, ,
chief NN
of IN
AIDS NNP
epidemiology NN
at IN
New NNP
Jersey NNP
Medical NNP
School NNP
in IN
Newark NNP
. .
Weiss NNP
is VBZ
already RB
undertaking VBG
such JJ
research NN
in IN
the DT
Newark NNP
and CC
New NNP
York NNP
area NN
. .
Acquired NNP
immune NN
deficiency NN
syndrome NN
is VBZ
caused VBN
by IN
the DT
human JJ
immunodeficiency NN
virus VBZ
, ,
or CC
HIV NNP
, ,
which WDT
usually RB
remains VBZ
dormant JJ
in IN
infected JJ
people NNS
for IN
years NNS
before IN
it PRP
may MD
be VB
activated VBN
to TO
cause VB
full-fledged JJ
AIDS NNS
, ,
which WDT
cripples NNS
the DT
disease-fighting JJ
immune NN
system NN
. .
Previous JJ
studies NNS
suggested VBD
almost RB
any DT
infection NN
may MD
help VB
trigger JJR
the DT
dormant JJ
AIDS NNP
virus NN
into IN
an DT
active JJ
killer NN
. .
Chen NNP
and CC
his PRP$
colleagues NNS
performed VBD
experiments NNS
in IN
laboratory NN
culture NN
dishes NNS
showing VBG
that IN
AIDS-infected JJ
white JJ
blood NN
cells NNS
called VBN
T NNP
cells NNS
produce VBP
large JJ
amounts NNS
of IN
active JJ
AIDS NNS
virus VBZ
if IN
the DT
cells NNS
also RB
are VBP
exposed VBN
to TO
the DT
human JJ
T-cell NN
leukemia NN
virus VBZ
type NN
I PRP
, ,
or CC
HTLV-I NNP
. .
People NNS
infected VBD
by IN
HTLV-I NNP
have VBP
a DT
1 CD
percent NN
lifetime NN
chance NN
of IN
developing VBG
a DT
blood NN
cancer NN
called VBN
adult NN
T-cell NNP
leukemia NN
, ,
which WDT
often RB
kills VBZ
quickly RB
. .
It PRP
is VBZ
an DT
important JJ
cause NN
of IN
leukemia NN
in IN
southern NN
Japan NNP
and CC
the DT
Caribbean NNP
. .
HTLV-I NN
also RB
is VBZ
linked VBN
to TO
a DT
potentially RB
fatal JJ
, ,
degenerative JJ
nerve NN
disease NN
that WDT
causes VBZ
spasticity NN
and CC
paralysis NN
of IN
the DT
legs NNS
. .
Last JJ
month NN
, ,
the DT
American NNP
Red NNP
Cross NNP
recommended VBD
that IN
all DT
donated VBN
blood NN
be VB
tested VBN
for IN
HTLV-I NNP
as IN
soon RB
as IN
scientists NNS
develop VB
a DT
practical JJ
test NN
. .
A DT
Red NNP
Cross NNP
study NN
found VBD
about IN
one CD
out IN
of IN
every DT
4 CD
, ,
286 CD
units NNS
of IN
donated VBN
blood NN
carries NNS
HTLV-I -NONE-
. .
The DT
risk NN
of IN
AIDS NNP
virus NN
in IN
blood NN
has VBZ
been VBN
reduced VBN
to TO
about IN
one CD
in IN
40 CD
, ,
000 CD
units NNS
because IN
donors NNS
are VBP
tested VBN
for IN
signs NNS
of IN
AIDS NNP
infection NN
. .
A DT
study NN
performed VBN
by IN
Weiss NNP
when WRB
he PRP
worked VBD
for IN
the DT
National NNP
Cancer NNP
Institute NNP
showed VBD
HTLV-I NNP
is VBZ
spreading VBG
among IN
intravenous JJ
drug NN
abusers NNS
, ,
with IN
infection NN
rates NNS
of IN
12 CD
percent NN
among IN
New NNP
Jersey NNP
addicts NNS
, ,
33 CD
percent NN
among IN
New NNP
Orleans NNP
addicts NNS
overall VBP
, ,
and CC
49 CD
percent NN
among IN
black JJ
addicts NNS
in IN
New NNP
Orleans NNP
. .
Intravenous JJ
drug NN
addicts NNS
also RB
are VBP
high JJ
risk NN
for IN
infection NN
by IN
the DT
AIDS NNP
virus VBZ
, ,
which WDT
also RB
is VBZ
spread VBN
in IN
blood NN
on IN
shared VBN
needles NNS
and CC
by IN
sexual JJ
contact NN
. .
Infection NN
by IN
HTLV-I NNP
apparently RB
activates VBZ
the DT
AIDS NNP
virus VBZ
by IN
stimulating NN
AIDS-infected JJ
white NN
blood NN
cells NNS
to TO
divide VB
, ,
according VBG
to TO
the DT
study NN
Chen NNP
performed VBD
with IN
molecular JJ
virologists NNS
Jerome NNP
Zack NNP
, ,
Alan NNP
Cann NNP
and CC
James NNP
Lugo NNP
. .
While IN
the DT
study NN
in IN
Science NNP
deals NNS
only RB
with IN
HTLV-I JJ
, ,
unpublished JJ
laboratory NN
results NNS
suggest VBP
full-fledged JJ
AIDS NNS
also RB
may MD
be VB
triggered VBN
in IN
AIDS-infected JJ
people NNS
who WP
also RB
are VBP
infected VBN
by IN
HTLV-II NNP
, ,
an DT
extremely RB
rare JJ
virus NN
that WDT
can MD
cause VB
another DT
type NN
of IN
leukemia NN
. .
The DT
AIDS NNP
virus VBZ
is VBZ
distantly RB
related VBN
to TO
the DT
leukemia NN
viruses VBZ
. .
Dr. NNP
Edward NNP
L. NNP
Murphy NNP
Jr. NNP
, ,
a DT
National NNP
Cancer NNP
Institute NNP
expert NN
on IN
HTLV-I NNP
, ,
agreed VBD
with IN
Chen NNP
that IN
the DT
problem NN
of IN
dual JJ
infection NN
by IN
the DT
AIDS NNP
and CC
leukemia NN
viruses NNS
is VBZ
mainly RB
a DT
problem NN
for IN
U.S. NNP
drug NN
addicts NNS
and CC
for IN
people NNS
in IN
areas NNS
such JJ
as IN
the DT
Caribbean NNP
. .

<DOCNO> AP881104-0025
An DT
early JJ
look NN
at IN
a DT
six-year JJ
study NN
of IN
the DT
health NN
effects NNS
of IN
radioactive JJ
fallout IN
shows NNS
`` ``
no DT
strong JJ
evidence NN
'' ''
of IN
a DT
link NN
between IN
exposure NN
and CC
leukemia NN
and CC
thyroid VBD
disorders NNS
, ,
the DT
project NN
's POS
director NN
says VBZ
. .
The DT
$ $
7 CD
million CD
study NN
, ,
funded VBD
by IN
the DT
National NNP
Cancer NNP
Institute NNP
, ,
is VBZ
intended VBN
to TO
determine VB
whether IN
people NNS
living VBG
downwind NN
of IN
above-ground JJ
atomic JJ
bomb NN
tests NNS
in IN
Nevada NNP
in IN
the DT
1950s CD
and CC
1960s CD
suffered VBD
an DT
increased VBN
rate NN
of IN
cancer NN
. .
Because IN
all DT
the DT
data NNS
has VBZ
not RB
been VBN
tabulated VBN
, ,
it PRP
is VBZ
not RB
possible JJ
to TO
say VB
definitely RB
`` ``
there EX
is VBZ
or CC
is VBZ
not RB
an DT
effect NN
, ,
'' ''
said VBD
Dr. NNP
Walter NNP
Stevens NNP
, ,
interim JJ
dean NN
of IN
the DT
University NNP
of IN
Utah NNP
Medical NNP
School NNP
and CC
director NN
of IN
the DT
study NN
. .
However RB
, ,
he PRP
said VBD
Thursday NNP
there RB
is VBZ
`` ``
no DT
strong JJ
evidence NN
that IN
would MD
convince VB
me PRP
... :
that IN
there EX
was VBD
a DT
relationship NN
'' ''
between IN
fallout IN
and CC
disease NN
. .
Stevens NNS
emphasized VBD
that IN
epidemiological JJ
findings NNS
still RB
are VBP
being VBG
analyzed VBN
and CC
that IN
no DT
final JJ
conclusions NNS
would MD
be VB
drawn VBN
until IN
a DT
draft NN
report NN
had VBD
been VBN
reviewed VBN
by IN
the DT
National NNP
Cancer NNP
Institute NNP
. .
The DT
draft NN
likely JJ
will MD
be VB
delivered VBN
to TO
NCI NNP
by IN
mid-November NNP
and CC
the DT
finished JJ
report NN
released VBN
next JJ
March NNP
, ,
he PRP
said VBD
. .
For IN
years NNS
, ,
people NNS
living VBG
in IN
southwestern NN
Utah NNP
, ,
southeastern JJ
Nevada NNP
and CC
northeastern VB
Arizona NNP
have VB
feared VBN
that IN
exposure NN
to TO
about IN
80 CD
open-air JJ
tests NNS
at IN
the DT
Nevada NNP
Test NNP
Site NNP
had VBD
increased VBN
the DT
potential JJ
for IN
leukemia NN
and CC
thyroid VBD
cancers NNS
. .
In IN
1979 CD
, ,
Dr. NNP
Joseph NNP
L. NNP
Lyon NNP
, ,
an DT
University NNP
of IN
Utah NNP
epidemiologist NN
who WP
is VBZ
working VBG
on IN
the DT
current JJ
study NN
, ,
published VBD
a DT
paper NN
showing VBG
a DT
2.4-fold JJ
increase NN
in IN
childhood NN
leukemia NN
in IN
the DT
areas NNS
of IN
southern NN
Utah NNP
heavily RB
dusted VBN
by IN
fallout IN
. .
Meanwhile RB
, ,
nearly RB
1 CD
, ,
200 CD
people NNS
living VBG
downwind NN
of IN
the DT
tests NNS
sued VBD
the DT
federal JJ
government NN
, ,
claiming VBG
that IN
exposure NN
to TO
fallout VB
caused VBN
sickness NN
and CC
death NN
. .
In IN
1982 CD
, ,
U.S. NNP
District NNP
Judge NNP
Bruce NNP
Jenkins NNP
ruled VBD
the DT
government NN
had VBD
failed VBN
to TO
warn VB
residents NNS
of IN
radiation NN
hazards NNS
. .
However RB
, ,
the DT
10th JJ
U.S NNS
. .
Circuit NN
Court NNP
of IN
Appeals NNPS
overturned VBN
the DT
ruling NN
and CC
the DT
U.S. NNP
Supreme NNP
Court NNP
concurred VBD
, ,
saying VBG
the DT
government NN
was VBD
immune JJ
from IN
damages NNS
. .
The DT
latest JJS
study NN
was VBD
conducted VBN
in IN
two CD
parts NNS
_ NNP
one CD
for IN
leukemia NN
and CC
the DT
other JJ
for IN
thyroid JJ
disorders NNS
_ NNP
and CC
was VBD
designed VBN
as IN
the DT
most RBS
comprehensive JJ
undertaking NN
of IN
its PRP$
kind NN
. .
Researchers NNS
located VBD
the DT
names NNS
of IN
1 CD
, ,
177 CD
people NNS
from IN
all DT
over IN
Utah NNP
who WP
had VBD
died VBN
of IN
leukemia NN
between IN
1952 CD
and CC
1966 CD
and CC
selected VBN
as IN
controls NNS
another DT
5 CD
, ,
600 CD
people NNS
who WP
had VBD
died VBN
of IN
other JJ
causes NNS
. .
The DT
subjects NNS
were VBD
matched VBN
where WRB
possible JJ
in IN
age NN
, ,
residence NN
, ,
health NN
and CC
lifestyle NN
to TO
ensure VB
valid JJ
comparisons NNS
, ,
Stevens NNP
said VBD
. .
In IN
the DT
thyroid JJ
study NN
, ,
2 CD
, ,
829 CD
subjects NNS
in IN
southern NN
Utah NNP
, ,
southeastern JJ
Nevada NNP
and CC
southern VB
Arizona NNP
were VBD
identified VBN
as IN
having NN
been VBN
exposed VBN
, ,
and CC
about IN
280 CD
were VBD
found VBN
to TO
have VB
thyroid JJ
abnormalities NNS
. .
Scientists NNS
closely RB
researched VBN
production NN
distribution NN
and CC
consumption NN
of IN
milk NN
, ,
thought VBD
to TO
be VB
one CD
of IN
the DT
primary JJ
ways NNS
children NNS
might MD
have VB
ingested VBN
radioactive JJ
materials NNS
from IN
fallout IN
. .
Stevens NNS
said VBD
the DT
research NN
has VBZ
been VBN
greatly RB
aided VBN
by IN
the DT
release NN
of IN
previously RB
classified VBN
information NN
from IN
the DT
Department NNP
of IN
Energy NNP
on IN
the DT
amount NN
of IN
radiation NN
emitted VBN
by IN
the DT
tests NNS
. .
Stevens NNS
said VBD
the DT
study NN
could MD
prove VB
to TO
be VB
a DT
milestone NN
in IN
research NN
on IN
the DT
effects NNS
of IN
exposure NN
to TO
radiation NN
, ,
with IN
particular JJ
significance NN
to TO
safety NN
concerns NNS
at IN
the DT
nation NN
's POS
nuclear JJ
production NN
plants NNS
. .

<DOCNO> AP880414-0254
A DT
pharmaceutical JJ
company NN
said VBD
Thursday NNP
it PRP
has VBZ
begun VBN
selling VBG
a DT
new JJ
leukemia NN
drug NN
, ,
the DT
fourth JJ
new JJ
cancer NN
agent NN
since IN
1983 CD
and CC
the DT
third JJ
leukemia NN
drug NN
in IN
10 CD
years NNS
to TO
gain VB
federal JJ
approval NN
. .
Novantrone NNP
mitoxantrone NN
hydrochloride NN
is VBZ
to TO
be VB
used VBN
in IN
combination NN
with IN
other JJ
agents NNS
for IN
treating VBG
adults NNS
with IN
acute JJ
nonlymphocytic JJ
leukemia NN
, ,
Lederle NNP
Laboratories NNPS
said VBD
in IN
a DT
statement NN
. .
The DT
disease NN
strikes VBZ
about IN
8 CD
, ,
000 CD
Americans NNS
a DT
year NN
, ,
the DT
statement NN
said VBD
. .
The DT
drug NN
apparently RB
disrupts VBZ
the DT
functioning NN
of IN
genetic JJ
material NN
in IN
cancer NN
cells NNS
, ,
the DT
company NN
said VBD
. .
Novantrone NNP
was VBD
approved VBN
by IN
the DT
Food NNP
and CC
Drug NNP
Administration NNP
in IN
1987 CD
, ,
but CC
the DT
agency NN
's POS
official NN
rating NN
of IN
the DT
drug NN
indicates VBZ
it PRP
represents VBZ
little JJ
or CC
no DT
advantage NN
over IN
other JJ
treatments NNS
. .
The DT
other JJ
three CD
new JJ
cancer NN
drugs NNS
approved VBD
in IN
the DT
past JJ
five CD
years NNS
are VBP
etoposide JJ
for IN
testicular JJ
cancer NN
, ,
approved VBD
in IN
1983 CD
; :
leuprolide JJ
acetate NN
for IN
advanced JJ
prostate NN
cancer NN
, ,
1985 CD
; :
and CC
interferon NN
, ,
approved VBD
in IN
1986 CD
to TO
fight NN
hairy NN
cell NN
leukemia NN
, ,
said VBD
Dr. NNP
John NNP
Johnson NNP
of IN
the DT
FDA NNP
. .
Lederle NNP
is VBZ
a DT
division NN
of IN
American JJ
Cyanamid NNP
Co NNP
. .

<DOCNO> AP900810-0046
A DT
college NN
student NN
with IN
leukemia NN
whose WP$
search NN
for IN
a DT
compatible JJ
bone-marrow NN
donor NN
drew VBD
celebrity NN
support NN
and CC
50 CD
, ,
000 CD
volunteers NNS
underwent NN
a DT
last-ditch JJ
transplant NN
using VBG
her PRP
mother's VBZ
marrow NN
. .
Allison NNP
Atlas NNP
, ,
20 CD
, ,
opted VBN
for IN
the DT
surgery NN
Thursday NNP
although IN
her PRP$
mother NN
's POS
tissue NN
is VBZ
not RB
a DT
perfect NN
match NN
. .
She PRP
said VBD
she PRP
wanted VBD
to TO
try VB
the DT
life-saving JJ
procedure NN
while IN
she PRP
was VBD
still RB
relatively RB
strong JJ
. .
Her PRP$
condition NN
today NN
at IN
Fred NNP
Hutchinson NNP
Cancer NNP
Research NNP
Center NNP
was VBD
withheld VBN
at IN
the DT
family NN
's POS
request NN
, ,
said VBD
hospital JJ
spokeswoman NN
Alice NNP
Burgess NNP
. .
The DT
transplant NN
team NN
was VBD
headed VBN
Dr. NNP
Edward NNP
Agura NNP
. .
The DT
marrow NN
from IN
her PRP$
54-year-old JJ
mother NN
, ,
Arline NNP
Atlas NNP
, ,
matched VBD
only RB
four CD
of IN
six CD
antigens NNS
, ,
or CC
cell NN
identifiers NNS
, ,
from IN
her PRP$
daughter's NNS
marrow NN
. .
The DT
operation NN
could MD
work VB
if IN
Miss NNP
Atlas NNP
' POS
body NN
does VBZ
not RB
reject VB
her PRP$
mother NN
's POS
tissue NN
. .
`` ``
They PRP
're VBP
both DT
fighters NNS
, ,
'' ''
said VBD
Sy NNP
Atlas NNP
, ,
a DT
cousin NN
. .
`` ``
They're JJ
both DT
people NNS
who WP
are VBP
determined VBN
to TO
beat VB
the DT
odds NNS
. .
Arline NNP
was VBD
excited VBN
to TO
be VB
the DT
donor NN
for IN
her PRP$
daughter NN
. .
'' ''
Miss NNP
Atlas NNP
, ,
a DT
student NN
at IN
New NNP
York NNP
University NNP
when WRB
she PRP
became VBD
ill RB
last JJ
year NN
, ,
heightened VBN
awareness NN
of IN
the DT
need NN
for IN
bone-marrow JJ
donors NNS
with IN
a DT
publicity NN
campaign NN
that WDT
drew VBD
50 CD
, ,
000 CD
volunteers NNS
in IN
the DT
United NNP
States NNPS
and CC
Israel NNP
. .
Supporters NNS
raised VBD
$ $
3 CD
million CD
, ,
including VBG
a DT
six-figure JJ
check NN
from IN
actor NN
Dustin NNP
Hoffman NNP
, ,
to TO
process NN
the DT
50 CD
, ,
000 CD
blood NN
tests NNS
. .
No DT
match NN
was VBD
found VBN
for IN
Miss NNP
Atlas NNP
, ,
but CC
10 CD
other JJ
leukemia NN
patients NNS
were VBD
matched VBN
with IN
donors NNS
. .
Bone NN
marrow NN
provides VBZ
necessary JJ
components NNS
of IN
the DT
human JJ
immune NN
system NN
, ,
and CC
transplant JJ
patients NNS
are VBP
at IN
high JJ
risk NN
of IN
infection NN
for IN
three CD
weeks NNS
after IN
the DT
operation NN
until IN
the DT
new JJ
marrow NN
begins NNS
to TO
work VB
. .
Miss NNP
Atlas NNP
, ,
of IN
Bethesda NNP
, ,
Md. NNP
, ,
will MD
recuperate VB
in IN
a DT
sterile NN
environment NN
at IN
the DT
cancer NN
center NN
, ,
where WRB
more JJR
than IN
3 CD
, ,
000 CD
bone-marrow NN
transplants NNS
have VBP
been VBN
performed VBN
, ,
more RBR
than IN
any DT
other JJ
clinic JJ
. .
Anatoly RB
Grishchenko NNP
, ,
a DT
leukemia-stricken JJ
Soviet JJ
helicopter NN
pilot NN
who WP
flew NN
firefighting VBG
missions NNS
over IN
the DT
damaged JJ
Chernobyl NNP
nuclear JJ
reactor NN
, ,
underwent NN
a DT
bone NN
marrow NN
transplant NN
at IN
the DT
center NN
earlier JJR
this DT
year NN
. .
He PRP
died VBD
July NNP
3 CD
of IN
complications NNS
of IN
a DT
lung JJ
infection NN
that WDT
took VBD
hold VBP
during IN
the DT
period NN
when WRB
he PRP
had VBD
no DT
natural JJ
defenses NNS
. .
In IN
leukemia NN
, ,
a DT
form NN
of IN
blood NN
cancer NN
, ,
white JJ
blood NN
cells NNS
multiply RB
out IN
of IN
control NN
. .
Since IN
bone NN
marrow NN
produces NNS
blood NN
, ,
doctors NNS
can MD
combat VB
leukemia NN
by IN
replacing NN
the DT
diseased VBN
marrow NN
with IN
healthy JJ
tissue NN
. .
Before IN
the DT
operation NN
, ,
Miss NNP
Atlas NNP
reassured VBD
her PRP
mother RB
with IN
humor NN
and CC
encouraged VBD
family NN
members NNS
. .
`` ``
She PRP
was VBD
really RB
cool JJ
, ,
'' ''
Sy NNP
Atlas NNP
said VBD
in IN
a DT
TV NN
interview NN
from IN
Washington NNP
, ,
D.C. NNP
`` ``
Last JJ
night NN
, ,
talking VBG
with IN
her PRP$
mom NN
, ,
she PRP
jokingly RB
said VBD
... :
`Mom JJ
, ,
your PRP$
marrow NN
better NN
be VB
good JJ
for IN
me PRP
tomorrow NN
. .
' POS
'' ''
`` ``
She PRP
's VBZ
really RB
positive JJ
. .
With IN
that DT
kind NN
of IN
attitude NN
, ,
we're JJ
confident NN
she PRP
's VBZ
going VBG
to TO
do VB
well RB
. .
'' ''

<DOCNO> AP880511-0277
A DT
biologist NN
said VBD
Wednesday NNP
that IN
a DT
newly RB
discovered VBN
herpes NNS
virus RB
spread VB
by IN
casual JJ
contact NN
might MD
be VB
a DT
sixth JJ
cancer-causing JJ
virus NN
and CC
appears VBZ
to TO
work VB
with IN
the DT
AIDS NNP
virus VBZ
in IN
wiping NN
out IN
the DT
immune NN
system NN
of IN
AIDS NNP
victims NNS
. .
Robert NNP
Gallo NNP
, ,
the DT
National NNP
Cancer NNP
Institute NNP
's POS
chief NN
of IN
tumor-cell NNP
biology NN
, ,
said VBD
more JJR
evidence NN
was VBD
needed VBN
before IN
the DT
highly RB
contagious JJ
Herpes NNS
6 CD
, ,
or CC
human JJ
B-lymphocyte JJ
virus NN
, ,
could MD
be VB
blamed VBN
for IN
causing NN
certain JJ
types NNS
of IN
cancers NNS
. .
Gallo NNP
spoke VBD
at IN
the DT
annual JJ
meeting NN
of IN
the DT
American NNP
Society NNP
for IN
Microbiology NNP
, ,
which WDT
convened VBN
here RB
Sunday NNP
. .
Researchers NNS
have VBP
found VBN
a DT
high JJ
prevalence NN
of IN
antibodies NNS
to TO
the DT
Herpes NNP
6 CD
virus NN
in IN
people NNS
with IN
Hodgkin NNP
's POS
disease NN
, ,
Burkitt's VBZ
lymphoma NN
, ,
non-Hodgkin JJ
's POS
lymphoma NN
and CC
childhood NN
acute NN
leukemia NN
, ,
Gallo NNP
said VBD
. .
`` ``
One NN
could MD
argue VB
the DT
virus NN
must MD
be VB
playing VBG
a DT
role NN
to TO
be VB
detected VBN
so RB
readily RB
in IN
those DT
tumors NNS
, ,
'' ''
Gallo NNP
said VBD
. .
Currently RB
, ,
five CD
other JJ
viruses NNS
are VBP
believed VBN
to TO
cause VB
cancer NN
. .
They PRP
are VBP
hepatitis NNS
B NNP
, ,
which WDT
can MD
cause VB
liver RB
cancer NN
; :
Epstein-Barr JJ
, ,
which WDT
can MD
cause VB
nasopharyngeal NN
cancer NN
; :
HTLV NNP
, ,
which WDT
can MD
cause VB
leukemia NN
; :
papillomavirus NN
, ,
which WDT
may MD
cause VB
cervical JJ
cancer NN
; :
and CC
cytomegalovirus VBZ
, ,
linked VBN
to TO
prostate VB
cancer NN
. .
The DT
Herpes NNP
6 CD
virus NN
also RB
has VBZ
been VBN
found VBN
alongside NN
the DT
AIDS NNP
virus VBZ
in IN
T-4 -NONE-
cells NNS
, ,
which WDT
mastermind NN
the DT
immune NN
system NN
and CC
are VBP
the DT
prime JJ
target NN
of IN
acquired VBN
immune NN
deficiency NN
syndrome NN
, ,
Gallo NNP
said VBD
. .
Since IN
the DT
AIDS NNP
virus VBZ
kills NNS
only RB
a DT
small JJ
percentage NN
of IN
T-4 -NONE-
cells VBZ
at IN
a DT
time NN
, ,
Gallo NNP
said VBD
, ,
the DT
new JJ
herpes NNS
virus VBZ
might MD
explain VB
the DT
total JJ
annihilation NN
of IN
T-4 -NONE-
cells VBZ
in IN
AIDS NNP
patients NNS
. .
Tests NNS
to TO
detect VB
Herpes NNS
6 CD
have VBP
differed VBN
widely RB
on IN
its PRP$
prevalence NN
in IN
the DT
United NNP
States NNPS
. .
One CD
test NN
indicated VBD
that IN
it PRP
is VBZ
carried VBN
by IN
between IN
5 CD
percent NN
and CC
30 CD
percent NN
of IN
the DT
population NN
; :
another DT
indicated VBN
between IN
70 CD
percent NN
and CC
90 CD
percent NN
. .

<DOCNO> AP900928-0040
First NNP
a DT
patient NN
hears NNS
the DT
cancer NN
diagnosis NN
and CC
then RB
learns VBZ
that IN
the DT
needed VBN
chemotherapy NN
may MD
cause VB
temporary JJ
baldness NN
. .
For IN
many JJ
, ,
the DT
loss NN
of IN
hair NN
is VBZ
a DT
huge JJ
cosmetic NN
burden NN
piled VBD
on IN
the DT
already RB
terrible JJ
physical JJ
trauma NN
of IN
disease NN
. .
But CC
help VBP
may MD
be VB
on IN
the DT
way NN
, ,
according VBG
to TO
a DT
study NN
published VBN
today NN
in IN
the DT
journal NN
Science NNP
. .
Dr. NNP
A.A. NNP
Yunis NNP
, ,
of IN
the DT
University NNP
of IN
Miami NNP
Jackson NNP
Memorial NNP
Hospital NNP
Medical NNP
Center NNP
, ,
reports VBZ
that IN
he PRP
and CC
his PRP$
colleagues NNS
have VBP
discovered VBN
`` ``
by IN
chance NN
'' ''
that WDT
an DT
experimental JJ
cancer NN
drug NN
blocks NNS
hair NN
loss NN
in IN
laboratory NN
rats NNS
injected VBD
with IN
some DT
chemotherapy NN
agents NNS
. .
If IN
the DT
finding NN
can MD
be VB
translated VBN
into IN
drugs NNS
to TO
treat VB
humans NNS
, ,
an DT
expert NN
said VBD
, ,
`` ``
it PRP
would MD
be VB
of IN
tremendous JJ
benefit NN
'' ''
to TO
cancer NN
patients NNS
who WP
now RB
must MD
endure VB
the DT
characteristic JJ
mark NN
of IN
chemotherapy NN
baldness NN
. .
Yunis NNP
said VBD
his PRP$
team NN
made VBD
the DT
discovery NN
while IN
testing NN
cancer-fighting NN
drugs NNS
on IN
lab NN
rats NNS
that WDT
had VBD
been VBN
injected VBN
with IN
leukemia NN
cells NNS
. .
Half NNP
of IN
the DT
rats NNS
were VBD
treated VBN
with IN
a DT
drug NN
called VBN
cytosine NN
arabinoside NN
, ,
or CC
ARA-C JJ
. .
The DT
rest NN
were VBD
treated VBN
with IN
a DT
combination NN
of IN
ARA-C JJ
and CC
an DT
experimental JJ
drug NN
called VBN
ImuVert NNP
. .
`` ``
We PRP
found VBD
, ,
lo NN
and CC
behold VBD
, ,
that IN
the DT
rats NNS
with IN
ARA-C JJ
only RB
became VBD
nude NN
. .
They PRP
lost VBD
all PDT
their PRP$
hair NN
, ,
'' ''
said VBD
Yunis NNP
. .
`` ``
The DT
ones NNS
with IN
both DT
ARA-C JJ
and CC
ImuVert NNP
, ,
however RB
, ,
did VBD
not RB
lose VB
hair JJ
at IN
all DT
. .
'' ''
Yunis NNP
said VBD
his PRP$
group NN
then RB
tested VBN
ImuVert NNP
with IN
another DT
common JJ
cancer NN
drug NN
, ,
doxorubicin NN
, ,
or CC
DX NNP
. .
He PRP
said VBD
they PRP
found VBD
that IN
rats NNS
with IN
the DT
DX-ImuVert JJ
combination NN
also RB
experienced VBD
no DT
hair NN
loss NN
, ,
while IN
rats NNS
receiving VBG
only RB
the DT
DX NNP
lost VBD
hair NN
on IN
their PRP$
heads NNS
and CC
shoulders NNS
. .
ImuVert NNP
combined VBD
with IN
a DT
third JJ
cancer NN
drug NN
, ,
cyclophosphamide NN
, ,
however RB
, ,
did VBD
not RB
prevent VB
hair JJ
loss NN
in IN
the DT
rats NNS
, ,
said VBD
Yunis NNP
. .
Dr. NNP
Ed NNP
Gelmann NNP
, ,
chief NN
of IN
the DT
department NN
of IN
medical JJ
oncology NN
at IN
Georgetown NNP
University NNP
in IN
Washington NNP
, ,
said VBD
that IN
if IN
a DT
way NN
can MD
be VB
found VBN
to TO
prevent VB
hair NN
loss NN
`` ``
patients NNS
will MD
feel VB
much JJ
better RBR
about IN
chemotherapy NN
. .
'' ''
Chemotherapy NNP
baldness NN
is VBZ
nearly RB
always RB
temporary JJ
. .
The DT
hair NN
usually RB
grows VBZ
back RB
after IN
the DT
treatment NN
cycle NN
. .
Nonetheless RB
, ,
said VBD
Gelmann NNP
: :
`` ``
A DT
lot NN
of IN
patients NNS
focus VBZ
on IN
hair NN
loss NN
because IN
it PRP
is VBZ
so RB
apparent JJ
. .
It PRP
can MD
be VB
quite RB
a DT
stigma NN
. .
It PRP
would MD
be VB
a DT
tremendous JJ
benefit NN
to TO
eliminate VB
hair NN
loss NN
as IN
long RB
as IN
it PRP
did VBD
not RB
change VB
the DT
efficacy NN
of IN
the DT
cancer NN
chemotherapy NN
. .
'' ''
Yunis NNP
said VBD
that IN
ImuVert NNP
appears VBZ
to TO
help VB
combat JJ
leukemia NN
while IN
it PRP
is VBZ
preventing VBG
chemotherapy NN
baldness NN
. .
He PRP
said VBD
the DT
drug NN
teamed VBD
with IN
ARA-C JJ
halted VBN
the DT
progression NN
of IN
leukemia NN
in IN
all DT
but CC
20 CD
percent NN
of IN
the DT
laboratory NN
rats NNS
tested VBD
. .
This DT
result NN
was VBD
better RBR
than IN
among IN
rats NNS
treated VBN
with IN
ARA-C JJ
alone NN
, ,
he PRP
said VBD
. .
Dr. NNP
Gregory NNP
Curt NNP
, ,
director NN
of IN
the DT
clinical JJ
oncology NN
department NN
at IN
the DT
National NNP
Cancer NNP
Institute NNP
, ,
said VBD
controlling VBG
hair NN
loss NN
during IN
chemotherapy NN
`` ``
is VBZ
a DT
very RB
serious JJ
thing NN
for IN
patients NNS
. .
'' ''
`` ``
The DT
two CD
things NNS
that WDT
concern NN
patients VBZ
the DT
most RBS
about IN
chemotherapy NN
are VBP
nausea NN
and CC
that IN
some DT
people NNS
can MD
get VB
bald VBN
, ,
'' ''
he PRP
said VBD
. .
There EX
are VBP
drugs NNS
to TO
control NN
the DT
nausea NN
, ,
but CC
there EX
is VBZ
no DT
pill NN
to TO
block VB
the DT
hair NN
loss NN
. .
`` ``
For IN
both DT
men NNS
and CC
women NNS
, ,
it PRP
is VBZ
one CD
of IN
the DT
side NN
effects NNS
that WDT
concerns NNS
people NNS
the DT
most JJS
because IN
it PRP
changes VBZ
one CD
's POS
body NN
image NN
, ,
'' ''
said VBD
Curt NNP
. .
The DT
physician JJ
said VBD
he PRP
remembers NNS
at IN
least JJS
two CD
patients NNS
who WP
were VBD
so RB
concerned VBN
about IN
the DT
loss NN
of IN
hair NN
that IN
they PRP
actually RB
refused VBD
lifesaving VBG
chemotherapy NN
. .
ImuVert NNP
now RB
is VBZ
being VBG
tested VBN
as IN
a DT
chemotherapy NN
agent NN
against IN
brain NN
cancer NN
. .
Yunis NNP
said VBD
it PRP
could MD
be VB
several JJ
years NNS
before IN
it PRP
is VBZ
approved VBN
for IN
use NN
on IN
patients NNS
. .
He PRP
said VBD
the DT
discovery NN
also RB
gives VBZ
researchers NNS
a DT
clue NN
that WDT
may MD
help VB
find VB
even RB
more RBR
effective JJ
drugs NNS
to TO
block VB
hair NN
loss NN
among IN
chemotherapy NN
patients NNS
. .
He PRP
said VBD
ImuVert NNP
is VBZ
a DT
drug NN
known VBN
as IN
a DT
biological JJ
response NN
modifier NN
because IN
it PRP
alters VBZ
the DT
way NN
some DT
cells NNS
in IN
the DT
immune NN
system NN
act NN
. .
If IN
the DT
precise NN
effect NN
of IN
this DT
drug NN
on IN
the DT
hair NN
follicles NNS
could MD
be VB
identified VBN
, ,
then RB
new JJ
drugs NNS
with IN
this DT
action NN
could MD
be VB
developed VBN
, ,
said VBD
Yunis NNP
. .
Science NN
, ,
which WDT
today NN
published VBD
the DT
University NNP
of IN
Miami NNP
research NN
report NN
, ,
is VBZ
the DT
journal NN
of IN
the DT
American NNP
Association NNP
for IN
the DT
Advancement NNP
of IN
Science NNP
. .
Coauthors NNS
of IN
the DT
paper NN
with IN
Yunis NNP
are VBP
Atif NNP
M. NNP
Hussein NNP
and CC
Joaquin NNP
J. NNP
Jimenez NNP
of IN
the DT
University NNP
of IN
Miami NNP
, ,
and CC
Catherine NNP
A. NNP
McCall NNP
of IN
Cell NNP
Technology NNP
Inc NNP
. .

<DOCNO> LA011590-0100
Loss NN
of IN
genes NNS
that WDT
make VBP
interferon RP
, ,
a DT
natural JJ
disease-fighting NN
substance NN
, ,
has VBZ
been VBN
linked VBN
with IN
development NN
of IN
a DT
form NN
of IN
leukemia NN
, ,
researchers NNS
said VBD
. .
The DT
researchers NNS
speculate VBP
that IN
the DT
interferon NN
genes NNS
may MD
act VB
as IN
regulators NNS
that IN
stop NN
the DT
body NN
's POS
cells NNS
from IN
becoming VBG
cancerous JJ
. .
Researchers NNS
from IN
the DT
University NNP
of IN
Chicago NNP
found VBD
an DT
association NN
between IN
loss NN
of IN
the DT
genes NNS
and CC
development NN
of IN
acute NN
lymphoblastic JJ
leukemia NN
, ,
a DT
blood NN
cancer NN
that WDT
is VBZ
the DT
most RBS
common JJ
form NN
of IN
childhood NN
leukemia NN
. .
They PRP
tested VBD
62 CD
patients NNS
with IN
this DT
kind NN
of IN
leukemia NN
and CC
found VBD
that IN
29 CD
% NN
of IN
them PRP
lacked VBD
the DT
interferon NN
genes NNS
. .
Their PRP$
work NN
, ,
directed VBD
by IN
Dr. NNP
Manuel NNP
O. NNP
Diaz NNP
, ,
was VBD
published VBN
in IN
the DT
New NNP
England NNP
Journal NNP
of IN
Medicine NNP
. .
It PRP
adds VBZ
to TO
the DT
growing VBG
list NN
of IN
cancers NNS
that WDT
have VBP
been VBN
associated VBN
with IN
the DT
presence NN
or CC
absence NN
of IN
particular JJ
genes NNS
. .
Interferon NNP
plays VBZ
a DT
variety NN
of IN
roles NNS
in IN
regulating VBG
the DT
body NN
's POS
immune NN
defenses NNS
and CC
controlling VBG
cell NN
growth NN
. .

<DOCNO> SJMN91-06307182
Stem NNP
cells NNS
-- :
whose WP$
existence NN
had VBD
only RB
been VBN
inferred VBN
until IN
now RB
-- :
are VBP
extremely RB
rare JJ
in IN
the DT
bone NN
marrow NN
, ,
and CC
scientists NNS
believe VBP
a DT
single JJ
stem NN
cell NN
may MD
have VB
the DT
ability NN
to TO
rebuild VB
a DT
person NN
's POS
entire JJ
immune NN
system NN
. .
Given RB
that IN
extraordinary JJ
power NN
, ,
the DT
search NN
for IN
the DT
bone NN
marrow NN
stem NN
cell NN
has VBZ
been VBN
called VBN
the DT
Holy NNP
Grail NNP
of IN
blood NN
research NN
. .
; :
If IN
borne NN
out IN
by IN
scientific JJ
data NNS
-- :
the JJ
researchers NNS
may MD
present VB
their PRP$
work NN
next IN
week NN
-- :
the DT
discovery NN
means VBZ
physicians NNS
would MD
soon RB
be VB
able JJ
to TO
restore VB
a DT
patient NN
's POS
blood NN
and CC
immune NN
systems NNS
when WRB
damaged JJ
by IN
radiation NN
, ,
chemotherapy NN
or CC
disease NN
. .
; :
Great NNP
potential NN
; :
`` ``
This DT
finding NN
is VBZ
extremely RB
exciting VBG
and CC
important JJ
, ,
'' ''
said VBD
Dr. NNP
Samuel NNP
Broder NNP
, ,
National NNP
Cancer NNP
Institute NNP
director NN
. .
; :
Dr. NNP
R. NNP
Michael NNP
Blaese NNP
agreed VBD
. .
`` ``
This DT
is VBZ
potentially RB
very RB
important JJ
for IN
gene NN
therapy NN
for IN
dozens NNS
of IN
diseases NNS
, ,
'' ''
said VBD
the DT
NCI NNP
immunologist NN
who WP
last JJ
year NN
became VBD
the DT
first JJ
physician NN
to TO
use VB
gene NN
therapy NN
to TO
treat VB
patients NNS
-- :
two CD
children NNS
suffering VBG
from IN
a DT
lethal JJ
immune NN
system NN
disease NN
known VBN
as IN
adenisine NN
deaminase NN
deficiency NN
. .
; :
The DT
discovery NN
of IN
the DT
stem NN
cell NN
also RB
promises VBZ
to TO
be VB
extremely RB
controversial JJ
. .
; :
It PRP
was VBD
not RB
announced VBN
in IN
a DT
scientific JJ
journal JJ
but CC
by IN
a DT
for-profit JJ
company NN
that WDT
kept VBD
quiet JJ
about IN
its PRP$
work NN
until IN
it PRP
had VBD
obtained VBN
U.S. NNP
patents NNS
on IN
the DT
process NN
of IN
isolating VBG
the DT
stem NN
cell NN
and CC
on IN
the DT
cell NN
itself PRP
. .
; :
Patenting NNP
of IN
life NN
forms NNS
-- :
genes NNS
, ,
cells NNS
, ,
tissues NNS
, ,
even RB
animals NNS
-- :
is VBZ
the DT
heart NN
of IN
the DT
burgeoning NN
biotechnology NN
industry NN
, ,
but CC
the DT
idea NN
still RB
makes VBZ
many JJ
uneasy JJ
. .
; :
Ethical NNP
questions NNS
; :
By NNP
patenting NN
the DT
bone NN
marrow NN
stem NN
cell NN
, ,
Systemix NNP
`` ``
introduces NNS
us PRP
into IN
a DT
new JJ
era NN
of IN
ethical JJ
problems NNS
in IN
medicine NN
, ,
'' ''
said VBD
Dr. NNP
Peter NNP
Quesenberry NNP
, ,
vice NN
president NN
of IN
medical JJ
and CC
scientific JJ
affairs NNS
of IN
the DT
Leukemia NNP
Society NNP
of IN
America NNP
. .
`` ``
The DT
idea NN
. .
. .
. .
you PRP
could MD
have VB
commercial JJ
restrictions NNS
on IN
the DT
use NN
of IN
such JJ
cells NNS
in IN
transplants NNS
would MD
be VB
very RB
disturbing JJ
. .
`` ``
; :
Systemix NNP
plans VBZ
clinical JJ
trials NNS
to TO
test NN
bone NN
marrow NN
stem NN
cell NN
therapy NN
in IN
people NNS
early JJ
next JJ
year NN
. .
The DT
first JJ
participants NNS
will MD
be VB
patients NNS
who WP
have VBP
otherwise VBP
untreatable JJ
breast NN
cancer NN
, ,
leukemia NN
and CC
neuroblastoma NN
, ,
a DT
form NN
of IN
brain NN
cancer NN
. .

<DOCNO> AP891110-0134
Increases NNS
in IN
leukemia NN
among IN
young JJ
people NNS
living VBG
near IN
nuclear JJ
plants NNS
are VBP
not RB
caused VBN
by IN
exposure NN
to TO
radiation NN
, ,
said VBD
a DT
study NN
released VBN
Friday NNP
. .
Researchers NNS
found VBD
that IN
death NN
rates NNS
from IN
leukemia NN
and CC
Hodgkin's VBZ
disease NN
among IN
young JJ
people NNS
were VBD
about IN
as IN
high JJ
in IN
areas NNS
that WDT
were VBD
only RB
considered VBN
for IN
nuclear JJ
plants NNS
as IN
in IN
areas NNS
that WDT
actually RB
contained VBD
nuclear JJ
plants NNS
. .
Hodgkin NNP
's POS
disease NN
is VBZ
a DT
cancer NN
of IN
the DT
lymph NN
glands NNS
. .
Researchers NNS
said VBD
it PRP
has VBZ
never RB
been VBN
linked VBN
to TO
radiation NN
exposure NN
. .
The DT
cause NN
of IN
heightened VBN
cancer NN
rates NNS
found VBD
in IN
the DT
study NN
remains VBZ
a DT
mystery NN
. .
But CC
the DT
researchers NNS
said VBD
their PRP$
findings NNS
indicate VBP
an DT
increased VBN
risk NN
of IN
leukemia NN
is VBZ
not RB
associated VBN
with IN
exposure NN
to TO
radiation NN
, ,
with IN
the DT
possible JJ
exception NN
of IN
the DT
Sellafield NNP
nuclear JJ
reprocessing NN
plant NN
on IN
England NNP
's POS
northwest JJS
coast NN
. .
The DT
Sellafield NNP
plant NN
has VBZ
been VBN
plagued VBN
by IN
radioactive JJ
leaks NNS
. .
Government NNP
studies NNS
have VBP
found VBN
a DT
10-fold JJ
increase NN
in IN
childhood NN
leukemia NN
a DT
mile NN
from IN
the DT
plant NN
, ,
and CC
concluded VBD
the DT
plant NN
is VBZ
linked VBN
to TO
the DT
disease NN
. .
In IN
the DT
study NN
released VBN
Friday NNP
, ,
researchers NNS
from IN
the DT
Medical JJ
Research NNP
Council NNP
and CC
the DT
Imperial NNP
Cancer NNP
Research NNP
Fund NNP
said VBD
the DT
new JJ
findings NNS
suggest VBP
that IN
areas NNS
near IN
existing VBG
and CC
potential JJ
nuclear JJ
sites NNS
might MD
share VB
`` ``
unrecognized VBN
risk NN
factors NNS
other JJ
than IN
environmental JJ
radiation NN
pollution NN
. .
'' ''
Dr. NNP
Sarah NNP
Darby NNP
of IN
the DT
Imperial NNP
Cancer NNP
Research NNP
Fund NNP
said VBD
the DT
findings NNS
point VBP
to TO
something NN
possibly RB
`` ``
in IN
the DT
lifestyle NN
of IN
the DT
young JJ
but CC
at IN
the DT
present NN
time NN
we PRP
do VBP
n't RB
have VB
a DT
great JJ
deal NN
of IN
handle NN
on IN
it PRP
. .
'' ''
The DT
researchers NNS
investigated VBD
death NN
statistics NNS
in IN
400 CD
districts NNS
of IN
England NNP
and CC
Wales NNP
near IN
existing VBG
or CC
potential JJ
nuclear JJ
sites NNS
. .
The DT
results NNS
were VBD
published VBN
in IN
the DT
The NNP
Lancet NNP
, ,
a DT
weekly JJ
medical JJ
journal JJ
. .
`` ``
Excess JJ
mortality NN
due JJ
to TO
leukemia VB
and CC
Hodgkin NNP
's POS
disease NN
in IN
young JJ
people NNS
who WP
lived VBN
near IN
potential JJ
sites NNS
was VBD
similar JJ
to TO
that DT
in IN
young JJ
people NNS
who WP
lived VBN
near IN
existing VBG
sites NNS
, ,
'' ''
researchers NNS
wrote VBD
. .
Ms. NNP
Darby NNP
said VBD
: :
`` ``
There EX
was VBD
a DT
16 CD
percent NN
increase NN
in IN
childhood NN
leukemia NN
mortality NN
in IN
areas NNS
near IN
nuclear JJ
installations NNS
compared VBN
with IN
the DT
rest NN
of IN
the DT
country NN
after IN
adjusting VBG
for IN
factors NNS
such JJ
as IN
urban-rural JJ
status NN
. .
When WRB
the DT
same JJ
analysis NN
was VBD
carried VBN
out RP
for IN
areas NNS
near IN
potential JJ
installations NNS
, ,
there EX
was VBD
a DT
14 CD
percent NN
increase NN
. .
'' ''
`` ``
We PRP
carried VBD
out RP
this DT
study NN
because IN
estimates NNS
of IN
radiation NN
received VBD
by IN
children NNS
living VBG
near IN
nuclear JJ
installations NNS
are VBP
extremely RB
low JJ
, ,
and CC
it PRP
has VBZ
been VBN
suggested VBN
that IN
increases NNS
in IN
the DT
number NN
of IN
deaths NNS
are VBP
not RB
caused VBN
by IN
the DT
presence NN
of IN
the DT
installations NNS
, ,
but CC
by IN
some DT
other JJ
feature NN
of IN
the DT
districts NNS
in IN
which WDT
they PRP
tend VBP
to TO
be VB
built VBN
, ,
'' ''
she PRP
said VBD
. .
The DT
new JJ
findings NNS
on IN
leukemia NN
bolster NN
this DT
hypothesis NN
, ,
the DT
researchers NNS
wrote VBD
. .
Other JJ
previous JJ
theories NNS
, ,
such JJ
as IN
those DT
involving VBG
exposure NN
to TO
radon VB
gas NN
or CC
viruses NNS
, ,
could MD
not RB
account VB
for IN
all PDT
the DT
excess NN
cancers NNS
in IN
young JJ
people NNS
, ,
they PRP
said VBD
. .
Ms. NNP
Darby NNP
said VBD
the DT
study NN
also RB
would MD
disprove VB
stress NN
or CC
psychosomatic JJ
illness NN
being VBG
a DT
possible JJ
cause NN
since IN
most JJS
people NNS
living VBG
around IN
the DT
potential NN
sites VBZ
`` ``
would MD
n't RB
have VB
been VBN
worried VBN
about IN
it PRP
. .
'' ''
She PRP
said VBD
the DT
main JJ
theory NN
that WDT
needs VBZ
investigation NN
is VBZ
`` ``
that IN
people NNS
who WP
are VBP
exposed VBN
less RBR
frequently RB
to TO
infection NN
very RB
early JJ
in IN
life NN
are VBP
at IN
a DT
slightly RB
higher JJR
risk NN
of IN
leukemia NN
later JJ
on IN
. .
'' ''
Mel NNP
Greaves NNP
of IN
the DT
Leukemia NNP
Research NNP
Fund NNP
, ,
who WP
originated VBN
the DT
theory NN
, ,
`` ``
has VBZ
biological JJ
reasons NNS
for IN
thinking VBG
that IN
is VBZ
the DT
case NN
, ,
'' ''
she PRP
said VBD
. .
`` ``
Our PRP$
data NNS
support NN
that IN
, ,
'' ''
she PRP
said VBD
, ,
explaining NN
that IN
areas NNS
with IN
a DT
higher JJR
proportion NN
of IN
people NNS
in IN
the DT
upper JJ
social JJ
classes NNS
had VBD
a DT
slightly RB
higher JJR
risk NN
of IN
leukemia NN
than IN
people NNS
in IN
areas NNS
with IN
a DT
higher JJR
proportion NN
of IN
manual JJ
workers NNS
. .

<DOCNO> AP880505-0077
A DT
mysterious JJ
paralyzing NN
disease NN
that WDT
occurs VBZ
in IN
tropical JJ
climates NNS
may MD
be VB
caused VBN
by IN
a DT
virus NN
that WDT
also RB
triggers VBZ
a DT
rare NN
form NN
of IN
blood NN
cancer NN
, ,
according VBG
to TO
a DT
report NN
today NN
. .
The DT
virus NN
, ,
first JJ
isolated VBN
in IN
1980 CD
, ,
is VBZ
called VBN
human NN
T-cell NNP
lymphoma-leukemia NNP
virus VBZ
Type NNP
1 CD
, ,
or CC
HTLV-I NNP
. .
It PRP
causes VBZ
cancer NN
of IN
a DT
variety NN
of IN
white NN
blood NN
cells NNS
known VBN
as IN
T NNP
cells NNS
. .
Recently RB
, ,
doctors NNS
have VBP
found VBN
that IN
people NNS
with IN
a DT
mysterious JJ
disease NN
called VBN
chronic JJ
progressive JJ
myelopathy JJ
, ,
or CC
tropical JJ
spastic JJ
paraparesis NN
, ,
sometimes RB
show VB
signs NNS
in IN
their PRP$
blood NN
of IN
infection NN
with IN
HTLV-I NNP
. .
In IN
the DT
latest JJS
study NN
, ,
doctors NNS
found VBD
direct JJ
evidence NN
of IN
the DT
virus NN
in IN
these DT
people NNS
, ,
strengthening VBG
the DT
suspicion NN
that IN
HTLV-I NNP
can MD
be VB
one CD
cause NN
of IN
the DT
disease NN
. .
`` ``
HTLV-I JJ
appears NNS
to TO
be VB
causally RB
associated VBN
with IN
many JJ
cases NNS
of IN
otherwise NN
unexplained VBN
myelopathy JJ
in IN
patients NNS
from IN
the DT
tropics NNS
, ,
'' ''
they PRP
wrote VBD
. .
The DT
research NN
was VBD
directed VBN
by IN
Dr. NNP
Satyakam NNP
Bhagavati NNP
of IN
the DT
State NNP
University NNP
of IN
New NNP
York NNP
Health NNP
Science NNP
Center NNP
in IN
Brooklyn NNP
. .
It PRP
was VBD
published VBN
in IN
the DT
New NNP
England NNP
Journal NNP
of IN
Medicine NNP
. .
Health NNP
experts NNS
say VBP
HTLV-I JJ
is VBZ
spreading VBG
among IN
drug NN
addicts NNS
in IN
the DT
United NNP
States NNPS
. .
Surveys NNS
estimate VBP
that IN
about IN
two CD
of IN
every DT
10 CD
, ,
000 CD
units NNS
of IN
blood NN
used VBN
for IN
transfusions NNS
contain VBP
the DT
virus NN
. .
Blood NNP
bank NN
officials NNS
have VBP
said VBN
they PRP
will MD
start VB
checking NN
donations NNS
for IN
the DT
virus NN
when WRB
screening VBG
tests NNS
are VBP
available JJ
. .
Clusters NNS
of IN
chronic JJ
progressive JJ
myelopathy JJ
occur NN
in IN
tropical JJ
parts NNS
of IN
the DT
world NN
, ,
including VBG
the DT
Caribbean NNP
, ,
where WRB
the DT
virus NN
is VBZ
also RB
relatively RB
common JJ
. .
The DT
disease NN
results NNS
in IN
weakness NN
, ,
numbness NN
and CC
gradual JJ
paralysis NN
of IN
the DT
legs NNS
. .
In IN
their PRP$
study NN
, ,
doctors NNS
found VBD
direct JJ
evidence NN
of IN
the DT
virus NN
in IN
12 CD
patients NNS
who WP
also RB
had VBD
antibodies NNS
to TO
HTLV-I NNP
. .
In IN
an DT
accompanying NN
editorial NN
, ,
Drs NNP
. .
Bruce NNP
J NNP
. .
Brew NNP
and CC
Richard NNP
W. NNP
Price NNP
of IN
Memorial NNP
Sloan-Kettering JJ
Cancer NNP
Center NNP
in IN
New NNP
York NNP
said VBD
it PRP
's VBZ
puzzling VBG
why WRB
the DT
disease NN
is VBZ
rare JJ
even RB
where WRB
the DT
virus NN
is VBZ
widespread JJ
. .
Even RB
though IN
there EX
are VBP
other JJ
examples NNS
of IN
low JJ
disease NN
rates NNS
from IN
common JJ
viruses NNS
, ,
they PRP
wrote VBD
, ,
`` ``
it PRP
nonetheless VBZ
raises VBZ
the DT
question NN
of IN
what WP
other JJ
factors NNS
contribute VBP
to TO
the DT
development NN
of IN
the DT
disease NN
. .
'' ''

<DOCNO> LA022290-0150
Medical JJ
researchers NNS
unveiled VBD
new JJ
evidence NN
Wednesday NNP
showing NN
that WDT
doctors NNS
do VBP
n't RB
need VB
a DT
perfect NN
match NN
when WRB
they PRP
try VBP
to TO
transplant VB
bone NN
marrow NN
into IN
someone NN
whose WP$
blood-producing JJ
cells NNS
have VBP
been VBN
damaged VBN
by IN
leukemia NN
or CC
another DT
deadly RB
illness NN
. .
Bone NN
marrow NN
transplants NNS
are VBP
usually RB
most JJS
successful JJ
when WRB
the DT
marrow NN
is VBZ
donated VBN
by IN
a DT
brother NN
or CC
sister NN
whose WP$
cells NNS
have VBP
the DT
same JJ
pattern NN
of IN
surface NN
proteins NNS
. .
When WRB
the DT
protein NN
pattern NN
matches NNS
, ,
it PRP
reduces VBZ
the DT
likelihood NN
that IN
the DT
donated JJ
marrow NN
will MD
be VB
rejected VBN
or CC
produce VB
serious JJ
side NN
effects NNS
. .
But CC
researchers NNS
at IN
the DT
Medical NNP
College NNP
of IN
Wisconsin NNP
, ,
using VBG
special JJ
techniques NNS
to TO
cleanse VB
the DT
donated VBN
marrow NN
, ,
found VBD
that IN
transplants NNS
can MD
be VB
successful JJ
when WRB
the DT
protein NN
pattern NN
in IN
the DT
donor NN
's POS
marrow NN
is VBZ
similar JJ
to TO
, ,
but CC
not RB
identical JJ
to TO
, ,
the DT
recipient JJ
's POS
. .
The DT
findings NNS
, ,
reported VBD
in IN
the DT
current JJ
New NNP
England NNP
Journal NNP
of IN
Medicine NNP
, ,
suggest VBP
that IN
`` ``
we PRP
can MD
now RB
start VB
tapping VBG
into IN
the DT
enlarging NN
pool NN
of IN
volunteer NN
marrow NN
donors NNS
'' ''
whose WP$
marrow NN
`` ``
will MD
lead VB
to TO
satisfactory JJ
results NNS
for IN
many JJ
patients NNS
, ,
'' ''
said VBD
Dr. NNP
Robert NNP
C. NNP
Ash NNP
, ,
chief NN
author NN
of IN
the DT
study NN
. .
The DT
ability NN
to TO
use VB
marrow NN
from IN
unrelated VBN
donors NNS
is VBZ
important JJ
because IN
only RB
about IN
30 CD
% NN
of IN
patients NNS
who WP
might MD
benefit VB
from IN
a DT
bone NN
marrow NN
transplant NN
will MD
have VB
a DT
brother NN
or CC
sister NN
whose WP$
marrow NN
is VBZ
perfectly RB
matched VBN
, ,
Ash NNP
said VBD
. .
This DT
issue NN
was VBD
dramatized VBN
last JJ
week NN
when WRB
a DT
43-year-old JJ
Walnut NNP
woman NN
disclosed VBD
that IN
she PRP
was VBD
having VBG
a DT
baby NN
in IN
the DT
hope NN
that IN
the DT
newborn NN
can MD
become VB
a DT
bone NN
marrow NN
donor NN
for IN
her PRP$
17-year-old JJ
daughter NN
, ,
who WP
has VBZ
leukemia VBP
. .
Tests NNS
have VBP
shown VBN
that IN
the DT
fetus NN
's POS
bone NN
marrow NN
is VBZ
nearly RB
identical JJ
. .
The DT
birth NN
is VBZ
expected VBN
in IN
April NNP
. .
In IN
the DT
four-year JJ
study NN
of IN
55 CD
patients NNS
, ,
the DT
transplants NNS
were VBD
successful JJ
in IN
48 CD
% NN
of IN
patientswith NN
early RB
leukemia NN
, ,
32 CD
% NN
of IN
the DT
volunteers NNS
whose WP$
leukemia NN
had VBD
reached VBN
an DT
advanced JJ
stage NN
, ,
and CC
63 CD
% NN
of IN
the DT
patients NNS
who WP
suffered VBN
from IN
diseases NNS
other JJ
than IN
leukemia NN
. .
In IN
all DT
, ,
31 CD
of IN
the DT
55 CD
patients NNS
died VBD
, ,
usually RB
from IN
infection NN
. .
Graft-versus-host JJ
disease NN
, ,
a DT
potentially RB
deadly RB
reaction NN
that IN
appears NNS
when WRB
the DT
cells NNS
of IN
the DT
transplanted VBN
marrow NN
attack NN
the DT
body NN
, ,
occurred VBD
in IN
nearly RB
half NN
the DT
patients NNS
. .
Ash NNP
and CC
his PRP$
colleagues NNS
characterized VBD
that IN
rate NN
as IN
relatively RB
low JJ
. .
To TO
reduce VB
the DT
risk NN
of IN
graftversus-host JJ
disease NN
, ,
the DT
donated VBN
marrow NN
was VBD
initially RB
treatedwith IN
chemicals NNS
to TO
kill VB
white JJ
blood NN
cells NNS
that WDT
trigger JJR
an DT
immune NN
response NN
. .

<DOCNO> AP891128-0127
The DT
Food NNP
and CC
Drug NNP
Administration NNP
is VBZ
allowing VBG
wider NN
distribution NN
of IN
a DT
leukemia NN
drug NN
that WDT
has VBZ
been VBN
shown VBN
effective JJ
in IN
patients NNS
who WP
are VBP
n't RB
helped VBN
by IN
other JJ
treatments NNS
, ,
an DT
FDA NNP
spokesman NN
said VBD
Tuesday NNP
. .
The DT
drug NN
, ,
fludarabine NN
phosphate NN
, ,
is VBZ
being VBG
used VBN
to TO
treat VB
patients NNS
with IN
chronic JJ
lymphocytic JJ
leukemia NN
, ,
which WDT
is VBZ
the DT
most RBS
common JJ
form NN
of IN
adult NN
leukemia NN
. .
The DT
drug NN
is VBZ
believed VBN
to TO
slow JJ
or CC
interrupt JJ
reproduction NN
of IN
abnormal JJ
white JJ
blood NN
cells NNS
that WDT
accumulate NN
in IN
the DT
bone NN
marrow NN
, ,
blood NN
and CC
liver NN
of IN
people NNS
with IN
the DT
disease NN
. .
The DT
FDA NNP
has VBZ
approved VBN
wider NN
distribution NN
of IN
the DT
drug NN
under IN
a DT
`` ``
treatment NN
IND NNP
, ,
'' ''
which WDT
is VBZ
shorthand VBP
for IN
treatment NN
use NN
of IN
an DT
investigational JJ
new JJ
drug NN
, ,
said VBD
FDA NNP
spokesman NN
Jeff NNP
Nesbit NNP
. .
A DT
treatment NN
IND NNP
allows VBZ
patients NNS
with IN
serious JJ
or CC
immediately RB
life-threatening JJ
diseases NNS
to TO
get VB
an DT
experimental JJ
drug NN
while IN
controlled JJ
testing NN
in IN
human NN
clinical JJ
trials NNS
continues VBZ
. .
The DT
drug NN
was VBD
developed VBN
by IN
Triton NNP
Biosciences NNP
Inc. NNP
, ,
a DT
Shell NNP
Oil NNP
Co. NNP
subsidiary NN
based VBN
in IN
Alameda NNP
, ,
Calif. NNP
and CC
clinical JJ
trials NNS
are VBP
being VBG
conducted VBN
by IN
National NNP
Cancer NNP
Institute NNP
. .
Triton NNP
plans VBP
to TO
market NN
the DT
drug NN
under IN
the DT
trade NN
name NN
Fludara NNP
I.V NNP
. .

<DOCNO> WSJ880909-0170
Men NNS
who WP
smoke NN
heavily RB
are VBP
nearly RB
twice NN
as IN
likely JJ
as IN
nonsmokers NNS
to TO
die VB
from IN
a DT
common JJ
form NN
of IN
leukemia NN
, ,
concludes VBZ
a DT
report NN
by IN
the DT
University NNP
of IN
Edinburgh NNP
. .
The DT
analysis NN
, ,
based VBN
on IN
a DT
previous JJ
study NN
of IN
248 CD
, ,
046 CD
U.S. NNP
veterans NNS
, ,
offers NNS
the DT
firmest JJS
link NN
yet RB
between IN
cigarette NN
consumption NN
and CC
the DT
disease NN
. .
The DT
finding NN
could MD
add VB
leukemia NN
to TO
the DT
already RB
lengthy JJ
list NN
of IN
suspected VBN
health NN
risks NNS
from IN
smoking VBG
. .
The DT
report NN
in IN
tomorrow NN
's POS
British JJ
Medical JJ
Journal NNP
`` ``
may MD
well RB
have VB
an DT
emotional JJ
impact NN
on IN
some DT
people NNS
who WP
are VBP
vacillating VBG
'' ''
about IN
quitting VBG
smoking NN
`` ``
and CC
for IN
one CD
reason NN
or CC
another DT
have VBP
a DT
fear NN
of IN
leukemia NN
, ,
'' ''
suggested VBD
Nicholas NNP
Wald NNP
, ,
an DT
epidemiologist NN
at IN
the DT
Medical NNP
College NNP
of IN
St. NNP
Bartholomew NNP
's POS
Hospital NNP
here RB
. .
`` ``
The DT
balance NN
of IN
evidence NN
suggests VBZ
that IN
smoking NN
may MD
cause VB
leukemia NN
, ,
'' ''
Dr. NNP
Wald NNP
wrote VBD
in IN
an DT
accompanying NN
commentary NN
on IN
the DT
analysis NN
, ,
which WDT
was VBD
conducted VBN
by IN
University NNP
of IN
Edinburgh NNP
epidemiologist NN
Leo NNP
Kinlen NNP
. .
Dr. NNP
Kinlen NNP
, ,
who WP
directs NNS
the DT
university NN
's POS
Cancer NNP
Epidemiology NNP
Unit NNP
, ,
examined VBD
leukemia NN
deaths NNS
from IN
a DT
U.S. NNP
study NN
that WDT
had VBD
tracked VBN
veterans NNS
' POS
smoking NN
between IN
1954 CD
and CC
1969 CD
. .
The DT
earlier JJR
study NN
tallied VBD
overall JJ
deaths NNS
from IN
various JJ
causes NNS
, ,
including VBG
723 CD
deaths NNS
due JJ
to TO
leukemia VB
. .
Dr. NNP
Kinlen NNP
found VBD
veterans NNS
who WP
had VBD
smoked VBN
more JJR
than IN
21 CD
cigarettes NNS
a DT
day NN
were VBD
the DT
most JJS
likely JJ
to TO
die VB
from IN
myeloid JJ
leukemia NN
, ,
the DT
most RBS
common JJ
form NN
of IN
the DT
disease NN
in IN
middle-aged JJ
people NNS
. .
These DT
heavy JJ
smokers NNS
had VBD
a DT
93 CD
% NN
greater JJR
chance NN
of IN
developing VBG
fatal JJ
leukemia NN
than IN
the DT
veterans NNS
who WP
never RB
had VBD
smoked VBN
. .
For IN
those DT
smoking VBG
between IN
10 CD
and CC
20 CD
cigarettes NNS
a DT
day NN
, ,
the DT
increased VBN
risk NN
was VBD
75 CD
% NN
. .
And CC
men NNS
using VBG
fewer JJR
than IN
10 CD
cigarettes NNS
daily RB
were VBD
31 CD
% NN
more JJR
likely JJ
to TO
die VB
from IN
leukemia NN
than IN
nonsmokers NNS
, ,
according VBG
to TO
the DT
report NN
. .
Previous JJ
studies NNS
have VBP
observed VBN
higher JJR
death NN
rates NNS
from IN
leukemia NN
among IN
smokers NNS
, ,
but CC
either DT
involved VBN
fewer JJR
patients NNS
or CC
did VBD
n't RB
compare VB
amounts NNS
smoked VBN
with IN
incidence NN
of IN
the DT
disease NN
. .
For IN
this DT
reason NN
, ,
leukemia NN
`` ``
has VBZ
in IN
general JJ
not RB
been VBN
regarded VBN
as IN
a DT
a DT
malignancy NN
related VBN
to TO
smoking NN
, ,
'' ''
Dr. NNP
Kinlen NNP
wrote VBD
. .
The DT
latest JJS
analysis NN
does VBZ
n't RB
prove VB
a DT
causal NN
link NN
, ,
Dr. NNP
Kinlen NNP
noted VBD
in IN
a DT
phone NN
interview NN
. .
But CC
`` ``
it PRP
is VBZ
the DT
best JJS
evidence NN
to TO
date NN
that IN
the DT
relationship NN
is VBZ
genuine JJ
. .
`` ``
If IN
the DT
link NN
is VBZ
causal JJ
, ,
an DT
editorial NN
in IN
the DT
medical JJ
journal JJ
said VBD
, ,
`` ``
then RB
smoking VBG
is VBZ
a DT
more RBR
important JJ
cause NN
of IN
leukemia NN
in IN
adults NNS
than IN
all DT
other JJ
known VBN
causes NNS
combined VBN
. .
`` ``
Current JJ
known NN
causes NNS
include VBP
radiation NN
and CC
exposure NN
to TO
the DT
chemical JJ
benzene NN
. .
Leukemia NNP
is VBZ
fairly RB
rare JJ
. .
An DT
estimated VBN
18 CD
, ,
100 CD
Americans NNPS
will MD
die VB
from IN
it PRP
this DT
year NN
, ,
making VBG
the DT
disease NN
the DT
fifth-greatest JJS
cause NN
of IN
cancer NN
deaths NNS
. .
But CC
leukemia IN
represents NNS
the DT
third-leading JJ
cause NN
of IN
death NN
in IN
U.S. NNP
children NNS
, ,
behind IN
accidents NNS
and CC
birth JJ
defects NNS
, ,
according VBG
to TO
the DT
American NNP
Cancer NNP
Society NNP
. .

<DOCNO> AP900215-0131
Here RB
are VBP
some DT
developments NNS
on IN
the DT
health NN
front NN
Thursday NNP
: :
Thirty-five JJ
million NN
Americans NNS
report NN
suffering VBG
from IN
arthritis NNS
and CC
6 CD
million CD
admit NN
they PRP
have VBP
n't RB
seen VBN
a DT
doctor NN
about IN
it PRP
, ,
according VBG
to TO
a DT
nationwide JJ
survey NN
released VBN
Thursday NNP
by IN
the DT
Centers NNPS
for IN
Disease NNP
Control NNP
. .
`` ``
People NNS
are VBP
seeing VBG
( :
pain-killer JJ
) NN
ads NNS
on IN
TV NN
and CC
treating VBG
their PRP$
arthritis NNS
themselves PRP
_ NNP
and CC
very RB
possibly RB
doing VBG
damage NN
to TO
themselves PRP
, ,
'' ''
said VBD
Steve NNP
Erickson NNP
, ,
spokesman NN
for IN
the DT
Arthritis NNP
Foundation NNP
. .
The DT
problem NN
will MD
probably RB
get VB
worse NN
if IN
pain NN
relievers NNS
are VBP
the DT
only JJ
treatment NN
, ,
he PRP
said VBD
. .
Erickson NNP
said VBD
too RB
few JJ
people NNS
are VBP
aware JJ
of IN
the DT
warning NN
signs NNS
of IN
arthritis NNS
, ,
such JJ
as IN
joint JJ
swelling NN
, ,
early RB
morning VBG
stiffness NN
, ,
recurring VBG
joint JJ
pain NN
or CC
inability NN
to TO
move VB
a DT
joint JJ
that IN
lasts NNS
for IN
more JJR
than IN
two CD
weeks NNS
. .
At IN
least JJS
14 CD
deaths NNS
and CC
1 CD
, ,
269 CD
cases NNS
of IN
a DT
rare NN
, ,
painful JJ
blood NN
disorder NN
known VBN
as IN
eosinophilia-myalgia NNP
syndrome NN
have VBP
been VBN
attributed VBN
to TO
the DT
health NN
food NN
supplement NN
L-tryptophan JJ
, ,
the DT
Centers NNPS
for IN
Disease NNP
Control NNP
reported VBD
Thursday NNP
. .
The DT
disorder NN
, ,
marked VBD
by IN
an DT
abnormally RB
high JJ
number NN
of IN
white JJ
blood NN
cells NNS
, ,
causes NNS
severe RB
muscle JJ
pain NN
and CC
can MD
cause VB
death NN
. .
The DT
median JJ
time NN
between IN
use NN
of IN
L-tryptophan JJ
and CC
the DT
onset NN
of IN
symptoms NNS
was VBD
152 CD
days NNS
. .
The DT
FDA NNP
issued VBD
a DT
recall NN
request NN
for IN
L-tryptophan JJ
on IN
Nov. NNP
17 CD
and CC
expanded VBD
it PRP
four CD
days NNS
later JJ
to TO
block VB
importation NN
of IN
the DT
product NN
, ,
a DT
protein NN
component NN
widely RB
taken VBN
as IN
a DT
nutritional JJ
supplement NN
. .
Last JJ
month NN
, ,
the DT
FDA NNP
cautioned VBD
consumers NNS
against IN
buying VBG
L-tryptophan JJ
products NNS
from IN
a DT
California NNP
company NN
that WDT
did VBD
not RB
comply RB
with IN
the DT
recall NN
request NN
. .
Researchers NNS
using VBG
an DT
intricate JJ
manipulation NN
of IN
genes NNS
and CC
transplantation NN
of IN
bone NN
marrow NN
have VBP
produced VBN
a DT
mouse NN
that WDT
suffers NNS
from IN
a DT
vicious JJ
form NN
of IN
human JJ
leukemia NN
, ,
giving VBG
scientists NNS
a DT
new JJ
way NN
to TO
test NN
therapies NNS
against IN
the DT
killer NN
disease NN
. .
In IN
a DT
report NN
to TO
be VB
published VBN
Friday NNP
in IN
the DT
magazine NN
Science NNP
, ,
researchers NNS
said VBD
they PRP
have VBP
discovered VBN
a DT
way NN
to TO
give VB
chronic JJ
myelogenous JJ
leukemia NN
, ,
CML NNP
, ,
to TO
laboratory NN
mice NN
. .
CML NNP
is VBZ
a DT
form NN
of IN
leukemia NN
that IN
usually RB
attacks VBZ
adults NNS
and CC
is VBZ
only RB
rarely RB
cured VBN
. .
Lead JJ
researcher NN
George NNP
Daley NNP
said VBD
the DT
study NN
also RB
proves VBZ
that IN
CML NNP
is VBZ
initiated VBN
by IN
the DT
fusion NN
of IN
parts NNS
from IN
two CD
broken VBN
chromosomes NNS
, ,
a DT
finding NN
that WDT
had VBD
been VBN
suggested VBN
by IN
earlier JJR
studies NNS
. .
Cells NNS
containing VBG
the DT
hybrid NN
gene NN
produce NN
a DT
protein NN
that WDT
changes NNS
healthy VBP
cells NNS
into IN
cancer NN
cells NNS
. .
Daley NNP
said VBD
it PRP
is VBZ
still RB
not RB
known VBN
precisely RB
what WP
causes NNS
the DT
two CD
chromosomes NNS
to TO
break VB
and CC
create VB
the DT
hybrid JJ
gene NN
, ,
but CC
a DT
high JJ
exposure NN
to TO
radiation NN
is VBZ
thought VBN
to TO
be VB
a DT
factor NN
. .
A DT
study NN
of IN
airline-cabin JJ
environment NN
found VBD
that IN
, ,
even RB
with IN
the DT
smoking NN
ban NN
that WDT
takes VBZ
effect NN
in IN
10 CD
days NNS
, ,
passengers NNS
and CC
crew VB
still RB
face VB
a DT
health NN
risk NN
from IN
increased VBN
radiation NN
from IN
the DT
sun NN
and CC
stars NNS
. .
The DT
study NN
released VBN
Thursday NNP
by IN
the DT
Transportation NNP
Department NNP
recommends VBZ
that IN
airlines NNS
schedule VBP
cabin NN
crews NNS
in IN
ways NNS
that WDT
will MD
reduce VB
their PRP$
risk NN
to TO
cosmic JJ
radiation NN
, ,
especially RB
those DT
crews NNS
who WP
regularly RB
fly RB
near IN
the DT
North NNP
Pole NNP
and CC
South NNP
Pole NNP
or CC
at IN
higher JJR
altitudes NNS
. .
The DT
study NN
found VBD
the DT
risk NN
of IN
cancer NN
death NN
from IN
cosmic JJ
radiation NN
comparable JJ
to TO
the DT
risk NN
of IN
death NN
from IN
exposure NN
to TO
smoke-filled JJ
cabins NNS
, ,
although IN
estimates NNS
of IN
cancer NN
caused VBN
by IN
cosmic JJ
rays NNS
had VBD
a DT
wider NN
range NN
because IN
of IN
uncertainty NN
over IN
the DT
effects NNS
of IN
low JJ
doses NNS
of IN
radiation NN
. .
It PRP
also RB
recommended VBD
a DT
total NN
smoking NN
ban NN
but CC
was VBD
superceded VBN
by IN
congressional JJ
action NN
banning VBG
smoking NN
on IN
all DT
flights NNS
of IN
six CD
hours NNS
or CC
less JJR
beginning NN
Feb. NNP
25 CD
. .

<DOCNO> AP900418-0106
An DT
experimental JJ
cancer NN
drug NN
that WDT
works VBZ
after IN
a DT
single JJ
round NN
of IN
treatment NN
appears VBZ
to TO
be VB
the DT
most JJS
effective JJ
medicine NN
yet RB
for IN
a DT
rare NN
form NN
of IN
leukemia NN
, ,
according VBG
to TO
a DT
study NN
. .
The DT
drug NN
_ NNP
called VBD
2-chlorodeoxyadenosine CD
, ,
or CC
2-CdA CD
_ NNP
has VBZ
produced VBN
complete JJ
remissions NNS
in IN
almost RB
all DT
hairy NN
cell NN
leukemia NN
patients NNS
treated VBD
, ,
and CC
none NN
has VBZ
relapsed VBN
so RB
far RB
. .
Researchers NNS
who WP
developed VBD
and CC
tested VBN
the DT
medicine NN
report NN
that WDT
it PRP
`` ``
may MD
well RB
be VB
the DT
drug NN
of IN
choice NN
in IN
the DT
treatment NN
of IN
hairy NN
cell NN
leukemia NN
. .
'' ''
The DT
drug NN
also RB
has VBZ
been VBN
used VBN
successfully RB
against IN
chronic JJ
lymphocytic JJ
leukemia NN
. .
It PRP
, ,
like IN
hairy NN
cell NN
leukemia NN
, ,
is VBZ
a DT
cancer NN
of IN
the DT
white JJ
blood NN
cells NNS
, ,
which WDT
produce NN
disease-fighting JJ
antibodies NNS
. .
The DT
latest JJS
study NN
, ,
published VBD
in IN
Thursday NNP
's POS
New NNP
England NNP
Journal NNP
of IN
Medicine NNP
, ,
was VBD
directed VBN
by IN
Dr. NNP
Lawrence NNP
D. NNP
Piro NNP
of IN
the DT
Scripps NNP
Clinic NNP
and CC
Research NNP
Foundation NNP
in IN
La NNP
Jolla NNP
, ,
Calif. NNP
Scripps NNP
recently RB
made VBD
an DT
agreement NN
with IN
Johnson NNP
& CC
amp VB
; :
Johnson NNP
's POS
Ortho NNP
Pharmaceuticals NNPS
to TO
produce VB
and CC
distribute VB
the DT
drug NN
once RB
it PRP
's VBZ
approved VBN
by IN
the DT
U.S. NNP
Food NNP
and CC
Drug NNP
Administration NNP
. .
In IN
the DT
published JJ
work NN
, ,
doctors NNS
gave VBD
the DT
drug NN
to TO
12 CD
patients NNS
as IN
far RB
back RB
as IN
four CD
years NNS
ago RB
. .
In IN
11 CD
, ,
the DT
disease NN
disappeared VBD
and CC
they PRP
remain VBP
disease NN
free JJ
. .
In IN
all DT
, ,
the DT
Scripps NNP
doctors NNS
have VBP
treated VBN
24 CD
patients NNS
with IN
almost RB
complete JJ
success NN
. .
However RB
, ,
they PRP
caution VBP
that IN
longer JJR
follow NN
up RB
will MD
be VB
necessary JJ
before IN
they PRP
can MD
be VB
sure JJ
they PRP
have VBP
actually RB
cured VBN
the DT
disease NN
. .
Two CD
other JJ
treatments NNS
for IN
hairy NN
cell NN
leukemia NN
have VBP
been VBN
developed VBN
in IN
recent JJ
years NNS
. .
They PRP
are VBP
interferon RB
and CC
deoxycoformycin VB
, ,
a DT
drug NN
that WDT
is VBZ
similar JJ
to TO
2-CdA CD
. .
However RB
, ,
interferon NN
is VBZ
less JJR
effective JJ
, ,
and CC
both DT
of IN
those DT
treatments NNS
produce VBP
serious JJ
side NN
effects NNS
. .
By IN
contrast NN
, ,
the DT
only JJ
unwanted JJ
effect NN
of IN
2-CdA CD
was VBD
a DT
few JJ
days NNS
of IN
fever NN
. .
Patients NNS
experienced VBD
no DT
nausea NN
, ,
hair NN
loss NN
, ,
rashes VBZ
or CC
other JJ
symptoms NNS
typical JJ
of IN
cancer NN
therapy NN
. .
Also RB
unlike VBP
other JJ
treatments NNS
, ,
this DT
one CD
appears VBZ
to TO
work VB
after IN
a DT
single JJ
seven-day NN
course NN
of IN
therapy NN
. .

<DOCNO> AP880429-0036
The DT
American NNP
Red NNP
Cross NNP
is VBZ
`` ``
right RB
on IN
target NN
'' ''
with IN
plans NNS
to TO
start VB
testing NN
donated VBN
blood NN
for IN
a DT
rare NN
virus NN
linked VBD
to TO
a DT
vicious JJ
form NN
of IN
adult NN
leukemia NN
, ,
says VBZ
the DT
National NNP
Cancer NNP
Institute NNP
researcher NN
who WP
first RB
discovered VBD
the DT
virus NN
. .
Dr. NNP
Robert NNP
Gallo NNP
, ,
a DT
scientist NN
credited VBN
with IN
discovering NN
the DT
human NN
T-lymphotropic JJ
virus NN
type NN
1 CD
, ,
or CC
HTLV-1 -NONE-
, ,
said VBD
the DT
nation's NNP
blood NN
supply NN
should MD
be VB
tested VBN
to TO
protect VB
future JJ
generations NNS
from IN
the DT
slow-acting JJ
but CC
dangerous JJ
virus NNS
. .
In IN
a DT
Science NNP
magazine NN
report NN
published VBD
today NN
, ,
Red NNP
Cross NNP
scientist NN
recommended VBD
that IN
blood NN
donated VBD
across IN
the DT
country NN
should MD
be VB
tested VBN
for IN
the DT
HTLV-1 -NONE-
virus VBZ
as IN
soon RB
as IN
a DT
practical JJ
test NN
be VB
developed VBN
. .
The DT
recommendation NN
was VBD
made VBN
after IN
a DT
Red NNP
Cross NNP
survey NN
found VBD
10 CD
units NNS
infected VBN
with IN
the DT
virus NNS
out IN
of IN
39 CD
, ,
898 CD
units NNS
tested VBN
. .
`` ``
I PRP
think VBP
there RB
are VBP
as IN
many JJ
people NNS
infected VBN
with IN
this DT
virus NN
as IN
are VBP
infected VBN
with IN
the DT
AIDS NNP
virus VBZ
, ,
'' ''
Gallo NNP
said VBD
. .
Alan NNP
E. NNP
Williams NNP
, ,
a DT
research NN
scientist NN
at IN
the DT
Red NNP
Cross NNP
laboratory NN
in IN
Rockville NNP
, ,
Md. NNP
, ,
said VBD
his PRP$
research NN
team NN
estimates NNS
that WDT
the DT
risk NN
of IN
becoming VBG
infected VBN
with IN
the DT
HTLV-1 -NONE-
leukemia NN
virus VBZ
is VBZ
about IN
2 CD
, ,
800 CD
in IN
12 CD
million CD
, ,
or CC
about IN
1 CD
chance NN
in IN
4 CD
, ,
286 CD
for IN
every DT
unit NN
of IN
blood NN
transfused VBN
annually RB
. .
`` ``
The DT
danger NN
is VBZ
minimal JJ
but CC
not RB
insignificant JJ
, ,
'' ''
Williams NNP
said VBD
. .
For IN
that DT
reason NN
, ,
he PRP
said VBD
, ,
the DT
Red NNP
Cross NNP
`` ``
wants VBZ
to TO
take VB
an DT
active JJ
stance NN
to TO
keep VB
the DT
situation NN
from IN
getting VBG
worse NN
, ,
as IN
it PRP
possibly RB
could MD
. .
'' ''
Williams NNP
said VBD
current JJ
methods NNS
of IN
testing NN
donated VBN
blood NN
for IN
the DT
virus NN
take NN
up RP
to TO
three CD
days NNS
and CC
a DT
more RBR
practical JJ
test NN
must MD
be VB
developed VBN
before IN
HTLV-1 -NONE-
screening VBG
can MD
begin VB
. .
He PRP
said VBD
at IN
least JJS
three CD
drug NN
companies NNS
, ,
which WDT
he PRP
declined VBD
to TO
name VB
, ,
are VBP
trying VBG
to TO
develop VB
screening NN
tests NNS
, ,
but CC
these DT
are VBP
months NNS
from IN
possible JJ
approval NN
by IN
the DT
Food NNP
and CC
Drug NNP
Administration NNP
. .
The DT
NCI NNP
researcher NN
discovered VBD
and CC
identified VBD
the DT
HTLV-1 -NONE-
virus VBZ
in IN
1978 CD
. .
Gallo NNP
said VBD
his PRP$
understanding NN
of IN
HTLV-1 -NONE-
, ,
a DT
retrovirus NN
that WDT
takes VBZ
over IN
genetic JJ
control NN
of IN
cells NNS
it PRP
attacks VBZ
, ,
led VBN
him PRP
to TO
look VB
for IN
a DT
retrovirus NN
as IN
the DT
cause NN
of IN
AIDS NNP
. .
He PRP
is VBZ
credited VBN
as RB
co-discoverer JJ
of IN
the DT
HIV NNP
virus VBZ
that IN
causes NNS
AIDS NNS
. .
Gallo NNP
said VBD
HTLV-1 -NONE-
may MD
be VB
rare JJ
in IN
the DT
continental JJ
United NNP
States NNPS
, ,
but CC
it PRP
is VBZ
endemic JJ
in IN
parts NNS
of IN
Europe NNP
, ,
Alaska NNP
, ,
Africa NNP
and CC
the DT
Orient NNP
. .
`` ``
In IN
time NN
, ,
due JJ
to TO
increased VBN
travel NN
and CC
increased VBD
sexual JJ
contact NN
, ,
these DT
kinds NNS
of IN
virus NN
are VBP
all DT
increasing VBG
( NN
in IN
the DT
continental JJ
U.S. NNP
) NNP
, ,
'' ''
said VBD
Gallo NNP
. .
Because IN
HTLV-1 -NONE-
has VBZ
a DT
long JJ
latent NN
period NN
before IN
it PRP
causes VBZ
disease NN
, ,
he PRP
said VBD
, ,
`` ``
it PRP
is VBZ
not RB
as IN
readily RB
seen VBN
as IN
AIDS NNP
, ,
but CC
our PRP$
children NNS
and CC
our PRP$
children NNS
's POS
children NNS
will MD
see VB
it PRP
if IN
we PRP
do VBP
n't RB
start VB
eliminating VBG
it PRP
from IN
the DT
blood NN
supply NN
. .
'' ''
Gallo NNP
added VBD
, ,
`` ``
I PRP
'm VBP
very RB
glad JJ
to TO
see VB
the DT
way NN
the DT
Red NNP
Cross NNP
has VBZ
responded VBN
. .
'' ''
Dr. NNP
Edward NNP
Murphy NNP
, ,
a DT
National NNP
Cancer NNP
Institute NNP
researcher NN
who WP
has VBZ
studied VBN
the DT
HTLV-1 -NONE-
virus VBZ
extensively RB
, ,
said VBD
it PRP
is VBZ
linked VBN
to TO
adult VB
T-cell JJ
leukemia-lymphoma NN
, ,
a DT
type NN
of IN
blood NN
cancer NN
usually RB
fatal JJ
within IN
six CD
months NNS
. .
Another DT
disease NN
closely RB
linked VBN
to TO
the DT
virus NN
, ,
said VBD
Murphy NNP
, ,
is VBZ
tropical JJ
spastic JJ
paraparesis NN
, ,
in IN
which WDT
the DT
virus NN
attacks NNS
nerve VBP
cells NNS
that IN
control NN
the DT
lower JJR
extremities NNS
and CC
causes NNS
paralysis NN
and CC
eventually RB
death NN
. .
The DT
incubation NN
period NN
for IN
expression NN
of IN
the DT
leukemia NN
is VBZ
thought VBN
to TO
be VB
30 CD
years NNS
or CC
more JJR
, ,
but CC
people NNS
exposed VBD
to TO
the DT
virus NN
become NN
infectious JJ
within IN
two CD
weeks NNS
to TO
six CD
months NNS
, ,
said VBD
Murphy NNP
. .
Incubation NN
for IN
paraparesis NN
is VBZ
slightly RB
shorter JJR
. .
The DT
virus NN
can MD
be VB
spread VBN
in IN
ways NNS
similar JJ
to TO
the DT
AIDS NNP
virus VBZ
: :
by IN
sexual JJ
contact NN
or CC
the DT
exchange NN
of IN
body NN
fluids NNS
such JJ
as IN
by IN
sharing NN
drug NN
needles NNS
. .
HTLV-1 -NONE-
also RB
is VBZ
thought VBN
to TO
be VB
spread VBN
through IN
mother's JJ
milk NN
, ,
said VBD
Murphy NNP
. .
Williams NNP
said VBD
the DT
Red NNP
Cross NNP
survey NN
checked VBD
for IN
HTLV-1 -NONE-
in IN
samples NNS
from IN
eight CD
different JJ
blood NN
banks NNS
. .
Blood NNP
donors NNS
who WP
tested VBN
positive JJ
for IN
the DT
virus NN
were VBD
found VBN
in IN
Atlanta NNP
, ,
Washington NNP
, ,
Birmingham NNP
, ,
Ala. NNP
and CC
Los NNP
Angeles NNP
. .
Blood NNP
also RB
was VBD
tested VBN
in IN
St. NNP
Paul NNP
, ,
Minn. NNP
, ,
Portland NNP
, ,
Ore. NNP
, ,
Baltimore NNP
and CC
Miami NNP
, ,
but CC
no DT
HTLV-1 -NONE-
was VBD
found VBN
. .
Though IN
the DT
positive JJ
tests NNS
totaled VBD
only RB
10 CD
out IN
of IN
more JJR
than IN
39 CD
, ,
000 CD
samples NNS
tested VBN
, ,
Williams NNP
said VBD
, ,
`` ``
a DT
highly RB
selective JJ
group NN
'' ''
was VBD
used VBN
. .
`` ``
They PRP
go VBP
through IN
several JJ
levels NNS
( :
of IN
screening NN
) :
before IN
the DT
blood NN
is VBZ
ever RB
drawn VBN
, ,
'' ''
he PRP
said VBD
. .

<DOCNO> AP901211-0040
Cigarette NNP
smoking NN
appears VBZ
to TO
increase VB
the DT
risk NN
of IN
developing VBG
leukemia NN
, ,
and CC
kicking VBG
the DT
habit NN
may MD
not RB
be VB
enough RB
to TO
dodge VB
the DT
dreaded VBN
blood NN
disease NN
, ,
a DT
study NN
says VBZ
. .
Paul NNP
K. NNP
Mills NNP
, ,
a DT
professor NN
at IN
Loma NNP
Linda NNP
University NNP
and CC
the DT
principal NN
author NN
of IN
the DT
study NN
, ,
said VBD
research NN
suggests NNS
that WDT
even RB
former JJ
smokers NNS
are VBP
at IN
high JJ
risk NN
. .
`` ``
It PRP
's VBZ
very RB
discouraging VBG
, ,
'' ''
Mills NNP
said VBD
Monday NNP
. .
`` ``
We PRP
saw VBD
a DT
strong JJ
association NN
between IN
prior RB
cigarette JJ
smoking NN
and CC
the DT
risk NN
of IN
developing VBG
leukemia NN
. .
'' ''
The DT
study NN
's POS
results NNS
are VBP
being VBG
published VBN
this DT
month NN
in IN
the DT
Journal NNP
of IN
the DT
National NNP
Cancer NNP
Institute NNP
. .
Cigarette NNP
smoking NN
also RB
has VBZ
been VBN
linked VBN
to TO
cancers NNS
of IN
the DT
lung NN
, ,
bladder NN
, ,
pancreas VBZ
, ,
esophagus VBZ
, ,
throat JJ
and CC
cervix NN
. .
The DT
study NN
is VBZ
part NN
of IN
the DT
Adventist NNP
Health NNP
Study NNP
, ,
a DT
major JJ
epidemiological JJ
investigation NN
of IN
the DT
causes NNS
of IN
various JJ
cancers NNS
among IN
California NNP
members NNS
of IN
the DT
Seventh-day JJ
Adventist NNP
Church NNP
. .
About IN
34 CD
, ,
000 CD
Adventists NNS
responded VBD
to TO
the DT
study NN
. .
Although IN
the DT
vast JJ
majority NN
of IN
Adventists NNPS
do VBP
not RB
smoke VB
by IN
church NN
proscription NN
, ,
many JJ
are VBP
adult VBN
converts NNS
to TO
the DT
religion NN
who WP
smoked VBN
cigarettes VBZ
prior RB
to TO
their PRP$
baptism NN
into IN
the DT
church NN
. .
The DT
researchers NNS
found VBD
that IN
the DT
ex-smokers NNS
had VBD
twice NN
the DT
risk NN
of IN
developing VBG
leukemia NN
than IN
non-smokers NNS
. .
For IN
people NNS
who WP
regularly RB
smoked VBD
more JJR
than IN
25 CD
cigarettes NNS
a DT
day NN
, ,
the DT
risk NN
of IN
developing VBG
leukemia NN
increased VBD
threefold NN
. .
The DT
Adventists NNPS
who WP
had VBD
smoked VBN
for IN
more JJR
than IN
15 CD
years NNS
had VBD
a DT
2 CD
{ CD
-fold JJ
increased VBN
leukemia NN
risk NN
. .
Leukemia NNP
is VBZ
a DT
bone NN
marrow NN
cancer NN
in IN
which WDT
the DT
marrow NN
is VBZ
replaced VBN
by IN
immature NN
, ,
abnormal JJ
white JJ
blood NN
cells NNS
. .
The DT
disease NN
kills NNS
18 CD
, ,
000 CD
people NNS
a DT
year NN
in IN
the DT
United NNP
States NNPS
. .
Dr. NNP
Clark NNP
Heath NNP
Jr. NNP
of IN
the DT
American NNP
Cancer NNP
Society NNP
said VBD
the DT
causes NNS
of IN
leukemia NN
are VBP
largely RB
unknown VBN
. .
But CC
several JJ
studies NNS
in IN
recent JJ
years NNS
, ,
including VBG
a DT
large JJ
study NN
of IN
U.S. NNP
military JJ
veterans NNS
, ,
have VBP
suggested VBN
smoking VBG
as IN
a DT
cause NN
, ,
he PRP
said VBD
. .
The DT
Loma NNP
Linda NNP
study NN
estimates VBZ
that IN
about IN
20 CD
percent NN
of IN
leukemia NN
cases NNS
were VBD
linked VBN
to TO
smoking NN
. .

<DOCNO> AP900814-0015
In IN
a DT
medical JJ
first JJ
, ,
five CD
tablespoons NNS
of IN
umbilical JJ
cord NN
blood NN
saved VBD
after IN
the DT
birth NN
of IN
a DT
baby NN
were VBD
given VBN
to TO
her PRP$
4-year-old JJ
brother NN
in IN
hopes NNS
it PRP
will MD
help VB
him PRP
form VB
new JJ
bone NN
marrow NN
and CC
beat VB
fast-acting JJ
leukemia NN
. .
Michael NNP
Sancilio NNP
received VBD
the DT
transfusion NN
at IN
Johns NNP
Hopkins NNP
Oncology NNP
Center NNP
on IN
Monday NNP
. .
His PRP$
3-month-old JJ
sister NN
, ,
Christina NNP
, ,
is VBZ
too RB
young JJ
to TO
donate VB
bone NN
marrow NN
, ,
the DT
usual JJ
treatment NN
for IN
Michael NNP
's POS
form NN
of IN
leukemia NN
, ,
and CC
doctors NNS
were VBD
afraid VBN
he PRP
would MD
n't RB
survive VB
the DT
three-month JJ
wait NN
before IN
his PRP$
sister NN
became VBD
old JJ
enough RB
. .
`` ``
We PRP
did VBD
n't RB
have VB
any DT
other JJ
choice NN
, ,
'' ''
said VBD
the DT
youngsters' NNP
mother NN
, ,
Denise NNP
Sancilio NNP
. .
`` ``
We PRP
could MD
n't RB
put VB
our PRP$
baby NN
through IN
a DT
bone NN
marrow NN
aspiration NN
. .
It PRP
's VBZ
very RB
dangerous JJ
for IN
her PRP
. .
We PRP
were VBD
in IN
a DT
situation NN
where WRB
we PRP
had VBD
to TO
do VB
it PRP
. .
'' ''
It PRP
was VBD
the DT
first JJ
time NN
the DT
rare NN
operation NN
was VBD
undertaken VBN
to TO
treat VB
leukemia NN
, ,
an DT
often RB
fatal JJ
blood NN
cancer NN
. .
It PRP
has VBZ
been VBN
performed VBN
three CD
other JJ
times NNS
, ,
once RB
in IN
Cincinnati NNP
and CC
twice NN
in IN
France NNP
, ,
to TO
treat VB
a DT
different JJ
disease NN
, ,
Fanconi NNP
's POS
anemia NN
. .
Umbilical JJ
cord NN
blood NN
is VBZ
rich JJ
in IN
stem NN
cells NNS
, ,
used VBN
by IN
the DT
recipient JJ
to TO
form NN
marrow NN
. .
Doctors NNS
said VBD
they PRP
will MD
know VB
in IN
about IN
three CD
weeks NNS
whether IN
the DT
operation NN
worked VBD
. .
Michael NNP
, ,
who WP
has VBZ
juvenile JJ
chronic JJ
myelogenous JJ
leukemia NN
, ,
is VBZ
at IN
extreme NN
risk NN
of IN
infection NN
in IN
the DT
meantime NN
because IN
his PRP$
cancerous JJ
bone NN
marrow NN
had VBD
to TO
be VB
destroyed VBN
as IN
part NN
of IN
the DT
treatment NN
. .
Marrow NNP
is VBZ
critical JJ
to TO
the DT
immune NN
system NN
. .
`` ``
He PRP
's VBZ
been VBN
on IN
and CC
off IN
sleeping VBG
all DT
day NN
, ,
'' ''
Michael NNP
's POS
father NN
, ,
Tony NNP
, ,
said VBD
Monday NNP
night NN
. .
`` ``
This DT
afternoon NN
he PRP
got VBD
up RP
and CC
walked VBD
down RP
the DT
hall NN
and CC
to TO
the DT
children NNS
's POS
playroom NN
. .
He PRP
's VBZ
up RP
and CC
alert NN
. .
A DT
little RB
groggy NN
but CC
holding VBG
his PRP$
own JJ
. .
'' ''
Mrs. NNP
Sancilio NNP
said VBD
she PRP
was VBD
7 CD
{ CD
months NNS
pregnant JJ
with IN
Christina NNP
when WRB
she PRP
learned VBD
Michael NNP
had VBD
a DT
form NN
of IN
leukemia NN
that IN
can MD
not RB
be VB
controlled VBN
with IN
drugs NNS
and CC
usually RB
kills VBZ
within IN
a DT
year NN
of IN
diagnosis NN
. .
The DT
umbilical JJ
cord NN
blood NN
was VBD
frozen VBN
when WRB
Christina NNP
was VBD
born VBN
May NNP
1 CD
. .
A DT
total NN
of IN
2.7 CD
ounces NNS
were VBD
given VBN
to TO
Michael NNP
after IN
chemotherapy NN
to TO
destroy VB
his PRP$
cancerous JJ
marrow NN
. .
The DT
transplant NN
carries VBZ
the DT
same JJ
risk NN
as IN
a DT
bone-marrow NN
transplant NN
. .
Besides IN
the DT
risk NN
of IN
infection NN
, ,
the DT
body NN
often RB
rejects VBZ
foreign JJ
cells NNS
. .
Michael NNP
's POS
blood NN
type NN
does VBZ
not RB
match VB
his PRP$
sister NN
's POS
, ,
but CC
doctors NNS
found VBD
that IN
he PRP
was VBD
not RB
overly RB
likely JJ
to TO
reject VB
the DT
umbilical JJ
cord NN
blood NN
. .
Tests NNS
on IN
Michael NNP
's POS
parents NNS
and CC
his PRP$
7-year-old JJ
brother NN
, ,
also RB
named VBD
Tony NNP
, ,
showed VBD
they PRP
were VBD
not RB
compatible JJ
marrow NN
donors NNS
. .
The DT
family NN
lives VBZ
in IN
Virginia NNP
Beach NNP
, ,
Va. NNP
`` ``
The NNP
odds NNS
were VBD
we PRP
thought VBD
he PRP
had VBD
the DT
chance NN
of IN
surviving VBG
for IN
a DT
couple NN
of IN
months NNS
, ,
but CC
it PRP
was VBD
unknown VBN
when WRB
the DT
disease NN
would MD
accelerate VB
and CC
become VB
life-threatening JJ
, ,
'' ''
said VBD
Dr. NNP
John NNP
Wagner NNP
. .
`` ``
We PRP
decided VBD
to TO
go VB
ahead RB
and CC
take VB
the DT
chance NN
on IN
the DT
cord NN
blood NN
rather RB
than IN
waiting VBG
until IN
the DT
donor NN
was VBD
old JJ
enough RB
. .
'' ''
If IN
the DT
transfusion NN
works VBZ
, ,
it PRP
could MD
lead VB
to TO
creation NN
of IN
a DT
bank NN
of IN
umbilical JJ
cord NN
blood NN
to TO
aid NN
similarly RB
afflicted VBN
youngsters NNS
, ,
doctors NNS
said VBD
. .
The DT
transfusion NN
can MD
be VB
performed VBN
only RB
on IN
young JJ
children NNS
because IN
not RB
enough RB
blood NN
is VBZ
in IN
the DT
umbilical JJ
cord NN
for IN
use NN
with IN
adults NNS
, ,
said VBD
Dr. NNP
Richard NNP
Champlin NNP
, ,
chief NN
of IN
the DT
bone-marrow JJ
transplant NN
program NN
at IN
M.D JJ
. .
Anderson NNP
Cancer NNP
Center NNP
in IN
Houston NNP
. .
`` ``
In IN
the DT
long JJ
run NN
it PRP
could MD
provide VB
the DT
potential JJ
to TO
protect VB
and CC
store VB
umbilical JJ
blood NN
from IN
every DT
baby NN
and CC
create VB
a DT
bank NN
of IN
cells NNS
for IN
transplantation NN
that WDT
could MD
be VB
used VBN
if IN
a DT
patient NN
did VBD
n't RB
have VB
a DT
donor NN
within IN
the DT
family NN
, ,
'' ''
he PRP
said VBD
. .

<DOCNO> AP900802-0028
Scientists NNS
today NN
reported VBD
finding VBG
the DT
first JJ
treatment NN
capable JJ
of IN
relieving NN
and CC
even RB
curing VBG
chronic JJ
hepatitis NNS
B NNP
, ,
one CD
of IN
the DT
world NN
's POS
biggest JJS
killers NNS
. .
A DT
study NN
in IN
the DT
New NNP
England NNP
Journal NNP
of IN
Medicine NNP
indicates VBZ
that IN
shots NNS
of IN
a DT
synthetic JJ
form NN
of IN
the DT
natural JJ
protein NN
interferon NN
can MD
prevent VB
the DT
virus NN
from IN
destroying VBG
the DT
liver NN
in IN
nearly RB
half NN
the DT
people NNS
chronically RB
infected VBN
. .
One CD
in IN
10 CD
victims NNS
can MD
be VB
cured VBN
, ,
while IN
the DT
drug NN
had VBD
no DT
benefits NNS
for IN
60 CD
percent NN
of IN
the DT
169 CD
people NNS
studied VBN
in IN
clinical JJ
trials NNS
, ,
researchers NNS
said VBD
. .
Hepatitis NNP
B NNP
is VBZ
the DT
chief NN
underlying VBG
cause NN
of IN
liver NN
cancer NN
and CC
cirrhosis NN
and CC
the DT
world NN
's POS
ninth-leading JJ
cause NN
of IN
death NN
, ,
just RB
behind IN
lung JJ
disease NN
and CC
well RB
ahead RB
of IN
AIDS NNP
, ,
according VBG
to TO
the DT
World NNP
Health NNP
Organization NNP
. .
An DT
estimated VBN
1 CD
million CD
to TO
1.5 CD
million CD
people NNS
in IN
the DT
United NNP
States NNPS
are VBP
long-term JJ
carriers NNS
of IN
the DT
hepatitis NNS
B NNP
virus NN
. .
At IN
least JJS
half NN
of IN
them PRP
have VBP
liver RB
disease VB
. .
Worldwide NNP
, ,
300 CD
million CD
people NNS
, ,
or CC
5 CD
percent NN
of IN
the DT
world NN
's POS
population NN
, ,
are VBP
chronically RB
infected VBN
. .
Until IN
now RB
, ,
there EX
has VBZ
been VBN
no DT
treatment NN
or CC
cure NN
for IN
the DT
virus NN
. .
`` ``
This DT
is VBZ
an DT
encouraging VBG
result NN
. .
All DT
of IN
us PRP
would MD
feel VB
a DT
lot NN
happier NN
if IN
we PRP
had VBD
a DT
better JJR
treatment NN
. .
This DT
spurs NNS
us PRP
on IN
to TO
find VB
that IN
, ,
'' ''
said VBD
Dr. NNP
Baruch NNP
S. NNP
Blumberg NNP
of IN
the DT
Fox NNP
Chase NNP
Cancer NNP
Center NNP
in IN
Philadelphia NNP
. .
Blumberg NNP
won VBD
the DT
Nobel NNP
Prize NNP
in IN
medicine NN
in IN
1976 CD
for IN
identifying NN
the DT
virus NN
. .
The DT
latest JJS
research NN
, ,
which WDT
involved VBN
169 CD
people NNS
at IN
12 CD
hospitals NNS
, ,
confirms NNS
several JJ
smaller JJR
studies NNS
suggesting VBG
that IN
interferon NN
works NNS
. .
Other JJ
studies NNS
have VBP
also RB
shown VBN
that IN
interferon NN
works NNS
against IN
hepatitis NNS
C NNP
, ,
another DT
serious JJ
but CC
less JJR
common JJ
variety NN
of IN
the DT
virus NN
. .
Although IN
the DT
Food NNP
and CC
Drug NNP
Administration NNP
has VBZ
not RB
yet RB
recommended VBD
interferon NN
for IN
hepatitis NNS
B NNP
, ,
physicians VBZ
can MD
use VB
it PRP
any DT
way NN
they PRP
choose VBP
, ,
and CC
Blumberg NNP
said VBD
some DT
doctors NNS
have VBP
already RB
begun VBN
prescribing VBG
it PRP
for IN
this DT
disease NN
. .
Doctors NNS
said VBD
the DT
latest JJS
study NN
is VBZ
big JJ
enough RB
so RB
physicians NNS
can MD
use VB
the DT
results NNS
to TO
predict VB
how WRB
interferon NN
will MD
affect VB
their PRP$
patients NNS
if IN
_ NNP
as IN
seems NNS
likely JJ
_ NNP
it PRP
becomes VBZ
the DT
standard JJ
medicine NN
for IN
hepatitis NNS
B NNP
. .
`` ``
We PRP
can MD
be VB
relatively RB
sure JJ
what WP
doctors NNS
will MD
find VB
in IN
practice NN
: :
Ten NNP
percent NN
will MD
be VB
cured VBN
and CC
40 CD
or CC
50 CD
percent NN
will MD
be VB
made VBN
better JJR
and CC
their PRP$
liver NN
disease NN
will MD
be VB
stopped VBN
in IN
its PRP$
tracks NNS
, ,
'' ''
said VBD
Dr. NNP
Robert NNP
P. NNP
Perrillo NNP
of IN
the DT
St. NNP
Louis NNP
Veterans NNP
Affairs NNP
Medical NNP
Center NNP
, ,
the DT
principal JJ
author NN
of IN
the DT
study NN
. .
He PRP
defined VBD
a DT
cure NN
as IN
the DT
complete JJ
disappearance NN
of IN
the DT
virus NN
. .
Experts NNS
cautioned VBD
the DT
treatment NN
should MD
be VB
used VBN
only RB
for IN
those DT
with IN
chronic JJ
infections NNS
who WP
show NN
signs VBZ
of IN
liver JJR
damage NN
. .
The DT
results NNS
were VBD
published VBN
along IN
with IN
an DT
editorial NN
by IN
Dr. NNP
Jay NNP
H. NNP
Hoofnagle NNP
of IN
the DT
National NNP
Institute NNP
of IN
Diabetes NNPS
and CC
Digestive NNP
and CC
Kidney NNP
Diseases NNP
. .
`` ``
For IN
now RB
, ,
interferon NN
alpha NN
offers NNS
the DT
best JJS
hope NN
'' ''
for IN
treating VBG
chronic JJ
hepatitis NNS
B NNP
, ,
Hoofnagle NNP
wrote VBD
. .
Hepatitis NNP
is VBZ
likely JJ
to TO
become VB
the DT
first JJ
major JJ
use NN
for IN
interferon NN
. .
Isolating VBG
the DT
natural JJ
disease-fighting NN
substance NN
was VBD
one CD
of IN
the DT
early JJ
goals NNS
of IN
genetic JJ
engineering NN
. .
In IN
a DT
decade NN
of IN
testing NN
, ,
interferon NN
has VBZ
turned VBN
out RP
to TO
be VB
useful JJ
against IN
a DT
variety NN
of IN
diseases NNS
, ,
none NN
as IN
common JJ
as IN
hepatitis NNS
. .
The DT
FDA NNP
has VBZ
approved VBN
use NN
of IN
the DT
drug NN
for IN
hairy-cell JJ
leukemia NN
, ,
AIDS-related JJ
Kaposi NNP
's POS
sarcoma NN
and CC
genital JJ
warts NNS
. .
In IN
hepatitis NN
B NNP
, ,
Perrillo NNP
said VBD
the DT
treatment NN
appears VBZ
to TO
offer VB
the DT
best JJS
chance NN
of IN
a DT
cure NN
if IN
given VBN
during IN
the DT
first JJ
two CD
years NNS
of IN
infection NN
. .

<DOCNO> WSJ870722-0113
A DT
new JJ
class NN
of IN
drugs NNS
that WDT
may MD
aid VB
in IN
fighting NN
cancer NN
, ,
AIDS NNP
and CC
other JJ
diseases NNS
is VBZ
moving VBG
onto IN
biotechnology NN
's POS
center NN
stage NN
. .
The DT
experimental JJ
drugs NNS
are VBP
called VBN
blood-cell -NONE-
colony NN
stimulating VBG
factors NNS
, ,
or CC
CSFs NNP
. .
In IN
animal JJ
and CC
early RB
human JJ
tests NNS
, ,
the DT
drugs NNS
have VBP
boosted VBN
depressed VBN
numbers NNS
of IN
infection-fighting JJ
white JJ
blood NN
cells NNS
to TO
normal JJ
and CC
even RB
above-normal JJ
levels NNS
. .
`` ``
For IN
the DT
first JJ
time NN
, ,
we PRP
are VBP
able JJ
to TO
regulate VB
blood NN
cells NNS
, ,
'' ''
says VBZ
David NNP
Golde NNP
, ,
a DT
researcher NN
at IN
the DT
University NNP
of IN
California NNP
in IN
Los NNP
Angeles NNP
. .
`` ``
That DT
is VBZ
a DT
revolutionary JJ
thing NN
. .
`` ``
CSFs NNS
are VBP
n't RB
expected VBN
to TO
cure VB
cancer NN
or CC
acquired VBN
immune JJ
deficiency NN
syndrome NN
. .
But CC
they PRP
may MD
help VB
patients NNS
with IN
such JJ
diseases NNS
fight MD
off VB
potentially RB
fatal JJ
infections NNS
that WDT
take VB
advantage NN
of IN
their PRP$
weakened VBN
immune NN
systems NNS
. .
Scientists NNS
caution NN
that IN
the DT
CSFs NNP
' POS
benefits NNS
to TO
patients NNS
have VBP
n't RB
been VBN
established VBN
, ,
and CC
doing VBG
so RB
may MD
take VB
years NNS
. .
But CC
preliminary JJ
reports NNS
on IN
the DT
drugs NNS
, ,
including VBG
one CD
expected VBN
to TO
appear VB
soon RB
in IN
the DT
New NNP
England NNP
Journal NNP
of IN
Medicine NNP
, ,
show NN
they PRP
bolster VBP
certain JJ
kinds NNS
of IN
white JJ
blood NN
cells NNS
with IN
remarkable JJ
consistency NN
. .
That DT
has VBZ
created VBN
a DT
groundswell NN
of IN
optimism NN
among IN
medical JJ
researchers NNS
, ,
who WP
hope NN
the DT
drugs NNS
will MD
enable VB
them PRP
to TO
`` ``
dial JJ
up IN
'' ''
blood-cell NNP
levels NNS
in IN
patients NNS
as IN
if IN
they PRP
were VBD
turning VBG
up RP
the DT
volume NN
on IN
a DT
radio NN
. .
Jerome NNP
Groopman NNP
, ,
a DT
researcher NN
at IN
New NNP
England NNP
Deaconess NNP
Hospital NNP
in IN
Boston NNP
, ,
says VBZ
, ,
`` ``
Preliminary NNP
trials NNS
indicate VBP
that IN
the DT
CSFs NNP
are VBP
the DT
most RBS
exciting JJ
and CC
promising JJ
'' ''
of IN
biotechnology NN
's POS
immune-system JJ
modifiers NNS
, ,
which WDT
include VBP
much-touted JJ
drugs NNS
like IN
interferon NN
and CC
interleukin-2 -NONE-
. .
CSFs NNS
also RB
are VBP
winning VBG
acclaim NN
among IN
analysts NNS
, ,
who WP
note NN
that IN
the DT
drugs NNS
are VBP
aimed VBN
at IN
well-defined JJ
markets NNS
. .
And CC
compared VBN
with IN
drugs NNS
like IN
interferon NN
, ,
which WDT
have VBP
broad VBN
actions NNS
that IN
are VBP
difficult JJ
to TO
register NN
, ,
`` ``
CSFs NNP
have VBP
very RB
direct JJ
effects NNS
that WDT
make VBP
it PRP
easy JJ
to TO
devise VB
clinical JJ
trials NNS
needed VBN
to TO
get VB
them PRP
approved VBD
'' ''
for IN
marketing NN
, ,
says VBZ
Stuart NNP
Weisbrod NNP
, ,
an DT
analyst NN
with IN
Prudential-Bache NNP
Securities NNPS
Inc. NNP
Two NNP
of IN
the DT
new JJ
drugs NNS
are VBP
in IN
clinical JJ
trials NNS
: :
GM-CSF JJ
, ,
made VBN
by IN
both DT
Genetics NNP
Institute NNP
Inc. NNP
and CC
Immunex NNP
Corp. NNP
, ,
which WDT
promotes VBZ
infection-fighting JJ
cells NNS
called VBN
granulocytes NNS
and CC
macrophages NNS
; :
and CC
GCSF NNP
, ,
made VBD
by IN
Amgen NNP
Corp. NNP
, ,
which WDT
boosts NNS
granulocytes VBZ
. .
Scientists NNS
often RB
mention NN
a DT
closely RB
related VBN
substance NN
, ,
erythropoietin NN
, ,
or CC
EPO NNP
, ,
in IN
the DT
same JJ
breath NN
with IN
CSFs NNP
. .
EPO NNP
, ,
made VBD
by IN
both DT
Amgen NNP
and CC
Genetics NNP
Institute NNP
, ,
boosts VBZ
oxygen-carrying JJ
red VBN
blood NN
cells NNS
and CC
also RB
has VBZ
proved VBN
very RB
promising JJ
in IN
early JJ
clinical JJ
trials NNS
. .
Scientists NNS
working VBG
with IN
CSFs NNP
emphasize NN
that WDT
the DT
benefits NNS
of IN
higher JJR
white-blood-cell JJ
counts NNS
induced VBN
by IN
the DT
drugs NNS
remain VBP
to TO
be VB
shown VBN
. .
But CC
many JJ
researchers NNS
say VBP
they PRP
believe VBP
the DT
drugs NNS
will MD
help VB
fight NN
diseases NNS
, ,
citing VBG
the DT
well-established JJ
fact NN
that IN
patients NNS
with IN
very RB
low JJ
white-blood-cell JJ
counts NNS
are VBP
prone VBN
to TO
infections NNS
. .
In IN
fact NN
, ,
patients NNS
taking VBG
anti-cancer NN
drugs NNS
-- :
which IN
can MD
almost RB
knock VB
out RP
the DT
immune NN
system NN
-- :
sometimes RB
die VB
of IN
pneumonia NN
and CC
other JJ
infectious JJ
diseases NNS
rather RB
than IN
cancer NN
. .
Sadly RB
, ,
such JJ
patients NNS
often RB
have VBP
cancers NNS
that IN
might MD
be VB
arrested VBN
. .
Indeed RB
, ,
doctors NNS
are VBP
more RBR
willing JJ
to TO
risk VB
giving VBG
heavy JJ
doses NNS
of IN
anti-cancer JJ
drugs NNS
to TO
patients NNS
they PRP
might MD
save VB
than IN
to TO
those DT
with IN
untreatable JJ
tumors NNS
. .
If IN
CSFs NNP
can MD
prevent VB
infections NNS
, ,
physicians NNS
may MD
be VB
able JJ
to TO
prescribe VB
larger JJR
and CC
more JJR
frequent NN
chemotherapy NN
doses NNS
-- :
perhaps RB
extending VBG
cancer NN
victims NNS
' POS
lives NNS
by IN
years NNS
. .
Thus RB
, ,
CSFs NNP
may MD
turn VB
out RP
to TO
be VB
potent JJ
weapons NNS
in IN
the DT
anti-cancer NN
arsenal JJ
-- :
without IN
having NN
to TO
pass VB
muster NN
in IN
long JJ
, ,
expensive JJ
anti-cancer NN
tests NNS
. .
To TO
get VB
marketing NN
approval NN
for IN
the DT
drugs NNS
, ,
`` ``
I PRP
think VBP
it PRP
will MD
only RB
be VB
necessary JJ
to TO
show VB
reduced VBN
morbidity NN
from IN
infections NNS
rather RB
than IN
from IN
cancer NN
, ,
'' ''
says VBZ
Jordan NNP
Gutterman NNP
, ,
a DT
cancer NN
researcher NN
testing NN
GM-CSF NN
at IN
Houston NNP
's POS
M.D JJ
. .
Anderson NNP
Hospital NNP
. .
A DT
spokesman NN
for IN
the DT
Food NNP
and CC
Drug NNP
Administration NNP
says VBZ
it PRP
's VBZ
too RB
early JJ
to TO
comment NN
on IN
possible JJ
standards NNS
to TO
be VB
applied VBN
to TO
CSFs NNP
. .
Scientists NNS
also RB
are VBP
testing VBG
GM-CSF JJ
in IN
AIDS NNP
patients NNS
. .
The DT
AIDS NNP
virus VBZ
mainly RB
bludgeons NNS
immune VBP
cells NNS
that IN
GM-CSF JJ
is VBZ
n't RB
expected VBN
to TO
revive VB
. .
But CC
researchers NNS
hope VBP
that IN
by IN
revving NN
up IN
other JJ
immune NN
cells NNS
with IN
GM-CSF JJ
, ,
they PRP
can MD
ward VB
off RP
`` ``
opportunistic JJ
'' ''
infections NNS
in IN
AIDS NNP
patients NNS
caused VBD
by IN
bacteria NN
, ,
fungi NN
and CC
other JJ
microbes NNS
. .
The DT
drug NN
also RB
may MD
offset VB
immune NN
suppression NN
caused VBD
by IN
antibiotics NNS
and CC
AZT NNP
, ,
the DT
only JJ
drug NN
approved VBD
so RB
far RB
to TO
treat VB
AIDS NNP
. .
According VBG
to TO
early JJ
reports NNS
, ,
CSFs NNP
cause NN
only RB
minor JJ
flu-like JJ
side NN
effects NNS
, ,
such JJ
as IN
fever NN
, ,
chills NNS
and CC
body NN
aches NNS
. .
Ironically RB
, ,
three CD
of IN
18 CD
patients NNS
in IN
an DT
AIDS NNP
study NN
reported VBD
in IN
May NNP
developed VBD
signs NNS
of IN
infection NN
by IN
a DT
tuberculosis-like JJ
bacteria NN
after IN
taking VBG
GM-CSF JJ
. .
Boston NNP
's POS
Dr. NNP
Groopman NNP
, ,
who WP
codirected VBN
the DT
study NN
, ,
says VBZ
the DT
patients NNS
apparently RB
had VBD
been VBN
harboring VBG
the DT
bug NN
without IN
showing NN
it PRP
. .
He PRP
explains VBZ
that IN
before IN
they PRP
took VBD
GM-CSF JJ
their PRP$
immune NN
systems NNS
were VBD
too RB
depressed VBN
to TO
mount VB
normal JJ
responses NNS
to TO
the DT
bacteria NN
-- :
such JJ
as IN
fever NN
, ,
a DT
sign NN
that IN
the DT
body NN
is VBZ
fighting VBG
back RB
. .
If IN
CSFs NNP
are VBP
approved VBN
for IN
marketing NN
, ,
their PRP$
uses NNS
could MD
expand VB
rapidly RB
-- :
especially RB
if IN
larger JJR
clinical JJ
trials NNS
support NN
the DT
conclusion NN
that IN
they PRP
have VBP
few JJ
side NN
effects NNS
. .
The DT
drugs NNS
might MD
be VB
used VBN
, ,
for IN
example NN
, ,
to TO
push VB
normal JJ
immune NN
systems NNS
into IN
overdrive JJ
as IN
a DT
preventive JJ
measure NN
in IN
frail NN
, ,
older NN
patients NNS
hospitalized VBD
for IN
broken VBN
bones NNS
. .
`` ``
A DT
lot NN
of IN
people NNS
die VB
of IN
pneumonia NN
, ,
'' ''
says VBZ
Dr. NNP
Golde NNP
, ,
the DT
UCLA NNP
researcher NN
, ,
who WP
is VBZ
working VBG
with IN
GM-CSF JJ
. .
`` ``
I PRP
would MD
like VB
to TO
ask VB
whether IN
we PRP
could MD
reduce VB
that IN
death NN
rate NN
. .
`` ``
Scientists NNS
' POS
excitement NN
about IN
CSFs NNP
stems NNS
partly RB
from IN
the DT
light JJ
they PRP
are VBP
shedding VBG
on IN
the DT
immune NN
system NN
, ,
a DT
complex JJ
system NN
whose WP$
actions NNS
are VBP
controlled VBN
by IN
messenger NN
molecules NNS
such JJ
as IN
CSFs NNP
. .
Last JJ
year NN
, ,
for IN
example NN
, ,
Genetics NNP
Institute NNP
scientists NNS
identified VBD
a DT
new JJ
member NN
of IN
the DT
CSF NNP
family NN
called VBN
interleukin-3 -NONE-
, ,
or CC
IL-3 -NONE-
, ,
which WDT
apparently RB
affects VBZ
a DT
broad JJ
range NN
of IN
cells NNS
and CC
may MD
amplify VB
effects NNS
of IN
other JJ
CSFs NNS
. .
Moreover RB
, ,
researchers NNS
are VBP
finding VBG
that IN
CSFs NNP
have VBP
other JJ
roles NNS
besides VBZ
increasing VBG
blood-cell NN
counts NNS
. .
`` ``
When WRB
granulocytes NNS
sense VBP
bacteria NNS
, ,
they PRP
get VBP
very RB
angry JJ
and CC
dump VB
out RP
a DT
toxic JJ
substance NN
that WDT
's VBZ
essentially RB
like IN
bleach NN
, ,
'' ''
says VBZ
Robert NNP
Kamen NNP
, ,
Genetics NNP
Institute NNP
's POS
senior JJ
vice NN
president NN
, ,
scientific JJ
affairs NNS
. .
`` ``
Their PRP$
ability NN
to TO
be VB
angered VBN
is VBZ
increased VBN
by IN
GM-CSF JJ
, ,
so RB
with IN
the DT
drug NN
, ,
we PRP
can MD
both DT
increase NN
granulocyte NN
numbers NNS
and CC
prime JJ
them PRP
for IN
action NN
. .
`` ``
And CC
G-CSF JJ
may MD
prove VB
directly RB
useful JJ
as IN
a DT
treatment NN
for IN
certain JJ
kinds NNS
of IN
leukemia NN
, ,
or CC
blood-cell NNP
cancers NNS
. .
In IN
test-tube JJ
studies NNS
, ,
the DT
drug NN
has VBZ
converted VBN
leukemia NN
cancer NN
cells NNS
that WDT
are VBP
multiplying VBG
out RP
of IN
control NN
into IN
normal JJ
cells NNS
, ,
says VBZ
Philip NNP
Whitcome NNP
, ,
Amgen NNP
's POS
director NN
of IN
strategic JJ
planning NN
. .
Ultimately RB
, ,
researchers NNS
hope VBP
to TO
use VB
combinations NNS
of IN
CSFs NNP
, ,
perhaps RB
with IN
other JJ
immune-system JJ
hormones NNS
, ,
to TO
manipulate VB
the DT
immune NN
system NN
with IN
even RB
more JJR
power NN
and CC
precision NN
. .
Immunex NNP
, ,
for IN
example NN
, ,
recently RB
reported VBD
that IN
CSFs NNP
appear VBP
to TO
work VB
synergistically RB
with IN
interleukin-1 -NONE-
, ,
another DT
immune NN
messenger NN
, ,
to TO
boost VB
white JJ
blood NN
cells NNS
. .
Christopher NNP
Henney NNP
, ,
Immunex NNP
's POS
scientific JJ
director NN
, ,
says VBZ
the DT
company NN
hopes VBZ
the DT
combination NN
will MD
help VB
offset VB
cancer NN
patients NNS
' POS
immune NN
suppression NN
from IN
radiation NN
treatments NNS
. .

<DOCNO> AP901119-0032
A DT
4-year-old JJ
with IN
a DT
rare JJ
form NN
of IN
leukemia NN
once RB
considered VBN
incurable JJ
has VBZ
apparently RB
beaten VBN
the DT
disease NN
after IN
being VBG
given VBN
a DT
transfusion NN
of IN
umbilical JJ
cord NN
blood NN
from IN
his PRP$
baby NN
sister NN
, ,
doctors NNS
say VBP
. .
Michael NNP
Sancilio NNP
of IN
Virginia NNP
Beach NNP
left VBD
Johns NNP
Hopkins NNP
Hospital NNP
in IN
Baltimore NNP
on IN
Saturday NNP
three CD
months NNS
after IN
becoming VBG
the DT
first JJ
leukemia NN
patient NN
to TO
undergo VB
the DT
experimental JJ
transplant NN
. .
`` ``
Although IN
doctors NNS
are VBP
reluctant JJ
to TO
say VB
Michael NNP
is VBZ
cured VBN
, ,
Michael NNP
appears VBZ
to TO
have VB
defeated VBN
a DT
rare NN
form NN
of IN
leukemia NN
for IN
which WDT
previously RB
existed VBD
no DT
known NN
cure NN
, ,
'' ''
Virginia NNP
BEach NNP
General NNP
Hospital NNP
said VBD
in IN
a DT
statement NN
. .
Doctors NNS
there EX
had VBD
collected VBN
so-called JJ
stem NN
cells NNS
from IN
his PRP$
sister NN
's POS
umbilical JJ
cord NN
for IN
transplant NN
in IN
Baltimore NNP
. .
Umbilical JJ
blood NN
, ,
usually RB
discarded VBD
at IN
birth JJ
, ,
is VBZ
rich JJ
in IN
stem NN
cells NNS
, ,
which WDT
multiply RB
rapidly RB
to TO
form NN
bone NN
marrow NN
. .
Doctors NNS
gave VBD
Michael NNP
five CD
tablespoons NNS
of IN
the DT
blood NN
. .
Within NNP
one CD
month NN
, ,
he PRP
began VBD
producing VBG
healthy JJ
bone NN
marrow NN
, ,
doctors NNS
said VBD
. .
`` ``
What WP
we PRP
are VBP
viewing VBG
this DT
afternoon NN
is VBZ
nothing NN
short RB
of IN
a DT
miracle NN
, ,
'' ''
Dr. NNP
Leslie NNP
Wasserman NNP
Jr. NNP
said VBD
Sunday NNP
. .
`` ``
God NNP
deserves VBZ
all DT
the DT
credit NN
, ,
'' ''
said VBD
Michael NNP
's POS
grandmother NN
, ,
Rachel NNP
Sancilio NNP
. .
`` ``
I PRP
prayed VBD
for IN
a DT
miracle NN
. .
It PRP
was VBD
the DT
most JJS
devastating VBG
thing NN
. .
My PRP$
heart NN
goes VBZ
out RP
to TO
any DT
family NN
that IN
has VBZ
to TO
go VB
through RP
something NN
like IN
this DT
. .
'' ''
Umbilical NNP
cord NN
blood NN
transplants NNS
have VBP
been VBN
performed VBN
three CD
other JJ
times NNS
, ,
once RB
in IN
Cincinnati NNP
and CC
twice NN
in IN
France NNP
, ,
to TO
treat VB
a DT
different JJ
disease NN
, ,
Fanconi NNP
's POS
anemia NN
. .
Leukemia NNP
is VBZ
a DT
cancer NN
of IN
the DT
blood NN
and CC
bone NN
marrow NN
. .
Eight NNP
months NNS
ago RB
, ,
Michael NNP
was VBD
diagnosed VBN
with IN
a DT
form NN
known VBN
as RB
chronic JJ
myelogenous JJ
leukemia NN
, ,
which WDT
can MD
not RB
be VB
controlled VBN
with IN
drugs NNS
and CC
usually RB
kills VBZ
within IN
a DT
year NN
of IN
diagnosis NN
. .
The DT
boy NN
's POS
sister NN
, ,
Christina NNP
, ,
was VBD
born VBN
May NNP
1 CD
. .
Michael NNP
's POS
blood NN
type NN
did VBD
not RB
match VB
hers NNS
, ,
but CC
the DT
siblings NNS
were VBD
otherwise RB
compatible JJ
, ,
and CC
doctors NNS
found VBD
that IN
he PRP
was VBD
not RB
overly RB
likely JJ
to TO
reject VB
the DT
umbilical JJ
cord NN
blood NN
. .
Because IN
of IN
the DT
procedure NN
, ,
Michael NNP
has VBZ
`` ``
another DT
chance NN
at IN
life NN
'' ''
- :
and CC
a DT
new JJ
blood NN
type NN
, ,
the DT
hospital NN
said VBD
. .
Doctors NNS
will MD
not RB
know VB
for IN
about IN
two CD
years NNS
whether IN
the DT
boy NN
is VBZ
cured VBN
. .
Christina NNP
is VBZ
healthy JJ
. .

